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Summary
Since the 1970's community pharmacists in the UK increasingly have maintained 
patient medication records (PMRs). The aim of this project is to assess the impact of 
PMRs on community pharmacy practice in England and Wales. Using a postal survey, 
this study has shown the extent to which PMRs are used in community pharmacy 
practice, with particular reference to the recording of patient and product details. A 
further study, by means of an audit of all patients' clinical conditions in a PMR system 
in one community pharmacy, has compared data from the PMR system with national 
morbidity statistics; this is a method that community pharmacists could use to develop 
patient services. A separate investigation of community pharmacists' motives for 
purchasing PMR systems showed that community pharmacists maintain PMRs 
primarily to provide improved clinical services to their patients, rather than for 
commercial reasons or for financial reward.
A postal survey of general practitioners (GPs) showed a majority in support of 
pharmacy-held PMRs, but little support for PMR retention by Family Health Service 
Authorities. GPs also supported the use of patient information leaflets in conjunction 
with PMR systems. The readability of such leaflets has been compared with original 
pack inserts using computer analysis. Patient information leaflets were shown to have 
no effect on the compliance of a group of patients receiving antibiotic therapy.
A multi-centre study showed important benefits of pharmacists using PMRs to monitor 
a patient's therapy for potential drug interactions, contraindicated products, 
incorrectly-prescribed medication, and incorrectly-prescribed doses. The survey 
identified that PMRs are of particular benefit in monitoring for potential drug 
interactions between previously-dispensed and newly-prescribed medication. The 
nature of interventions made by community pharmacists demonstrated a particular need 
to maintain records for those patients with cardio-vascular disease, asthmatics, 
diabetics and the young.
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An analysis of potential drug interactions reported by community pharmacists showed 
considerable inconsistency between five PMR systems in their ability to detect drug 
interactions. Reasons for the inadequate performance of some systems are described, 
and recommendations are made for their improvement. Further recommendations are 
that community pharmacists must have access to patient medication histories, and 
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1 Introduction
1.1 Community Pharmacy in the United Kingdom
Pharmacy is both the science of the research, development and production of 
medicines, and the profession of those individuals involved in the supply of medicinal 
products to patients and the general public. In order to be a member of the 
pharmaceutical profession in the United Kingdom (UK), individuals must be registered 
as a pharmaceutical chemist (pharmacist) with the Royal Pharmaceutical Society of 
Great Britain (RPSGB). In the UK, the majority of pharmacists practice their 
profession in community pharmacy, while others are engaged in hospital practice, in 
the pharmaceutical industry or in academia.
The typical community pharmacy has been described as the shop in the high street 
where prescriptions are dispensed and medicines sold * At present, there are about 
12 000 such pharmacies in the UK, representing about one for every 5 000 members of 
the public. Premises to be used as a pharmacy must be registered with the RPSGB. 
The main legal requirements for pharmacies in the UK are derived from the Medicines 
Act 1968. In particular, the Medicines Act 1968 sets out in detail how medicines may 
be sold or supplied. Legislation categorises General Sales List (GSL) medicines which 
are considered safe to be sold anywhere and Prescription Only Medicines (POM) 
which pharmacists may only supply on the written order of a registered medical or 
dental practitioner. The remaining medicines, known as Pharmacy (P) medicines, are 
not listed and can only be sold by or under the supervision of a pharmacist from a 
registered pharmacy.
Dispensing under the National Health Service (NHS) is carried out under a contract 
between the owner of the pharmacy, who need not be a pharmacist, and the local 
Family Health Service Authority (FHSA). Under the National Health Service Act 
1977, dispensing is required to be carried out normally under the supervision of a
25
pharmacist. However in some rural districts general practitioners (GPs) dispense for 
their patients. This arrangement has led to disputes between the medical and 
pharmaceutical professions.
The community pharmacy draws its pharmaceutical income from three sources: firstly 
from the NHS contract to dispense; secondly from the dispensing of private 
prescriptions; and thirdly from the sale of medicines and other health care related 
products. In addition, in contrast with pharmacies in many other European countries, 
income is also generated from the sale of non-pharmaceutical products, eg. cosmetics 
and toiletries, photographic requisites and other leisure goods. This is especially so in 
those pharmacies owned by large multiple companies.
1.2 Development of Patient Medication Records
In its simplest form, a patient medication record can be considered as a record 
containing a patient's details and the details of pharmaceutical products supplied to that 
individual patient. Such a record need contain no more than sufficient information to 
identify the patient, ie. their name and address, and the names of products supplied to 
them. In practice, there is the potential to record more product detail, eg. the form, 
strength and prescribed dose of supplied products, together with information about the 
source of a product, eg supplier and batch number. There is also the scope to record a 
considerable amount of clinical and administrative information about the patient, for 
example, clinical conditions, drug allergies and NHS numbers.
Pharmacists are not, as yet, legally or professionally bound to keep PMRs, despite a 
long-standing tradition of keeping records for various purposes in community 
pharmacy. Under the Medicines Act 1968, pharmacists are required to keep records of 
dispensed private (non-NHS) prescriptions, and under the Misuse of Drugs Act 1971
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and its regulations 1985, pharmacists are required to keep records of the supply of all 
Schedule 2 (CD Register) Controlled Drugs.
1.2.1 Manual Records
Dalglish used one of the first systems recorded.^ He maintained an alphabetical card 
index of patients, recording the name and address of the patient with the name, form 
and strength of medicines dispensed, and the date on which medicines were dispensed. 
He also had the facility within his card-index file to record drug allergies, for example 
to penicillins. He identified the main benefit of his system as being able to label 
dispensed medicines with full directions rather than "as directed". Although he 
considered his system to be very time-consuming; nevertheless he concluded that the 
benefits of his system, through the need for less time spent in contacting doctors, 
outweighed the inconvenience of the time taken to update his records. Dalglish argued 
that the use of PMRs would lead to pharmacists being accepted as "professional men 
and women and not just another high street trader."
Balmford described a system whereby he kept card records for elderly and chronically- 
sick patients.^ He used a colour-coded system to record special circumstances, for 
example: penicillin hypersensitivity. In addition, he described the use of his card 
system to record details about supply of appliances, eg. insulin needle sizes, and elastic 
hosiery particulars. Balmford believed that he increased patient confidence through 
keeping medication records.
O'Hara described the use of "patient medication profiles" in the USA.4 In this paper, 
he outlined the changes taking place in 1976 in community practice in the USA, and 
the changes being implemented in American pharmaceutical education at that time to 
accommodate those changes. In particular, he emphasised that the pharmacist's 
responsibility to the patient extended beyond the accurate filling of prescribed
27
medication orders (i.e. the dispensing of prescriptions), and that clinical components 
were being introduced to undergraduate curricula to prepare students for their future 
role. O'Hara described the intent of the patient medication profile as to consolidate 
pertinent facts relating to a patient's drug therapy, eg. name, age, sex, weight, height, 
allergies or drug sensitivities and all chronic disease conditions, plus all details of 
prescription and OTC (over-the-counter) medications being used.
The economics of maintaining PMRs was first assessed in 1977 by workers at the 
School of Pharmacy, University of Bradford. ^  They estimated that keeping a simple 
card system would take 18 hours per week: this agreed with Dalglish's estimate of the 
effect on time costs.^ They concluded that the maintenance PMRs could not be 
justified on commercial grounds alone.
Shulman and Shulman described a two-card system that could be used to monitor 
patient medication and provide a method of recording data that all health-care 
professions could access.^ Every patient was given a card containing his name and 
address which could be presented to all health professionals. The card was presented 
at pharmacies, so that details of medicines dispensed or purchased could be written on 
the card. A second card was held at Shulman's pharmacy which contained the above 
information, along with the name of the patient's general practitioner and details of any 
chronic conditions from which the patient was suffering. Any change in the strength or 
dose of long term treatment was indicated by a colour change on the card. In their 
paper they emphasised the benefits to patients of PMR use, including the ability to 
detect prescription errors including non-intentional changes of dose. Two important 
issues were raised by the authors of this important paper. They described how their 
use of a PMR system led to an increased time spent in monitoring for potential drug- 
related problems, and in patient counselling. They argued that the cost reimbursement 
of the pharmacist for the increased workload could be met as a result of the reduction 
in iatrogenic disease achieved by PMR use. In this context, the point was made that
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future negotiations on the payment for pharmaceutical services should address the 
issue of funding the pharmacist's altered role. The second issue addressed in the paper 
was that of the professional relationship between doctor and pharmacist. The authors 
described a reluctance on the part of some doctors to alter prescriptions on the 
pharmacist's advice, thus putting the patient at risk. These doctors could not accept 
that pharmacists were acting professionally, in the patient's interest, rather than for 
their own commercial advantage.
Shulman and Shulman went on to show that their two card system enabled them to 
detect potential drug interactions between medicines they dispensed for their patients 
and those which were obtained from other sources, eg. hospital pharmacies, describing 
the potential benefits to the population of fewer major adverse drug reactions.?
1.2.2 The Computerisation of Community Pharmacy
Computerisation of pharmacy in the USA took place about five years earlier than in the 
UK. In 1974, Karig et al described the exposure of pharmacy undergraduate students 
to a computerised PMR system as part of their clinical pharmacy course.** The late 
1970's saw the dawn of computerisation of community pharmacy in the UK. Unichem 
developed a keypad system in 1978, called Prosper (Prosper Rebate Orientation, Sales 
Planning and Evaluation Routine) to simplify ordering and stock control.^ This was 
followed in 1979 by the Pride system (Prescription Records In Dispensing 
Environment), which enabled pharmacists to produce labels and maintain a record of 
dispensed medication. 10 Pride was the first available patient medication record system 
using a computer to store records. Also, at this time Winters described the use of 
pharmacy computers in "drug surveillance" in Holland 11
In the UK, concerns about the impact of computers on the future of the profession 
were expressed at this time. For example, a report of a working party set up by the
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Pharmaceutical Society was received by the Society's Council in December 1979.10 
Two controversial issues were raised in the report; these were confidentiality and 
patient registration. The issue of confidentiality was to be fully addressed in 1984 by 
the Data Protection Act 1984,12 whereas the issue of patient registration has not yet 
been resolved. Problems associated with the lack of patient registration in community 
pharmacy have been described by Stevens in a review article on the development of 
PMRs in the U K . 13 The argument was made that without full patient registration, 
pharmacy-maintained PMRs would be at best incomplete, and at worst pointless.
The Pharmaceutical Society working party concluded that PMRs would benefit the 
community pharmacist, by giving him more time to spend with patients, and would 
enhance professionalism by making him better informed. The advantage of using 
computers to reinforce the pharmacist as a source of information on medicines was 
discussed by Teeling-Smith in an address to the College of Pharmacy Practice. 14 He 
argued that pharmacy could be on the verge of a "golden age" underpinned by a 
second pharmacological revolution and the concept of self-care. These would be 
enhanced by professional developments and the use of computers to manage 
information. At the 13th European Symposium on Clinical Pharmacy in 1984 Brian 
Hartley, then the deputy chief pharmacist at the Department of Health forecast that 
community pharmacists would have a computer network enabling them to exchange 
medication data and keep track of Controlled Drug users. 1 5 Also in 1984, Lutz 
predicted that computers would profoundly affect the quality, style and methods of 
health care delivery in the United S ta t e s .  *6 The requirements for pharmacy computer 
systems in the USA were described by McKay. ^  He described these requirements 
under three groups of functions: patient care functions, dispensing computer systems 
functions, and those files required to compose a working database.
The use of computers increased throughout the 1980s. An American study 
demonstrated the time saving advantages in using a computer to produce dispensing
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labels. However, another paper published by Berger at about the same time detailed 
how, in the USA, pharmacy computer systems were not increasing efficiency. ^
A milestone was reached in the UK in January 1984 when it became a requirement to 
have machine-printed labels on dispensed medicines. At this point several labelling 
systems were available from different suppliers using programmable electronic 
typewriters and 8-bit computers as hardware. Most computers used either a cassette 
tape or floppy disks to hold programs and data. Stevens and Crabbe published the 
results of a survey of all pharmacies on the NPA's mailing list (approximately 10 000) 
which showed that as well as for labelling products, 20% of respondents were using a 
computer for drug interaction monitoring and 4.9% of respondents maintained patient 
records.20 However the authors of that paper had a response rate of less than 9% to 
their questionnaire, and the figures published could be a gross over-estimate of the 
clinical use of pharmacy computer systems in the mid 1980s.
In the late 1980s, 8-bit computers including the BBC micro were superseded in 
practice by more powerful 16-bit computers based on the IBM PC. *2 These 
computers had fixed hard disks capable of holding around 40Mb of programs and data, 
that is, approximately 100 times greater capacity than a single floppy disk. Several 
companies marketing PMR systems emerged at this stage and 13 suppliers were listed 
in a review article.21 These companies were: Vestric, Talk Data Computer Systems, 
John Richardson Computers, Image Micro Systems, Park Systems, Channel Business 
Systems, Rombus Computers Ltd, Bracey's Pharmacy, Mike Hadley, Pharmaceutical 
Computer Systems, Graham Tatford, Mawdsley-Brooks and IDC Computer Systems.
The Nuffield inquiry's report Pharmacy: A report to the Nuffield Foundation1 
highlighted the benefits of medication records, particularly electronic ones, in checking 
for drug interactions and monitoring therapy. 22 This role was recognised by the 
Government in the White Paper Promoting Better H ealth^, in which it was proposed
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to introduce an allowance payable to those pharmacies maintaining a substantial 
number of records relating to elderly or confused patients on long term medication. 
Payments commenced to pharmacist contractors for this service in the latter half of
1989. The extent to which these payments have influenced the use of PMR systems by 
pharmacists is described in Chapter 3. More recently the Report of the Joint Working 
Party on the Future Role of Community Pharmacy Services Pharmaceutical Care: The 
Future fo r Community Pharmacy recommended that "all pharmacists should maintain 
patient medication records where they believe it will be of benefit to the patient to do
so. "24
The RPSGB published its guidelines on the use of pharmacy computer systems in 
March 1989. These were grouped under general points, labelling systems and patient 
medication records. The general points included the recommendation of IBM PC 
compatible hardware, with a minimum 32Mb hard disk and a tape streamer backup. 
All data relating to patients were recommended to be password protected to preserve 
confidentiality. Recommendations on labelling systems included the use of British 
National Formulary cautionary labels, and the highlighting of the two highest levels of 
interaction on the Stockley system. 25 A unique number should be given to each 
prescription to help produce an audit trail for use, for example, in a case of litigation. 
Several recommendations were made on the maintenance of computerised patient 
records. These included the data to be recorded in the record, which were: name, 
address including postcode, National Health Service number, sex, date of birth, 
telephone number, name of GP, drug sensitivities, allergies, chronic conditions and 
medicines purchased. A hard copy of records was required to be made available to 
patients to comply with the Data Protection Act 1984. It was also recommended that 
archived records were kept for 10 years for the purposes of the Consumer Protection 
Act 1987.
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Boakes et al published a landmark paper in 1990.26 That paper described the general 
state of the use of computer systems at the end of the 1980's. They found that 
computers were used in 95% of the pharmacies taking part in their survey. 
Computerised drug interaction monitoring was used by 30% of the respondents, and 
PMRs by 25%. However, PMR use was favoured by 82% of those responding.
1.2.3 Drug Interaction Monitoring Software
One major feature of computerised PMR systems is that they can monitor for drug 
interactions between drugs dispensed over a variable period of time. Strickland-Hodge 
summarised the criteria essential for an effective drug interaction system. 27 These 
included that, if required, the searching period for interactions should extend to two 
years; and that the drug interaction information should be obtained from a reputable 
source and be regularly updated in electronic form. Systems should be able to 
recognise both generic and proprietary drug names and identify individual drug 
constituents within compound preparations. The clinical use of drug interaction 
software has been researched and reported by Stevens and Crabbe.28 in that paper 
they described the nature of all potential drug interactions detected by a PMR system 
with drug interaction monitoring software over a one-month period. In particular 
Stevens and Crabbe highlighted drug interactions with potentially very serious 
consequences for patients.
1.2.4 Examples of Computer Systems Available at the End of the 1980's
Strickland-Hodge reviewed five examples of PMR s y s te m s .  29 These represented the 
three systems in greatest use, along with two innovative systems with novel features. 
A brief description of these five systems is given below.
The John Richardson Computers system at that time used a Sanyo IBM-compatible 
computer. The system could hold 32 000 patient records and 200 000 individual
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prescriptions. The system recorded patients' names, addresses and telephone numbers; 
their age, sex and drug allergies; and their doctor's name. A drug interaction facility 
was incorporated, developed in conjunction with Dr Ivan Stockley. The system 
offered an ordering facility from a choice of wholesalers.
Park Systems had an IBM-compatible based system which featured a drug interaction 
program, providing on-screen details about the nature of the interaction. This system 
recorded patient allergies, sensitivities and conditions. In some conditions, this 
information interacted with the drug database to warn the pharmacist about 
contraindicated drugs, for example displaying a warning if the pharmacist dispensed 
non-cardioselective P-blockers for a patient previously recorded as asthmatic.
AAH offered a system that was IBM-compatible, and had a patient record database, 
the size of which was limited only by hard disk capacity. This system featured a tape 
streamer for data backup. The program had a drug interaction monitoring facility and 
the Philex (Pharmaceutical Industry Lexicon) product database.^
Hadley Hutt Computing Ltd. produced an innovative computer system. A novel 
feature of the program was that it could produce a patient information leaflet on a 
second printer at the time of label production. Some advantages of this form of 
information provision have been described by Hadley.^ * The role of the provision of 
written information to improve compliance has been reviewed in detail by L e y .  32 The 
use of patient information leaflets, in conjunction with PMRs, is discussed in Chapter 
5.
Channel Business Systems produced a system called Charm. This system had a unique 
feature to help the pharmacist in responding to symptoms. It had distinct areas of 
patient counselling with comprehensive diagnostic and interaction features.
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Other systems were noted by Strickland-Hodge,29 including a selection of those 
available from pharmacy wholesalers. These included Macarthys Choice, Mawdsley- 
Brooks and Graham Tatford.
1.3 Patients* Views on Medication Records
A number of papers have been published to support the view that community 
pharmacists’ use of PMRs appear to have been well received by p a t i e n t s  .33,34 ^  js 
less clear whether the use of PMRs increases patient loyalty to a particular pharmacy. 
Davis and Rubinstein reported that they could not conclude whether or not PMRs 
increased patient loyalty, or increased patient-pharmacist interaction, although patients 
accepted PMR use.33 Di Ponio et al disagreed with Davis and Rubinstein’s conclusion 
on patient lo y a l ty .  35 More recently, in a larger survey than used in Davis and 
Rubinstein’s previous work, Britten et al concluded that a large majority of customers 
in four community pharmacies in London were in favour of computerised record 
keeping.34 Patients endorsed specified advantages of the use of PMRs, including 
prescription checking and monitoring for drug interactions. Britten et al also found 
that in the pharmacies concerned, there were large numbers of patients almost always 
taking their prescriptions to those pharmacies, and that it would be possible to maintain 
complete medication records.34
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1.4 Possible Methods of Data Transfer Within Primary Healthcare
Traditionally, information has passed between health care professionals by paper-based 
means, eg. prescription forms and consultants' letters to GPs, or by the spoken word, 
eg. telephone conversations. Two other possible methods of information flow within 
the NHS are described below: the use of "smart cards" and networked computing.
1.4.1 Smart Cards
The computer systems described in Section 1.2.4 store patients' records on the PC's 
hard disk. An alternative approach to storing records in a pharmacy or general medical 
practice computer system, is to give each patient a device, referred to as a "smart 
card", containing all their personal medical information. Credit-card sized smart cards 
were derived from cards developed for banking systems in the 1970s.36 The first 
smart cards were produced in France by the Bull Company. Bull produced a card that 
contained a memory chip and m i c r o p r o c e s s o r . ^  The first generation of cards 
contained a programmable read-only memory (PROM) chip. These cards could only 
be programmed once and data subsequently burnt on to the card could not be 
overwritten. An alternative method of production is to use electronically erasable 
read-only memory (EEPROM) cards. Cost and limited memory size have hindered the 
development of EEPROM cards. The GEC Company has developed an intelligent 
contactless (ic) card. This type of card has advantages in that it lacks surface contacts, 
unlike the other types of cards described above. Power and data transfer are achieved 
by an inductive radio frequency.
Using the concept of the smart card, patient data becomes the responsibility of the 
patient himself, who takes the card between health care providers. The providers of 
health care have security access to different parts of the record. For example, a 
pharmacist might be able to access data about medication history and drug allergies,
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whereas general practitioners would be able to access the whole of a patient's medical 
history.
The first trial of smart cards in the NHS was in Rhydyfelin, South Wales, in 1986- 
1987.38 This trial used a Sinclair QL microcomputer and PROM cards produced by 
the MIPS Company of Japan. It showed that the card system worked, although with a 
card failure rate of 4.6%. The trial was further hindered by patients not carrying their 
card to the surgery or pharmacy. This trial was continued for a further two years, and 
in a second report on the trial the authors concluded that the interchange of data 
between pharmacies and GP surgeries was feasible on patient-retained computer- 
accessible devices. 3 9
A more comprehensive trial of smart cards has been completed in Exmouth, Devon.40 
This second UK trial involved the use of 8500 patient Care cards. In the Exmouth 
trial, the concept of a portable patient record was expanded to include clinical data. 
Two general medical practices, eight community pharmacies, one dental practice and 
two hospitals participated in the Exmouth trial. Several problems became apparent 
including access times of 50-60 seconds for large records, sparse records being placed 
on the cards at surgeries and problems of poor patient education. In the published 
report on the project findings, no conclusive advantages in patient care could be 
demonstrated by the use of the Care card.41 A third UK trial of smart cards is 
currently being undertaken in Scotland.41
A new type of computer mass storage is the PCMCIA card (Personal Computer 
Memory Card International Association). This could have potential uses in medical 
applications, including the transfer of patient-held data between providers of health 
care.43
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1.4.2 NHS Computer Networking
Stevens highlighted the possible advantages of the smart card, including the use of 
cards to replace paper prescriptions.^? However, smart cards have not yet proved to 
be effective. Evidence presented in the literature leads one to the conclusion that smart 
cards do not have a positive future in the NHS due to their inherent high cost, 
unproved technology and patient non-compliance. In addition valuable research data 
could be lost if smart cards were to become the only means of storing patient records. 
To maintain a research database of patient records, patient data would need to be 
stored on a computer system elsewhere in the health care system; therefore it could be 
argued that there is little need for smart cards, due to duplicity.
Electronic data interchange is an alternative way forward for the health service. 
Essentially, within this approach, all providers and managers of health care delivery 
would use computers that are linked to each other, either directly on a network or 
using a modem over telephone lines. For example, a general practice surgery could 
send prescriptions to a pharmacy by electronic mail. The pharmacy could, in return, 
update patient records to and from the surgery computer. The Prescription Pricing 
Authority (PPA) could pay pharmacists for medicines as soon as they are dispensed, 
and then feed data about dispensed medicines back to the surgery. Dentists, 
optometrists and hospitals could all be linked into this network. While programming 
and co-ordinating the network would be a formidable task, most links in the above 
network are already computerised. A possible model for electronic data interchange is 
shown in Figure 1.1.
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Figure 1.1: Possible model for electronic data interchange within the NHS.
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Plans for a project to make community pharmacists' dispensary computers compatible 
with those used in doctors' surgeries were announced by the Department of Health in 
November 1991.44 while this project was never implemented, a project to 
"benchmark" test a number of community pharmacy computer systems was announced 
by the RPSGB in January 1993. The purpose of this latter project was to be able to 
make meaningful comparisons between those systems that were available for use by 
community pharmacists.
1.5 Clinical C oding
Clinical coding can be considered as a means by which details of patients and their 
clinical conditions can be encoded, thus facilitating automated processing of the coded 
patient data. At the time of writing, there is no standard form of coding pharmacy-held 
patient records. A number of clinical coding systems are used across the world.45 
These include the World Health Organisation's International Classification of Diseases 
(ICD-9) and the International Classification of Primary Care (ICPC), developed by the 
World Organisation of National Colleges, Academies, and Academic Associations of 
General Practitioners / Family Physicians (WONCA).46
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In the UK, however, the medical profession has started to move towards a 
standardised system 47 The Secretary of State for Health has acquired the Read 
clinical classification, for the purpose of its implementation throughout the National 
Health Service. This is the most comprehensive medical coding system in the world, 
containing over 250 000 codes. The classification provides codes for the following: 
diseases; history and symptoms; examination findings and signs; preventative, 
operative, therapeutic, and administrative procedures; drugs and appliances; and 
occupations and social information. The Read coding system was described by its 
originator, Dr James Read, as a system for coding the whole of medicine.48 Read 
summarised the clinical uses of his system as including: structured medical records and 
notes; call and recall systems for preventive medical care; expert systems and clinical 
protocols for diagnosis, treatment and follow-up care of patients; self audit, peer audit 
and policy planning; administration, including accountancy and financial control. He 
described the statistical applications of his coding system as: clinical trials and research; 
health service management and planning; health and sickness surveys and 
epidemiology; pharmaceutical and actuarial market research; and international 
comparisons.
The use of the Read clinical classification (Read codes) will help in clinical care by 
facilitating the recording and retrieval of information as part of a medical record, 
enabling statistical analysis of data for planning and research purposes, and beciming a 
key element in the electronic transfer of information from one computer to another.
The benefits of the Read clinical classification for the medical profession and 
pharmacists have been documented.49 Pringle recognised that having access to 
standardised patient information would benefit patients, those in health care provision, 
and to those managing the internal market of the NHS. It is therefore important that 
those who provide computer systems for pharmacists should be fully aware of
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developments in medical computing to ensure that the pharmacy profession is not left 
behind as these developments are implemented in the NHS.
1.6 Aims and Objectives of Project
The aims of this project are to assess the impact of the use of PMRs on the practice of 
community pharmacy in England and Wales; to determine the types and uses of PMR 
systems in use; and to evaluate the clinical benefits to patients of PMR use.
The first objectives of the project are to determine the extent to which PMRs are used; 
to determine the types of system in use and the uses to which PMR systems are put; 
and to evaluate the clinical benefits to patients of pharmacists' use of PMR systems. A 
survey of 744 community pharmacies has been undertaken to achieve these objectives. 
This survey is presented in Chapter 2 of the thesis.
Patient information leaflets are provided for patients by some PMR systems. The 
objectives of the survey described in Chapter 5 are to determine the use of patient 
information leaflets in community pharmacy, and to examine the effect that the use of 
patient information leaflets has on compliance.
PMR systems are also used in the United States of America (USA); the objective of the 
study outlined in Chapter 6 is to compare and contrast PMR systems used in the UK 
with those used in the USA.
One of the principle objectives of the project is to demonstrate that the use of PMRs by 
a community pharmacist, through his making a clinical intervention, can reduce the risk 
to a patient of adverse effect from a drug interaction, the supply of a contraindicated 
medication, or an inappropriate dose. The use of PMR systems in safeguarding 
patients is described in Chapter 7.
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Patients views on pharmacists' use of PMR have been solicited, and published.34 
However, preservers' opinions have not been published in the literature. An objective 
of this research project is to determine general practitioners' (GPs) views on the 
retention of patients' medication records in primary health care, with particular 
reference to community pharmacy-held PMRs. A survey of all GPs in contract with 
Avon and Devon FHSAs is presented in Chapter 9.
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2 The Extent to Which PMRs are Used in Community Pharmacy
2.1 Data Gathering and Survey Methods
Research in the traditional pharmaceutical sciences has used laboratory experiments 
that directly measure certain variables to produce data which can be measured on an 
interval or ratio scale of measurement.^ This approach is inappropriate for many 
studies in pharmacy practice which require the application of survey methods 
developed by social scientists.
Social scientists use a number of basic techniques to gather data to prove or disprove a 
hypothesis. One method is to examine data retrospectively using documented 
literature sources; an example of this method is a longitudinal time study of population 
census data. Another method involves measuring and assessing observations in a 
normal or controlled environment; a research worker examining the sex of patients 
using a pharmacy could use this method by observing the number of male and female 
patients walking through the front door of the pharmacy.
Social scientists often refer to the use of data gathering in surveys by interview or 
questionnaire as the "experimental method. "51 Research may be carried out to 
measure a variable and/or derive some statistical inferences from the variable(s). The 
latter requiring the researcher to state the hypotheses he wishes to test, and develop a 
plan of how to gather the data needed to prove or disprove the hypotheses.
Factors which must be considered in social science research include the costs in terms 
of time and finance, the problems of sampling, non-respondents and the limits of data 
measurement. Most research projects are undertaken within financial limits. 
Experimental methods must be used which can be accommodated within such limits. 
For example, if a researcher needs to interview 10 000 customers to determine attitude 
to a product, but funds are only available to interview 5000 customers, he must accept 
the use of a smaller sample or use a less expensive method of gathering data.
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Generally it is not possible to gather data from all the individuals making up a total 
population. Researchers use the method of sampling to obtain a smaller data set which 
is representative of the total population. Two sampling methods are commonly used. 
These are random sampling and stratified random sampling. Random sampling draws 
individual units from the total population at random, and assumes that all units in the 
total population have an equal probability of being drawn. Stratified random sampling 
is a refinement of random sampling which enables the use of smaller sample sizes. 
This method involves random sampling from defined sub-populations taken from the 
total population. Determining the minimum sample size is a complex process, but 
sample size tables can be produced to give approximate requirements. 52
A major problem in survey research is non-response. If 40% of a sample respond to a 
survey and 60% do not, then one must question whether the results from the 40% are 
representative of the whole sample. There are no absolute guidelines to resolve this 
problem, but increasing sample size and response rate increase the validity of results. 
Such bias must be acknowledged, and, where possible, accounted for statistically.
In order to quantify and assess the benefits of PMRs, held in pharmacies, to the 
profession, patients and to the NHS, the usage of PMRs needed to be quantified. 
Therefore, it was decided that the first stage of the research into the use of PMRs 
would be to conduct a detailed examination of how PMRs are currently used in 
England and Wales.
The survey method chosen to obtain the largest possible amount of data at the lowest 
possible cost was postal q u e s t i o n n a i r e .  51.52 other possible research methods were 
telephone survey and on-site data collection. Telephone methods are time-consuming 
and expensive and can produce high refusal rates. Although face-to-face interviews 
can generate high quality qualitative data, it was considered that visiting pharmacies to
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conduct such interviews on a national basis was not practicable due to cost and time 
limitations.
The purpose of the questionnaire was: to determine current attitudes towards PMRs 
and patient information leaflets; to quantify the number of pharmacies using PMRs; to 
identify the types and suppliers of PMRs used; and to elucidate which patient and 
product details were being recorded. Factors which may affect PMR use were 
recorded: these included the ownership, location and client base of a pharmacy; the 
age, sex, and status of the pharmacist in charge of the pharmacy; the numbers of 
prescriptions dispensed; the numbers of patients held in the PMR system; and the 
location of PMR computer terminals.
Statistical methods used in the research project are summarised in Appendix 1.
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2.2 Method 
2.2.1 Equipment and Materials Used
Questionnaire forms and other project documents were produced using Microsoft 
Word for Windows V l.l on a Viglen Genie 3SX IBM-compatible computer and a 
Hewlett-Packard Deskjet 500 printer. The program SP3S/PC+ V3.1 (formerly known 
as Statistical Package fo r Social Sciences)53 was used to record results from returned 
questionnaires and for statistical analysis of the data. A Freepost licence agreement 
was signed with the Post Office for the purpose of processing of returned 
questionnaires.
2.2.2 Design of Questionnaire
The survey questionnaire (Appendix 2, page 310) was developed by listing factors that 
could affect a pharmacist's use of PMRs. These were grouped into details about the 
pharmacy; the pharmacist working in that pharmacy; his attitude towards PMRs; use of 
PMRs; details stored in PMRs about patients; details stored in PMRs about products; 
and attitudes towards patient information leaflets.
The questionnaire was divided into eight sections as follows:
Section A: The pharmacy 
Section B: The pharmacist
Section C: Attitudes towards patient medication records
Section D: Use of PMR systems
Section £: Details of PMRs relating to patients
Section F: Details of PMRs relating to products
Section G: Patient information leaflets
Section H: Further research
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The first set of questions (Section A) included details about whether the pharmacy was 
independent, a small multiple (2-10 branches) or a large multiple (>10 branches). 
Pharmacy location was characterised by asking the respondent to describe the site of 
their pharmacy and the client base. The site covered options for city centre, suburban, 
village/small town centre, health centre, hospital and in-store pharmacies. There are 
several methods for classifying social class or socio-economic group. 54 From the 
author's management experience in community pharmacy, it was felt that pharmacists 
would be best able to classify their patients by the Market Research socio-economic 
classification.^ An approximation of the level of activity was sought by requesting 
the number of prescriptions dispensed each week.
The next set of questions (Section B) requested details about the pharmacist in charge 
of the pharmacy. Information was sought with regard to the pharmacist's status as 
owner/manager, sex, year of registration, and the number of pharmacists practising in 
the pharmacy at any one time. It was thought that some of these variables about 
pharmacists and the pharmacy in which they practised could affect attitudes to and use 
of PMR systems.
Leading into the use of PMR systems (Section C), questions were asked about the 
respondent's attitudes to the effects of PMRs on the community pharmacist's clinical 
role and professional status, and possible benefits of time and finance. Respondents 
were asked whether they used a PMR system (Section D), and if so, whether manual, 
computerised or smart card. If not, they were asked about their possible intention to 
set up PMRs. The date of installing the PMR system being used was requested along 
with the system supplier, listing those systems reviewed by Strickland-Hodge.^^ The 
number of patient records stored in the system was requested in order to analyse 
whether this increases with time, or is affected by other factors.
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Boots The Chemists and other multiple pharmacy groups have undertaken pilot studies 
in which computer equipment has been placed at the patient-pharmacist interface. 
Questions were asked as to where the PMR computer system was located and who 
normally entered patient details. This was to facilitate the examination of whether 
having the pharmacist and computer equipment away from the traditional dispensing 
area had an effect on the nature of data recorded.
The facility to record details about patients varies between PMR systems. Users of 
manual systems can record any information they wish, although such data is not 
"intelligent" in that it cannot interact automatically with data about prescribed 
medicines. Questions were then devised such that respondents were asked about the 
recording of a patient's name and title, address, telephone number, official reference 
numbers, and previous medication history (Section E).
A question was asked to determine whether pharmacists recorded information about 
the patient's race or ethnic origin, since the metabolism of some drugs is race- 
d e p e n d e n t , ^ ^  j t  was not anticipated that many pharmacists would be recording this 
information.
It was anticipated that most pharmacists maintaining PMRs would keep records about 
the patient's general practitioner, and possibly dentist. Questions were asked about the 
recording of this information and also family planning clinics, hospital outpatient 
departments and alternative practitioners.
Many patients experience allergies or sensitivities to drugs or pharmaceutical 
excipients. Respondents were requested to state whether they recorded adverse 
reactions to colourings, preservatives and flavourings, salicylates, penicillin and non­
steroidal anti- inflammatory drugs (NSAIDs). Several other drugs and allergens may 
provoke an adverse reaction, therefore respondents were also given an opportunity to
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list any other recorded allergens. Other information requested in this section of the 
questionnaire covered prescription charge exemption and a patient's inability to use 
child resistant closures.
Some suppliers of PMR systems provide pharmacists with an on-screen prompt of 
patient conditions which may be recorded. Park Systems' PMR program provided a 
list of 26 conditions which may be incorporated into the patient record. This was the 
most comprehensive list in the PMR systems available at the time of developing the 
questionnaire (Autumn 1990) and formed the basis for a list of conditions in the 
questionnaire. The list was edited and other conditions such as pregnancy and breast­
feeding were included in a revised list of 24 conditions about which respondents were 
asked to indicate whether or not they were referenced, as appropriate in patients' 
records.
Patients may cease to use a community pharmacy's service through death or relocation. 
Questions were therefore included to determine how pharmacists managed non-current 
records. Of particular interest was whether pharmacies passed information to patients 
or to another pharmacy in the event of a patient relocating.
The Data Protection Act 1984 requires confidentiality of information held on 
computer files and attributes to individuals the right to see their personal records. 58 
Questions were placed in the questionnaire to enquire whether patients are reminded 
about their rights to access their records, and whether patients acted upon these rights.
The Channel pharmacy computer system (Channel Business Systems Ltd.) offers 
pharmacists the option of recording patient lifestyle details in the PMR. Respondents 
were asked to state whether occupation, smoking habits, alcohol consumption and 
height and weight details were recorded in the PMR. This was of interest to the study 
as smoking and patient weight may affect the pharmacokinetic profile of some
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drugs. 56 Alcohol can potentiate the effects of a number of drugs including 
phenothiazines and barbiturates. 59
Some pharmacies offer diagnostic testing as part of the community pharmacist's 
"extended role." These tests include blood pressure, serum cholesterol level and 
pregnancy testing. Respondents were thus asked to indicate if the results of such 
services were incorporated into the PMR. It was not anticipated that many 
pharmacists would include diagnostic test results. However, the author believes that 
the handling of diagnostic data could be a future development in PMR use. For 
example, a positive pregnancy test result for a female patient could automatically 
interact with the computer drug file to highlight a list of medicines that are 
contraindicated in pregnancy.
A series of questions was devised to determine how much detail was recorded about 
the products that were dispensed in pharmacies (Section F). It was anticipated that the 
vast majority of pharmacists would include full details about the name, form, quantity, 
strength and dose of dispensed medicines. However, it was felt that fewer pharmacists 
would include details about the source of dispensed medicines, including 
manufacturers, wholesalers, product licence numbers and batch numbers. Therefore, 
respondents were asked to indicate whether such details were recorded. Similar 
questions were applied to the recording of details about surgical dressings and 
appliances.
Non-prescription medicines may be contraindicated in certain disease states, for 
example hyoscine in closed-angle glaucoma, or may interact with prescribed medicines, 
for example pseudoephedrine with monoamine-oxidase inhibitors. Respondents 
therefore were asked to give an indication of how often they recorded details about 
non-prescription medicines.
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General practitioners are currently able to prescribe drugs in whatever quantities they 
please. For example, many will prescribe in multiples of 28 or 30 for patients on repeat 
medication. Others will prescribe in quantities of 100 or some other number. The 
availability of calendar and original packs to the pharmacist may also influence the 
amount of medication dispensed to patients, since pharmacists will normally dispense 
the quantity closest to the nearest full calendar pack or sub-pack. 60 it is possible that 
patients could consistently receive more of one medicine than of another, giving 
potential for an excessive supply of some drugs. Pharmacists dispensing regular repeat 
medication for patients are in a position to monitor for such extravagant prescribing; 
respondents were therefore asked if they ever acted to prevent such excess medication 
from being dispensed. A research project has being undertaken to investigate fully this 
aspect of the community pharmacist's role in reducing unnecessary drug expenditure.^!
Computerised PMR systems record drugs dispensed and the relevant directions to the 
patient as part of the labelling process. Many prescriptions are presented either with 
no directions, or "as directed" or "as before". In such circumstances pharmacists have 
the option of labelling medicines with directions previously recorded. Respondents 
were asked how they reacted to such prescriptions. It was anticipated that there could 
be significant variation between PMR users and non-PMR users.
Finally, a series of questions was included to assess pharmacists' attitudes to the use of 
computer-generated patient information leaflets.
The questionnaire forms were designed with multiple choice responses to all questions. 
This enabled all responses to be coded prior to analysis. 62 a  codebook was produced 
enabling coders not familiar with the survey to code responses from returned 
questionnaires. Each response was coded with a possible number within the range 1-9. 
The coded responses were then entered into the SPSS/PC+ statistics program.
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Some questions included a space for pharmacists to comment upon their answers, 
either in order to clarify their responses, or in circumstances where none of the 
provided multiple choice answers applied. A page was provided at the end of the 
questionnaire for comments about the survey and use of PMR systems. Each 
questionnaire form was coded with an identity number enabling a follow up 
questionnaire to be sent if no reply was received after a given period.
All questionnaires were addressed to the pharmacist in charge of each pharmacy. Each 
questionnaire was accompanied by a covering letter (Appendix 2, page 310) explaining 
the purpose of the study, and assuring pharmacists of the confidentiality of data 
collected.
2.2.3 Bath Pilot Study
Questionnaires were posted to 27 pharmacies in the Bath area at the end of December
1990. Responses were obtained from 17 pharmacists (63.0% response). This group 
consisted mainly of pharmacies owned by individual proprietors that were not 
therefore representative of the general population. However the returned forms were 
used to refine the questionnaire before being used nationally.
Questions in the pilot questionnaire about quantity and price of surgical appliances 
were considered superfluous and were deleted. The question about the recording of 
the family practitioner number of the patient's GP was replaced by asking about the 
recording of the patient's computer reference number used by doctors' surgeries. This 
was considered to be of more use with regard to cross-referencing pharmacy records 
with those held by GPs. The series of questions about the recording of patient 
conditions was followed by a space for the coder to sum the number of conditions 
recorded; this produced a number measured on the interval scale, enabling the use of 
more powerful parametric statistical procedures on subsequent results.
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2.2.4 The National Survey
Determining the sample size for random sampling is a complex process, requiring 
knowledge of the population being measured and anticipating response rates. ^ 1 Since 
several parameters relating to the use of PMRs were being measured and since 
resources were limited within the research budget, a sample size of 1000 pharmacies 
was considered adequate. This represented approximately 1 in 11 pharmacies in the 
United Kingdom, and as such was considered sufficiently large to see evidence of 
innovative practice where a low response was anticipated, for example in the recording 
of diagnostic test results.
The assumption was made that regional variability in the use of PMRs would not be 
considerable. The Royal Pharmaceutical Society of Great Britain was requested to 
produce a random sample of 1000 pharmacies from their computer records. A list was 
produced comprising 928 pharmacies in England and 72 in Wales.
The revised questionnaire was sent to these 1000 pharmacies in March 1991. At the 
same time, the questionnaire was sent to 124 pharmacies in England and Wales using 
the Hadley Hutt PILLS system, and which had not been included in the Bath pilot 
study or the random sample. Follow up questionnaires were sent to those pharmacies 
that had not replied to the initial questionnaire after six weeks.
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2.3 Results
A total of 538 questionnaires (53.8%) was returned six weeks after issue. A further 
206 questionnaires were returned after posting a second questionnaire and reminder to 
the non-respondents. This represented a total response of 74.4%. Questionnaires 
were received from 83 P/LLS'-users (66.9% response).
2.3.1 Pharmacy and Pharmacist Data
Frequency data from Section A of the questionnaire are shown in Tables 2.1-2.5. 
Results are shown side by side for returned questionnaires from the national survey 
and the PILLS-user sample. These figures represent details about the pharmacies in 
the survey.
Table 2.1: Regional location of pharmacies in the national survey and PILLS-user 
survey (April 1991).______________________________________________________
National survey PILLS-users
Wales 61 (8.2%) 5 (6.0%)
London and Home Counties 97 13.1%) 20 (24.1%)
South East 121 (16.3%) 4 (4.8%)
South West 58 (7.8%) 10 (12.0%)
North East & Yorkshire 118(15.9%) 6 (7.2%)
Midlands 146 (19.7%) 27 (32.5%)
Northwest 116(15.7%) 11 (13.3%)
East Anglia 24 (3.2%) 0 (0.0%)
741 (100%) 83 (100%)
Table 2.2: Ownership of pharmacies in the national survey and PILLS-user survey 
(April 1991)._____________________________________________________________
National survey PILLS-users
Independent 365 (49.5%) 57 (68.7%)
Small multiple (2-10 branches) 155 (21.0%) 22 (26.5%)
Large multiple (>10 branches) 217 f29.4%^ 4 (A.8%)
737 (100%) 83 (100%)
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Table 2.3: Location of pharmacies in the national survey and PILLS-user survey 
(April 1991).___________________________________________________________
National survey PILLS-u sers
City centre 56 (7.6%) 5 (6.0%)
Suburban 329 (44.8%) 45 (54.2%)
Village/small town 296 (40.3%) 27 (32.5%)
Health centre 22 (3.0%) 4 (4.8%)
In-store 17 (2.3%) 1 (1.2%)
Other pharmacies 15 (2.0%) 1 (1.2%)
734 (100%) 83 (100%)
Table 2.4: Classification of patients' socio-economic group in the national survey
and PILLS-user survey (April 1991).
National survey PILLS-users
AB 88 (12.0%) 16 (19.3%)
C1 27 (3.7%) 3 (3.6%)
C2 46 (6.3%) 5 (6.0%)
DE 294 (40.1%) 24 (28.9%)
Mixture, unable to classify 279 (38.0%) 35 (42.2%)
734 (100%) 83 (100%)
Table 2.5: Average number of prescription items per week dispensed in pharmacies 
in the national survey and PILLS-user survey (April 1991)._______________________
National survey PILLS-users
0-199 18 (2.5%) 1 (1.2%)
200-399 89 (12.6%) 4 (4.9%)
400-599 187 (26.4%) 20 (24.7%)
600-799 148 (20.9%) 21 (25.9%)
800-999 83 (11.7%) 9(11.1%)
1000-1199 61 (8.6%) 11 (13.6%)
1200-1399 45 (6.3%) 7 (8.6%)
1400+ 78 (11.0%) 8 (9.9%)
709 (100%) 81 (100%)
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Table 2.6: Status of pharmacist in charge of pharmacy in national survey and PTLLS* 
users survey (April 1991).___________________________________________________
National survey PILLS- users
Proprietor 262 (35.7%) 44 (53.7%)
Partner 59 (8.0%) 7 (8.5%)
Superintendent 64 (8.7%) 7 (8.5%)
Manager 290 (39.5%) 22 (26.8%)
Locum 23 (3.1%) 0
Other 36 (4.9%1 2 (2.4%)
734 (100%) 82 (100%)
Table 2.7: Sex of pharmacist in charge of pharmacy in the national survey and 
PILLS-user survey (April 1991)._________________________________________
National survey PILLS-users
Male 518(72.1%) 64 (78.0%)
Female 200 (27.9%) 18 (22.0%)
718 (100%) 82 (100%)
Table 2.8: Year of registration of pharmacist in charge of pharmacy in the national 
survey and PILLS-user survey (April 1991).__________________________________
National survey PILLS-users
1986-1990 123 (16.9%) 9(11.0%)
1981-1985 124 (17.1%) 19 (23.2%)
1976-1980 112(15.4%) 11 (13.4%)
1971-1975 79 (10.9%) 8 (9.8%)
1966-1970 86 (11.8%) 12 (14.6%)
1961-1965 76 (10.5%) 15 (18.3%)
1956-1960 66 (9.1%) 6 (7.3%)
1955 or earlier 61 (8.4%1 2 (2.4%^
727 (100%) 82 (100%)
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Table 2.9: Number of full-time equivalent pharmacists working at any one time in 
national and PILLS-user survey pharmacies (April 1991)._____________________
National survey PILLS-users
1 608 (82.9%) 65 (79.3%)
1.5 66 (9.0%) 11 (13.4%)
2 42 (5.7%) 5 (6.1%)
2.5 7 (1.0%) 0
3 8(1.1%) 1 (1.2%)
More than 3 2.10.3%) 0
733 (100%) 82 (100%)
Tables 2.6-2.9 show the frequency data from Section B of the questionnaire relating to 
the pharmacist(s) working in the pharmacy.
In Section C of the questionnaire, pharmacists were asked about their agreement with a 
series of five statements about PMRs. Their responses are given in Tables 2.10-2.11. 
Table 2.10 shows the data from the national survey and Table 2.11 the data from the 
PILLS-user survey.
Factors which may have influenced a pharmacist's agreement with the statements about 
PMRs were examined by cross-tabulating the results from the national survey in Table 
2.10 with all the responses from Tables 2.1-2.9. The Kruskal-Wallis one-way analysis 
of v a r i a n c e ^  >64 was applied to the cross-tabulated responses to determine the 
significance of these influences.
Recently-qualified pharmacists were more positive about the use of PMRs in their 
response to all the statements. The pharmacist's year of registration had a significant 
effect on responses to the following three statements:
The use o f PMRs enables the community pharmacist to fu lfil a more clinical 
role (#=16.24, corrected forties, df=28, p<0.05).
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The use o f PMRs wastes pharmacist time (H -16.27, corrected for ties, df=28, 
p<0.05).
On balance, PMRs give a financial benefit to the pharmacist (H= 16.88, 
corrected for ties, df=28, p<0.05).
In each case younger pharmacists viewed the use of PMRs more positively than their 
less recently registered colleagues.







The use of PMRs 
enables the 
community pharmacist 
to fulfil a more clinical 
role
26.7 55.7 14.0 2.2 1.4 100%
(n=727)
The use of PMRs 
enhances the 
professional status of 
the pharmacist
27.1 52.7 15.9 3.3 1.0 100%
(n=728)
The use of PMRs 
wastes pharmacist 
time
1.0 6.4 12.5 44.2 36.0 100%
(n=720)
The use of PMRs 
saves ancillary staff 
time
7.5 34.3 34.7 20.6 2.9 100%
(n=720)
On balance, PMRs 
give a financial benefit 
to the pharmacist
4.9 23.8 43.1 21.4 6.9 100%
(n=720)
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Pharmacists from large multiples were more in agreement with the statement that 
PMRs provided financial benefits than those from small multiples or independents 
(//== 12.14, corrected for ties, df=8, p<0.01). No other significant influences were 
found.
Table 2.11: P/LLS-users" agreement with statements about PMRs.________
Strongly Agree Feel Disagree Strongly 
agree neutral disagree
The use of PMRs 48.8 42.7 8.5 0.0 0.0
enables the 
community 




The use of PMRs 
enhances the 
professional status of 
the pharmacist
51.2 40.2 7.3 1.2 0.0 100%
(n=82)
The use of PMRs 
wastes pharmacist 
time
0.0 0.0 7.3 28.0 64.6 100%
(n=82)
The use of PMRs 
saves ancillary staff 
time
17.1 39.0 25.6 14.6 3.7 100%
(n=82)
On balance, PMRs 
give a financial 
benefit to the 
pharmacist______
12.2 34.1 34.1 14.6 4.9 100%
(n=82)
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2.3.2 Use of PMR Systems
Tables 2.12-2.16 show the frequency data from Section D of the questionnaire. This 
Section concerned the use of PMRs and the types of systems used.
Table 2.12: Use of PMR systems (April 1991)
Manual system 45 (6.1%)
Computer-held 407 (55.4%)
Smart card 1 (0.1%)
Planning to install system 99 (13.5%)
Will possibly install system 85 (11.6%)
No intention to install system 97 (13.3%)
735 (100%)
From Table 2.12 it can be observed that 61.6% of the sample were using a PMR 
system at the time of the survey (April 1991). A further 13.5% were planning to install 
a PMR system and 11.6% stated that they may possibly install a PMR system. It can 
thus be postulated that 75-85% of community pharmacies would have been using 
PMRs subsequent to this survey.
Factors which may influence the use of PMRs were investigated by cross-tabulating the 
results in Table 2.12 with those from Tables 2.1-2.9. Regional variations in the use of 
PMRs existed, ranging from 50% of pharmacies in the South West and 51% in the 
South East maintaining a PMR system, to 74% in the North West and 75% in East 
Anglia.
Figure 2.1 shows that pharmacies dispensing less than 400 items per week were less 
likely to use a PMR system than those pharmacies dispensing a higher number of 
prescriptions. The use of PMR systems clearly was dependent upon dispensing volume 
(X2=62.2, df=35, jXO.Ol).
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Figure 2.1: Average number of items dispensed per week related to percentage of pharmacies maintaining a PMR
system (April 1991).
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Figure 2.2: Relationship between the use of PMR system s (April 1991) and the year of registration of pharmacist in
charge of pharmacy.
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The status of the pharmacist in charge of the pharmacy affected the use of PMRs 
(^2=50.9, df=25, p<0.01). Of those pharmacies where a locum was the pharmacist in 
charge 26.1% (n=23) used a PMR system. This figure rose to 81.4% (n=59) where 
partnerships existed. No significant difference in the use of PMR systems was found 
between managers and proprietors.
Figure 2.2 shows that older pharmacists were less likely to be in charge of a pharmacy 
where PMRs are maintained (x^=65.0, df=35, p<0.01).
Table 2.13. Year of installation of PMR system in use during April 1991.
National survey PILLS-users
1991 22 (4.9%) 0
1990 224 (50.3%) 63 (75.9%)
1989 121 (27.2%) 15(18.1%)
1988 50 (11.2%) 3 (3.6%)
1987 14 (3.1%) 2 (2.4%)
1986 or earlier 14 (3.1%1 0
445 (100%) 83 (100%)
Note: The PILLS group contained no entries for 1991 because the list of PILLS 
pharmacies was provided by Hadley Hutt Computing Ltd during December 1990.
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Figure 2.3 shows the market share, as of April 1991, for program suppliers of PMR 
systems.
Figure 2.3: Market shares held by suppliers of PMR systems in April 1991.
□  Park Systems
■  John Richardson
■  AAH
□  Hadley Hutt
□  Chemtec
□  In-house system 
H  Others
Table 2.14: Number of patient records held in manual and computer records (April 
1991)._________________________________________________________________
National survey PILLS -users
0-499 103 (23.3%) 0
500-999 72 (16.3%) 2 (2.4%)
1000-2499 103 (23.3%) 12(14.6% )
2500-4999 89 (20.1%) 21 (25.6%)
5000 or more 70 (15.8%) 45 (54.9%)
Don't know 6 (1.4%) 2 (2.4%)
443 (100%) 82 (100%)
Table 2.15: Location within the pharmacy of the PMR computer keyboard in the 
national survey and PILLS-user survey (April 1991).________________________
National survey PILLS -users
Dispensary 383 (94.8%) 79 (95.2%)
Reception / counselling area 16 (4.0%) 2 (2.4%)
Medicines counter 3 (0.7%) 0
Elsewhere 2 (0.5%) 2 (2.4%)
404 (100%) 83 (100%)
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Table 2.16: Person normally initiating a patient record.
National survey PILLS-users
Pharmacist 256 (63.2%) 49 (59.0%)
Dispensing assistant 16 (4.0%) 6 (7.2%)
Other assistant 3 (0.7%) 1 (1.2%)
Combination of the above 104 (25.7%) 27 (32.5%)
405 (100%) 83 (100%)
2.3.3 The Recording of Patient Information
In section E of the questionnaire, pharmacists were asked to state those details which 
were normally recorded about patients. Data from the national survey and, where 
appropriate the PILLS-ustr survey, are shown in Tables 2.17-2.32. The data was 
cross-tabulated with the data about the pharmacy and the pharmacist in charge, from 
Tables 2.1-2.9, and also with the computer system supplier. Significant findings are 
reported after the frequency data.
Table 2.17: Recording of patients' previous medication history by participants in 
the national survey and PILLS-user survey (April 1991).______________________
National survey PILLS-users
Always 23 (5.2%) 4 (4.8%)
Usually 44 (9.9%) 7 (8.4%)
Sometimes 114(25.7%) 18(21.7%)
Never 262 (59.1%) 54 (65.1%)
443 (100%) 83 (100%)
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Table 2.18: Percentage of respondents recording a patient's personal details in 









Age / date of birth 43.9 68.3
Telephone number 31.0 18.5
NHS number 3.1 3.7
National Insurance number 1.1 1.2
Race / nationality 0.2 0.0
Hospital record number 0.0 1.2
Patient medication records were maintained for all patients by 30.4% of respondents 
(75.6% of PILLS-users). The only factor that influenced the maintenance of records 
for all patients was system supplier (x2=21.35, df=6, p<0.01). Figure 2.4 illustrates 
this effect.
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Figure 2.4: The percentage of system users who recorded prescriptions for all patients (April 1991).
PILLS uj er survey result
% respondents 40
Table 2.19: Patient groups for whom records were kept if records were not 

















Table 2.20: Numbers of pharmacists indicating other groups of patients included in 
PMR where records were not maintained for all patients (national survey, April1991).
3 each Confused patients; Patients requiring hosiery; Coeliac patients
2 each Patients requiring oxygen; Hypertensives; Polypharmacy patients; Patients who
have repeat prescription errors; Patients on special formulations 
1 each Hypochondriacs; Catheterised patients; Patients on dialysis; Patients with 
unusual items; Pregnant women; Breast-feeding mothers; HRT users;
Psychiatric patients; Transplant patients; Truss wearers; Those with heart 
defects; Those on expensive drugs; Mentally handicapped patients; Allergic 
patients; Home delivery patients; Where time could be saved in dispensing 
process; All those with computer-generated prescriptions; Those who work 
_________locally; Patients in home for mentally handicapped young adults_______________
In the national sample all the pharmacists who recorded details about alternative 
practitioners served patients from the AB socio-economic group (Table 2.21). The 
alternative practitioners referred were two homoeopathic doctors, a private 
practitioner, chiropractor and a private consultant. In the PILLS-user group five out of 





9 each Epileptics; Residential and nursing home patients; Drug addicts 
6 Children
4 Women on oral contraceptives
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Table 2.21: Percentage of respondents recording details of a patient's prescriber 
(national and PILLS-user surveys, April 1991).______________________________
National survey P/LLS-users
(447=100%) (83=100%)
GP's name 96.4 96.4
GP's address 56.6 77.1
GP's computer patient reference 11.6 12.0
number
Dentist's name 27.7 49.4
Dentist's address 12.3 37.3
Family planning clinic 1.3 7.2
Hospital outpatients department 4.3 20.5
Alternative practitioners 1.8 9.6
Table 2.22: Percentage of respondents recording patients' allergies, sensitivities














3 House dust mite
2 Tetracyclines
1 each Ointments, Lactulose, Cephalexin, Co-Dydramol, Egg, Pollen, Wasp stings, 
________Nystatin, Eye ointments___________________________________________
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The suitability of child-resistant closures for elderly and arthritic patients was noted by
73.9% of the respondents, and by 78.3% of P/LLS-users.
Prescription charge exemption was recorded by 39.9% of the national sample, and by 
27.7% of P/LLS-users.
The recording of patient conditions was examined initially by determining the total 
number of conditions recorded by each pharmacy in the survey, and by noting the 
effect which parameters of the pharmacy and of the pharmacist in charge had an effect 
on this value. The effect of system supplier was also examined. Differences between 
population sub-groups were determined by performing a one-way analysis of variance 
test (ANOVA), which provided a 95% confidence interval for each mean value of 
conditions recorded. The exact population sub-groups contributing to the differences 
were detected by applying Fisher's LSD (Least Significant Differences) test. 64 Figures 
2.5-2.10 illustrate where influences were found.
Analysing the results from Figure 2.5 showed that pharmacists working for large 
multiples recorded more conditions than independent pharmacists (p<0.05). However 
this effect was diminished when corrected for year of registration of the pharmacist in 
charge, since younger pharmacists were found to record more information; also a high 
proportion of young pharmacists was found to work for large multiples.
Figure 2.6 shows the effect of the socio-economic group of the pharmacy's patients on 
the mean number of conditions recorded in the PMR system. Analysis showed that 
pharmacists serving AB groups recorded fewer conditions than those serving the C2, 
DE groups or a mixed clientele (p<0.05).
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Figure 2.6: The effect of patient socio-economic group on the mean number of patient conditions recorded in
PMR system s.
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Figure 2.7: The effect of the year of registration of the pharmacist in charge on the mean number of patient
conditions recorded in PMR system s
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Figure 2.7 shows the effect of the year of registration upon recording of patient 
conditions. Fisher's LSD te s t^  showed that pharmacists qualifying after 1980 
recorded more conditions than those qualifying between 1961-65 and 1971-1980 
(p<0.05). In addition those qualifying between 1966-70 recorded more than those 
qualifying between 1961-65.
The year of setting up the current PMR system produced interesting data as shown in 
Figure 2.8, where an almost linear trend is shown. The following results were 
confirmed by the LSD test, (all p<0.05):
1991>1986, 1987, 1988, 1989 
1990 > 1986, 1987 
1989 > 1986
Figure 2.9 shows that there were variations in the number of conditions recorded 
between users of different computer systems. Fisher's LSD test showed that users of a 
Park, In-house or AAH system recorded more information about patient conditions 
than users of Hadley Hutt, Chemtec or Richardson systems (p<0.05).
Figure 2.10 shows regional variations in the mean number of conditions recorded. The 
LSD test showed that the value for the South West was significantly greater than that 
for London & Home Counties, the North-East & Yorkshire, and the North West 
(p<0.05).
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Table 2.24: Percentage of respondents recording specified clinical conditions in their
PMR system (national survey, April 1991).______________________________________
Diabetes 75.9 Renal impairment 27.3
Asthma 69.6 Pregnancy 27.3
Epilepsy 66.9 Drug addict 26.9
Hypertension 48.4 Hepatic impairment 23.4
Cardiac disease 43.0 Skin disorders 21.4
Peptic ulcer 38.0 Cystic fibrosis 17.4
Arthritis 33.8 Depression 17.1
Coeliac disease 33.6 Physical handicap 14.2
Parkinson's disease 32.1 Breast-feeding 13.1
Glaucoma 31.3 Mental handicap 12.8
Confused 30.9 Haemophilia 11.3
Hay fever 29.3 HIV positive 7.2
Table 2.24 shows the percentage of pharmacists recording the patient conditions listed 
in the questionnaire. Figures 2.4-2.10 show the various parameters which affected the 
total number of patient conditions recorded in the PMR system. The individual patient 
conditions that contributed to this variation were determined by cross-tabulating the 
results in Table 2.24 with the program supplier and with the results about pharmacies 
and pharmacists presented in Tables 2.1-2.9, using the test of independence.*^ 
Tables 2.25-2.28 show those conditions that contributed to this variation, in order of 
statistical significance.
Table 2.25 shows that the program supplier produced a significant variation in the level 
of recording for 16 out of the 24 conditions listed in the questionnaire. Table 2.26 
shows that regional location had only a weak influence on the recording of patient 
conditions, although a higher number of pharmacists in the South West recorded hay 
fever than in all other regions (p<0.01).
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Table 2.25: Conditions where program supplier had an influence on PMR recording.
Percentage of users recording clinical condition
Park John AAH Hadley Chemtec In-house Others All users Statistics, df=6
Systems Richardson Hutt *2 P
Hypertension 76.1 35.2 60.0 16.7 16.7 71.7 36.8 49.9 51.5 <0.001
Cardiac disease 67.4 27.9 57.9 16.7 8.3 60.4 39.6 43.6 49.8 <0.001
Arthritis 58.7 18.0 45.3 25.0 16.7 52.8 24.6 35.0 43.6 <0.001
Confused 32.6 12.3 48.4 25.0 33.3 47.2 26.3 31.0 40.8 <0.001
Parkinsons disease 54.3 16.5 46.3 25.0 25.0 45.3 22.8 33.3 38.7 <0.001
Skin disorders 41.3 9.8 31.9 8.3 0.0 34.0 15.8 22.5 35.7 <0.001
Depression 34.8 5.7 29.5 8.3 0.0 20.8 15.8 18.1 33.3 <0.001
Asthma 91.3 68.9 73.7 41.7 83.3 86.8 54.4 72.5 30.3 <0.001
Hay fever 60.9 22.1 29.5 25.0 8.3 37.7 22.8 30.2 30.1 <0 001
Coeliac disease 60.9 26.2 31.6 33.3 8.3 47.2 24.6 33.8 28.3 <0.01
Epilepsy 84.8 67.2 73.7 33.3 66.7 81.1 52.6 69.5 24.7 <0.01
Glaucoma 50.0 26.2 44.2 25.0 8.3 37.7 22.8 33.8 20.5 <0.01
Peptic ulcer 51.1 36.4 47.4 16.7 8.3 47.2 26.3 39.2 18.5 <0.01
Breast-feeding 8.7 18.9 16.8 0.0 0.0 22.6 3.5 14.4 16.1 <0.05
Diabetes 91.3 75.4 76.8 66.7 91.7 88.7 66.7 78.3 15.4 <0.05
Cystic fibrosis 21.7 9.0 22.1 8.3 16.7 28.8 14.0 17.2 14.0 <0.05
Table 2.26: Clinical conditions for which regional location had an influence on PMR recording.
Percentage of users recording condition
Wales London SE SW NE& Midlands NW East All users Statistics, df=7
Yorks Anglia Cl*
Hay fever 34.3 25.5 31.1 55.6 14.3 34.8 26.5 33.3 29.3 20.0 <0.01
Cystic fibrosis 14.3 9.8 24.6 33.3 13.0 16.5 21.7 0.0 17.4 0.0 <0.05
Coeliac disease 28.6 31.4 37.7 63.0 26.0 35.9 31.3 2 2 . 2 33.6 14.9 <0.05
Table 2.27: Clinical conditions for which
Percentage of
patients' socio-economic group had an
users recording condition
influence on PMR recording.
Statistics, df=4
AB C1 C2 DE Mixture All users X2 P
Drug addict 8.6 17.6 21.7 36.4 24.1 26.8 20.1 <0.001
Mental handicap 5.2 0.0 34.8 14.0 12.7 12.9 15.6 <0.01
Cardiac disease 25.9 64.7 60.9 43.0 47.3 42.8 13.3 <0.05
Epilepsy 48.3 76.5 78.3 70.4 66.5 66.7 12.2 <0.05
Hypertension 34.5 76.5 60.9 48.9 47.5 48.2 11.4 <0.05
Diabetes 60.3 76.3 87.0 79.0 75.9 75.8 10.2 <0.05
Skin disorders 12.1 41.2 34.8 22.6 19.1 21.3 10.1 <0.05
Table 2.28: Conditions where the year of registration of the pharmacist in charge had an influence on PMR recording.
Percentage of users recording condition Statistics, df=7
1955 or 1956- 1961- 1966- 1971- 1976- 1981- 1986- All users X2 P
earlier 1960 1965 1970 1975 1980 1985 1990
Peptic ulcer 23.1 38.7 27.7 27.8 30.4 28.6 51.3 54.7 38.1 26.7 <0.001
Skin disorders 15.4 19.4 6.4 25.9 10.6 15.7 28.2 34.9 21.6 23.4 <0.01
Hypertension 30.8 48.4 34.0 42.6 40.4 42.9 63.3 61.6 48.6 22.9 <0.01
Arthritis 30.8 29.0 21.3 33.3 23.4 27.1 43.0 47.7 34.1 17.7 <0.05
Epilepsy 57.7 61.3 48.9 63.0 66.0 71.4 73.4 77.9 67.5 15.6 <0.05
Depression 7.7 22.6 14.9 14.8 4.3 12.9 22.8 25.6 17.0 15.2 <0.05
Asthma 61.5 67.7 53.2 64.8 70.2 70.0 77.2 80.2 70.2 14.3 <0.05
Table 2.27 shows where the socio-economic group of the pharmacy clientele 
influenced the recording of patients' clinical conditions. The level of recording of drug 
addiction increased markedly as the socio-economic ladder is descended. Fewer 
pharmacies serving the AB socio-economic group recorded details about diabetes and 
epilepsy than those serving lower socio-economic groups.
Figure 2.7 shows that the pharmacist's year of registration affected the mean number of 
conditions recorded in the PMR system. The patient conditions contributing to this 
variation are shown in Table 2.28.
Table 2.29 lists the other patient characteristics and clinical conditions that pharmacists 
reported they included in their PMRs.
Table 2.29: Number of reported cases of other clinical conditions and patient 
characteristics as recorded by pharmacists.____________________________________
10 Thyroid disorders
5 Blindness
4 each Cancer; Transplant
3 each Multiple sclerosis; Ostomy; Urinary tract disorders; Deafness; Migraine; Anaemia 
2 each Anorexia; Incontinence; High cholesterol; Housebound; Crohn's disease /
Ulcerative colitis; Altzheimer's disease; Menopause 
1 each Myasthenia gravis; Respiratory diseases; Non-compliance with medication;
Downs syndrome; Auto-immune disease; Hiatus hernia; Gout; Bowel disorders;
________ No English spoken; Contact lens wearing; CNS disorders; Gluten intolerance
Tables 2.31-2.32 show how pharmacists managed non-current records. The responses 
in Table 2.31 may be biased since many pharmacists acknowledged that they were not 
normally informed about a patient relocating. Table 2.32 shows the percentage of 
pharmacists that recorded details about patient lifestyle. Table 2.33 shows the 
incidence of pharmacists recording diagnostic test results in PMRs.
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Table 2.30: Action taken if patient dies (national and PILLS-user surveys, April 
1991).______________________________________________________________
National survey PILLS-users
Do nothing 169 (39.0%) 41 (50.6%)
Archive record 101 (23.3%) 19 (23.5%)
Print and retain record 38 (8.8%) 2 (2.5%)
Delete all patient details 125 (28.9%) 19 (23.5%)
433 (100%) 82 (100%)
Table 2.31: Action taken if patient leaves area (national and PILLS-user surveys, 
April 1991).___________________________________________________________
National survey PILLS-users
Make a note in PMR 95 (22.0%) 14(17.1%)
Give printout to patient 20 (4.6%) 6 (7.3%)
Give printout to another pharmacy 10 (2.3%) 1 (1.2%)
None of the above 306(71.0%) 61 (74.4%)
431 (100%) 82 (100%)
Table 2.32: Numbers of respondents recording of patient lifestyle details in the 




Height / weight 2 (0.5%)
Note: None of the lifestyle factors shown in Table 2.32 were recorded by PILLS-users.
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Table 2.33: Numbers of respondents recording in-pharmacy diagnostic test results




Note: Only one PILLS-user recorded blood pressure readings.
No pharmacy from the national survey sample; and only one pharmacy in the PILLS- 
user sample, indicated that patients often asked to see their records as provided for 
under the Data Protection Act 1984. According to 11.3% of pharmacies nationally, 
patients rarely requested this (36.6% in the PILLS-user group). In 36.4% of 
pharmacies in the national survey patients were reminded about their rights to access 
records, compared with 66.7% in the PILLS-user survey.
2.3.4 The Recording of Product Information
The recording of details about products is shown in Tables 2.34-2.38.
Table 2.34: Recording of non-prescription medicines (national and P/LLS-user 
surveys April 1991). _________________________________________________
National survey PILLS-users
No records 282 (64.5%) 28 (34.1%)
Counter-prescribed medicines 145 (33.2%) 52 (63.4%)
All purchased medicines 10 (2.3%> 2 (2.4%)
437 (100%) 82 (100%)
Factors that could influence the recording of non-prescription medicines were assessed 
by cross-tabulating the results from Table 2.34 with Tables 2.1-2.9 and with the system 
supplier. The only factor which was found to affect the recording of non-prescription 
medicines was system supplier, where users of the Hadley Hutt PILLS system were 





Table 2.35: Percentage of respondents recording of product details for prescribed
medicines, dressings and appliances (national and PILLS-user surveys, April 1991.)------------ -------------------rf---------- v..
National survey PILLS- users
Drug name 99.1 100.0
Quantity 98.9 100.0
Dose 98.9 100.0
Drug strength 98.7 100.0
Dosage form 98.2 100.0
Date of supply 98.0 100.0
Dressing / appliance type 85.2 92.5
Dressing / appliance size 84.5 90.0
Prescribers' name 82.2 95.1
Dressing / appliance re-order code 62.3 72.5
Type of prescription eg. NHS / private 50.5 81.7
Formulae for extemporaneously
dispensed products 46.8 46.3
Dressing / appliance supplier 33.7 53.8
Manufacturer of generic products 14.2 2.4
Supplier / wholesaler 9.7 17.1
Expiry date 2.7 6.1
Batch number 2.7 0.0
Note: Computer systems generally record each of the first six entries in Table 2.35 
automatically. Some of these values in Table 2.35 were not 100.0% due to manual records 
being incomplete in this respect.
Table 2.36: Use of PMR systems to maintain oxygen records (national and PILLS• 
user surveys April 1991).________________________________________________
National survey PILLS-users
Records maintained 146 (33.1) 25 (31.3%)
Records not maintained 93(21.1%) 21 (26.3%)
Not an Oxygen supplier 202 (45.8%) 34 (42.5%)
441 (100%) 80 (100%)
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2.3.5 The Use of PMR Systems by Pharmacists to Limit the Dispensing 
of Excess Medication
Respondents' use of PMR systems to monitor for the excessive use of medication is 
shown in Table 2.37.
Table 2.37: Use of PMR system to limit dispensing of excess medication (national 
and PILLS-user surveys April 1991).__________________________________________
National survey P/ilS-users
Often 78 (17.5%) 18 (22.0%)
Rarely 232 (52.0%) 35 (42.7%)
Never 136 (30.5%^ 29 (35.4%}
446 (100%) 82 (100%)
2.3.6 Labelling of medicines where dosage directions are not stated on 
the prescription.
The question "In principle, how do you label medication which is prescribed "as 
directed", "as before", or where no directions are stated?" was answered by 692 
respondents, comprising 444 pharmacists who used a PMR system (98% of the 
possible maximum), and 248 non-PMR-users (88% of the possible maximum). 
Responses to this question were also obtained from 80 pharmacists in the PILLS-user 
survey (96% of the possible maximum). The responses given by each group to the 
above question are shown in Table 2.38. A total of 131 pharmacists in the national 
sample replied that they could not give only one response to the question posed, and 
therefore indicated two or more responses. Where this occurred, the response was 
classified as Other action.
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Table 2.38: Labelling of medicines where dosage directions are not stated on the 
prescription.___________________________________________________________
PMR-users Non-PMR-users PILLS- users
Label exactly as per prescription 146 (32.9%) 152 (61.3%) 12(15.0%)
Consult patient and label accordingly 52 (11.7%) 59 (23.8%) 6 (7.5%)
Consult prescriber / receptionist and label 8 (1.8%) 1 (0.4%) 0 (0.0%)
accordingly
Label with directions held in PMR 107(24.1%) N/A 41 (51.3%)
Other action, or a combination of the above 131 (29.5%) 36 (14.5%) 21 (26.3%)
Total in each group: 444 (100%) 248 (100%) 80 (100%)
Applying the y? test of independence to the groups of PMR-users and non-PMR-users 
in Table 1, showed that the use of a PMR influenced the action taken by pharmacists 
when labelling prescriptions which failed to specify complete directions, (x^=121.26, 
df=4, p<0.001). Similarly, applyeng the test of independence to the groups of 
PMR-users and PILLS-users showed that PILLS-users acted differently to other PMR- 
users when labelling such prescriptions, (x^=27.66, df=4, p<0.001).
2.3.7 Patient Information Leaflets
The proportion of pharmacists using computer-generated patient information leaflets is 
shown in Table 2.39.
Table 2.39: Use of PMR systems producing patient information leaflets.____________
National survey
Leaflets used 36 (5.2%)




17 (21.3%^  
80 (100%)
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Table 2.40 represents the responses of pharmacists in the national survey to a series of 
statements about the use of these leaflets. The responses of pharmacists in the PILLS- 
user survey are shown in Table 2.41. The series of statements solicited respondents' 
views on the use of patient information leaflets to reinforce verbal information; on 
whether the use of information leaflets affected patient compliance, and whether their 
use undermined patients' confidence in their prescriber.
The responses from Table 2.40 were cross-tabulated with the results from Tables 2.1-
2.9 to examine factors influencing agreement with the statements about leaflets. The 
Kruskal-Wallis one-way analysis of variance was applied to the cross-tabulated 
responses. Factors which were found to have a significant influence on pharmacists' 
views are shown in Table 2.42.
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Table 2.40: Pharmacists' agreement with statements about patient information leaflets
(national survey April 1991).___________________________________________________
Patient information leaflets 
















Patient information leaflets 
reinforce information given to 
patients by pharmacists
14.4 69.9 14.9 0.6 0.1 100%
(n=672)
Patient information leaflets 
which give information about 
side effects may women 
compliance by alarming 
patients
13.5 58.2 20.6 7.0 0.7 100%
(n=674)
Patient information leaflets 
provide a basis for discussion 
between pharmacist and 
patient
6.8 64.4 24.7 3.3 0.7 100%
(n=675)
Pharmacists who issue patient 
information leaflets are at risk 
of undermining patients' 
confidence in their prescriber
2.7 18.7 28.1 43.9 6.6 100%
(n=669)
More widespread use of 
patient information leaflets 
would improve patient 
compliance
6.4 44.4 35.3 12.3 1.6 100%
(n=675)
The use of patient information 
leaflets reassures patients 
about their medicine
6.1 45.7 36.5 10.1 1.6 100%
(n=674)
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Table 2.41: PILLS-users' agreement with statements about patient information leaflets 
(April 1991).________________________________________________________________
Strongly Agree Feel Disagree Strongly
agree
Patient information leaflets 46.1
reinforce information given to 
patients by prescribes
Patient information leaflets 53.9
reinforce information given to 
patients by pharmacists
Patient information leaflets 8.0
which give information about
side effects may worsen
compliance by alarming
patients
Patient information leaflets 34.2
provide a basis for discussion 
between pharmacist and 
patient
Pharmacists who issue patient 5.3
information leaflets are at risk 
of undermining patients' 
confidence in their prescriber
More widespread use of 36.8
patient information leaflets 
would improve patient 
compliance
The use of patient information 25.0
leaflets reassures patients 
about their medicine
neutral disagree
35.5 13.2 3.9 1.3 100%
(n=76)
39.5 6.6 0.0 0.0 100%
(n=76)
37.3 17.3 30.7 6.7 100%
(n=75)
56.6 7.9 1.3 0.0 100%
(n=76)
6.6 22.4 34.2 31.6 100%
(n=76)
35.5 19.7 7.9 0.0 100%
(n=76)
53.9 14.5 5.3 1.3 100%
(n=76)
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Table 2.42: Factors which influence pharmacists' attitudes to the use of computer- 
generated patient information leaflets._____________________________________ _
Region Pharmacy Pharmacist Year of 
ownership status registration of
pharmacist in 
charge
Patient information leaflets pcO.OI  ^ pcO.OOl® p<0.05^ ns
reinforce information given to 
patients by prescribes
Patient information leaflets p<0.05^ p<0.0016 p<0.01**2 ns
reinforce information given to 
patients by pharmacists
Patient information leaflets which ns ns ns ns
give information about side 
effects may women compliance 
by alarming patients
Patient information leaflets ns p<0.057 ns p<0.0516
provide a basis for discussion 
between pharmacist and patient
Pharmacists who issue patient ns p<0.001® pcO.OOl^ p<0.01**7
information leaflets are at risk of 
undermining patients' confidence 
in their prescriber
More widespread use of patient p<0.053 p<0.0019 p<0.01**4 ns
information leaflets would 
improve patient compliance
The use of patient information p<0.0014 p<0 .0 0 1 1® p<0.001<*5 ns
leaflets reassures patients about
their medicine_____________________________________________________________
note: all H values corrected for ties
ns=not significant (Continued on next page)
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Table 2.42 (continued from previous page)
1 Pharmacists from Wales and East Anglia were more in agreement with this 
statement than those from the other regions (H= 19.89, df=28).
2 Pharmacists from Wales and East Anglia were more in agreement with this 
statement than those from the other regions (H=17.66, df=28).
3 Pharmacists from Wales were more inclined to agree with this statement and 
those from the North East and Yorkshire to disagree. (H=17.13, df=28).
4 Pharmacists from Wales were more inclined to agree with this statement and 
those from the North East and Yorkshire to disagree. (H=29.76, df=28).
5 Pharmacists from large multiples showed greater agreement with this statement than 
those from independent pharmacies (H=22.03, df=8).
6 Pharmacists from large multiples showed greater agreement with this statement 
those from independent pharmacies (H=16.08, df=8).
7 Independent pharmacists tended to disagree with the statement more than the 
other ownership groups (H=7.32, df=8).
8 Pharmacists from large multiples tended to disagree with this statement (H= 18.34, 
df=8).
9 Independent pharmacists tended to disagree with the statement more than the 
other ownership groups (W=17.84, df=8).
10 Independent pharmacists tended to disagree with the statement more than the 
other ownership groups (H=22.17, df=8).
11 Managers agreed with this statement more than proprietors (H= 13.27, df=20).
12 Managers agreed with this statement more than proprietors (H=15.78, df=20).
13 Managers disagreed with this statement more than proprietors (H= 31.57, 
df=20).
14 Managers agreed with this statement more than proprietors (H=17.33, df=20).
15 Managers agreed with this statement more than proprietors (tf=21.48, df=20).
16 Pharmacists qualifying before 1961 were less likely to agree with this statement than 
those qualifying in 1961 or later (H=15.78, df=28).
17 Pharmacists qualifying in 1986 or later were more likely to disagree or strongly 
disagree with the statement (W=20.28, df=28).
The principal findings from these surveys have been published.65-67
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2.4 Discussion
It is difficult to determine an acceptable response to a questionnaire. The answer 
depends on the nature of the data being collected and the sample population. The 
response of 74.4% for the national survey was higher than the figures of 9% and 65% 
for other similar pharmacy surveys reviewed in the l i t e r a t u r e  Posting a second
questionnaire to non-respondents proved highly valuable. Analysing the results from 
the first 538 responses showed that PMRs were maintained in almost 63% of these 
pharmacies. In the final analysis 61.5% of respondents maintained PMRs. There were 
no major differences between pharmacists who replied to the first and second reminder 
questionnaires. Therefore, the 266 pharmacies that did not respond at all are assumed 
not to vary significantly from the 744 from which results were calculated.
Sections 2.4.1-2.4.10 relate to findings from the national survey, and Sections 2.4.11- 
2.4.12 relate to findings from the PILLS-user survey and the use of patient information 
leaflets.
2.4.1 Government Influence on Community Pharmacists' use of PMRs.
The last published paper prior to the presented survey concerning the use of computers 
in community pharm acy,26 showed that 25% of a sample of 1 297 pharmacies were 
maintaining computerised PMRs. In our study, 55.4% of pharmacies had a 
computerised PMR system in April 1991. Assuming that our sample is representative 
of all the community pharmacies in the United Kingdom, of which there are about 
11 500 registered premises, one can deduce that approximately 3 500 pharmacies have 
installed a computerised PMR system between the dates of the two surveys. 
Government payments to pharmacists for the maintenance of PMRs may have been a 
contributory factor in the large number of pharmacies that had started using PMRs 
since 1989.
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Some pharmacists in the survey who did not maintain PMRs stated that they felt the 
level of funding to be inadequate. In view of the apparent response to funding 
provision, these pharmacists would seem to be in a minority. It would appear that 
Government funding, however meagre, for the use of PMRs may have encouraged 
pharmacists to accept this aspect of the "extended role" as envisaged in the Nuffield 
Inquiry Report. * The analysis of this hypothesis is more fully discussed in Chapter 3.
2.4.2 Pharmacy Ownership
The low percentage (26.1%) of those pharmacies under locum control that reported 
the use of a PMR system is of concern. Where there is no regular community 
pharmacist is in contact with a particular pharmacy's patients, comprehensive record 
keeping is probably more important than where a regular pharmacist has personal 
knowledge of patients' medication.
Pharmacists working for large multiples were more likely to believe that PMRs provide 
financial benefits than those in independent pharmacies or small multiples. This 
perception is perhaps explained by the fact that management decisions to purchase 
PMR equipment are made centrally within the large organisations. Promotion of the 
benefits of PMR systems by large multiples to their employees, coupled with the fact 
that the employee pharmacist does not receive an invoice for the cost of the 
equipment, may enhance his opinion of the system. Pharmacists working for 
independents and small multiples may be in a better position to evaluate the 
cost/benefit effects of maintaining PMRs. In these circumstances, pharmacists are 
more likely to have been involved in the decision-making process when evaluating 
whether or not to use a PMR system and which system to purchase or lease.
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2.4.3 Socio-Economic Group (SEG) of Pharmacy Clientele
It is surprising that few pharmacists classified their patients in the Cl or C2 SEGs 
(Table 2.4). However, some pharmacies classified as having a clientele of mixed SEG 
may actually belong to the Cl or C2 group. The request that was made to pharmacists 
to classify their clientele by dominant SEG may well have introduced some subjective 
bias in the response. Therefore, any results associated with that judgement, which are 
of marginal significance (0.01 < p < 0.05), should be interpreted with caution.
Figure 2.6 shows that pharmacists serving an AB group recorded fewer conditions 
than pharmacists with a mixed, C2 or DE clientele. This, in some respects, is a 
surprising observation and would merit further study. There are several possible 
reasons for this finding. First, a greater morbidity has been claimed among the lower 
S E G s .  54 Second, patients in the AB group may be more knowledgeable about their 
conditions than patients from lower SEGs. This may make the AB group more 
reluctant to disclose their clinical conditions to the pharmacist, and therefore may have 
some effect on what is recorded. Third, pharmacists serving the DE groups may adopt 
a more pro-active approach towards their patients, being aware of the possible 
limitations of a patient's knowledge about his clinical condition. Finally, patients in the 
higher SEGs may travel more than those from the lower SEGs, and may for example 
present their prescriptions to be dispensed close to their places of work; conversely 
those in the lower SEGs may be more likely to use pharmacies close to their home or 
general practice surgery. The consequence of this is that those patients from the lower 
SEGs are more likely to take their prescriptions to be dispensed at the same phamacy, 
thus increasing the opportunity for the community pharmacist to maintain fully- 
comprehensive records for these patients.
Of the seven conditions that contributed significantly to the variation between SEGs 
(Table 2.27), epilepsy and diabetes are especially important because of the high 
incidence in practice. Epileptic patients may move down the socio-economic scale,
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due to their condition disabling them from taking many forms of higher-paid 
employment. In the case of non-insulin-dependent diabetes, inadequate knowledge 
about the importance of maintaining ideal body weight, through correct diet and 
regular exercise, may contribute to a higher incidence of this condition in socially 
deprived areas.
Pharmacies serving the C2 and DE groups recorded mental handicap more often than 
those serving other groups. At first, this may seem an unexpected finding, but it has 
been shown that families with handicapped children may move down the social scale. 
Mental handicap has been reported to be nine times more prevalent among the children 
of unskilled manual workers than among those in non-manual occupations.*^
Skin disorders were more likely to be recorded in pharmacies serving Cl and C2 
groups than those serving AB and DE groups. Members of the Cl and C2 groups will 
include skilled and semi-skilled industrial workers, who may be more likely to 
encounter exposure to potential irritants and sensitising agents in the work 
environment.
The proportion of pharmacies recording details about drug addicts in their PMRs was 
8.6% in the AB socio-economic areas, rising to 36.4% in the DE areas (Table 2.27). 
This is a very significant result (p<0.001) and may reflect a prevalence of drug misuse 
in socially deprived areas, or an awareness by pharmacists of particular patients who 
are difficult to manage in the pharmacy.
We were surprised to find that the number of pharmacists recording HTV infection was 
as high as 7.2%. On examination, most of the pharmacies concerned were found to be 
located in major conurbations. It is of note that the AAH LINK PMR system features 
a prompt for this condition.
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Fewer pharmacies in the AB socio-economic areas recorded hypertension and cardiac 
disease than those serving lower SEGs (Table 2.27). These conditions are inter-related 
and a greater morbidity has been shown to exist in the lower social classes. 68 These 
findings may have implications for community pharmacists as they continue to develop 
their role in health promotion and diagnostic testing. There may be a special case for 
community pharmacists serving a DE SEG clientele to consider their role in the 
provision of health promotion advice, and diagnostic testing services. Government 
funding for health promotion in community may need to be targeted mainly towards 
those pharmacies located in socially deprived areas, since by definition, those 
individuals from a DE SEG have relatively low incomes.
2.4.4 Year of Registration of the Pharmacist in Charge of a Pharmacy
More recently registered pharmacists were found to be more positive about the clinical 
use of PMRs (Table 2.10 et seq.). Figure 2.2 shows that pharmacists qualifying before 
1960 are less likely to use PMRs than those colleagues qualifying after 1960. This may 
be due to a reluctance to use computer equipment^ or possibly to a more limited 
knowledge of clinical pharmacy. For example, before the 1960's pharmacy was mainly 
taught as a two-year diploma course, which became a three-year diploma in 1957. 
Eventually, a three-year degree course became the sole route of entry to the profession 
in England, Wales and Northern Ireland. ^ 0  A four year degree course became the sole 
route of entry in Scotland.
The introduction of degree courses introduced large elements of pharmacology into the 
undergraduate curricula. Associated with detailed knowledge about the action and use 
of drugs, graduates would have acquired a greater awareness of therapeutics and the 
conditions drugs are used to treat. From this one would expect that pharmacists who 
qualified with a degree from the 1960's onwards would record more patient conditions 
in the PMR. However, the results are not as simple as this. Figure 2.7 shows that it is
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pharmacists who qualified in the 1980's who recorded the most information about 
patients. This corresponds to the teaching of clinical pharmacy to undergraduates from 
the mid-1970's onwards.
Figure 2.7 shows that the mean number of conditions recorded by pharmacists who 
qualified before 1961 appears relatively high. However this graph does not show that 
the majority of pharmacists in this age group who did keep PMRs at all (Figure 2.2). It 
is the contribution of a minority of pharmacists in this age group that causes this effect 
in the results.
Table 2.25 shows patient conditions that contribute to this effect. The most significant 
finding (p<0.001) is that more pharmacists who qualified after 1980 recorded peptic 
ulceration in their PMRs than those who qualified before 1980. This may be related to 
the marketing of the first histamine H2-receptor antagonist cimetidine, in the product 
Tagamet in the UK from November 1976 (Personal communication: SmithKline 
Beecham PLC). Undergraduate education of pharmacy students would have included 
the pharmacology of histamine H2-receptor antagonists from this time. A knowledge 
of the therapeutics of histamine H2-receptor antagonists may have raised the 
awareness of pharmacists qualifying after this time to the prevalence of peptic ulcers, 
and the iatrogenic cause of many peptic ulcers.
2.4.5 Program Supplier
The market share held by the three major suppliers (John Richardson, AAH, Park 
Systems) did not alter significantly between 1989-91. However the decisions made by 
senior management in large multiple companies may indicate a hidden shift in market 
share. For example, Moss Chemists used the AAH LINK system between 1989 and 
1992, although subsequently they have been using the Mediphase program. This was 
reflected in an increase in AAFTs market share from 14% to nearly 24% during the
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period 1989-91. The basis of Boots The Chemists’ APECS program is a derivative of 
the program supplied by Park System. However, the Boots APECS program is 
classified here as an ”in-house" system: consequently Park Systems' apparent market 
share in Figure 2.3 does not reflect this.
Figure 2.9 shows that the number of clinical conditions entered in records was 
influenced by the PMR program supplier. In this respect, practice standards clearly are 
being influenced by the program suppliers. The results suggest that PMR users fell 
into two groups. First, those using a system which provided for the recording of 
clinical conditions by supplying a comprehensive range of clinical condition prompts 
(eg. Park Systems and AAH LINK); in that case, respondents recorded a large number 
of clinical conditions. Second, where a limited range of clinical condition prompts 
were provided (eg John Richardson, Hadley Hutt), pharmacists tended to record fewer 
clinical conditions. There are two implications of this finding: first, pharmacists using 
those systems with the facility to record a high number of clinical conditions may be 
better placed than their colleagues without such systems to monitor for contraindicated 
prescribed and non-prescription medicines; and second, if the facility of recording 
patients clinical conditions is used more comprehensive pharmacy-held patient record 
databases will evolve, providing a research resource.
2.4.6 Regional Factors
The overall response to the national survey questionnaire was 74.4%. However there 
were regional variations in response to the questionnaire ranging from 65.5% in 
London and the Home Counties to 84.7% in Wales. The low response in London and 
the Home Counties may have indicated a slightly lower percentage of pharmacies in 
this region using PMRs than the results suggest.
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The regional variation in the proportion of pharmacies using PMRs reflected the results 
found by workers at Aston University.26 They found that more pharmacists used 
computers in the North of England and the Midlands than might have been anticipated.
Our survey results show that pharmacists in the South West recorded a higher mean 
number conditions in their PMR systems than those from all other regions (Figure 
2.10). This is not surprising given the large number of retired people who have moved 
to the South West. This older population will probably have many chronic conditions 
requiring regular medication.
One particular condition, unrelated to an elderly population, which made a major 
contribution to this variation is hay fever (Table 2.26). The author has attempted to 
correlate regional variations in pollen counts with the data with in Table 2.26. 
However, no sufficiently detailed pollen count statistics are yet available to perform 
such an analysis, since the Pollen Research Unit monitors pollen counts from only 10 
sites in the UK.71 However, a report has been published showing higher percentages 
of hay fever sufferers in the South East and South West than in northern areas of the 
UK.72
2.4.7 Pharmacy Location
It was evident from the results that the place where a pharmacy is sited of the 
pharmacy does not affect use of PMRs to any significant extent, despite the influence 
of the socio-economic group of the pharmacy clientele (Section 2.4.3).
2.4.8 Sex of Pharmacist in Charge of Pharmacy
The sex of the pharmacist in charge of the pharmacy was not found to affect any of the 
responses in the national survey. No variations between the responses of male and 
female pharmacists were anticipated and the results confirmed this. However, a
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subsequent survey showed that the sex of the pharmacist in charge of the pharmacy 
affected pharmacists' attitudes towards reasons for acquiring a PMR system (Section
3.3 & Figure 3.4).
2.4.9 Manual Records
Table 2.14 shows that, of the pharmacies maintaining PMRs 23.3% kept records for 
fewer than 500 patients. Most of the pharmacies keeping manual records fell into this 
category. The Drug Tariff states that payments for PMRs may be granted if 100 
patient records are maintained.^ It is possible that some pharmacies may be keeping a 
minimum number of records to claim payment for this service.
2.4.10 Recording of Product Information
PMR computer systems have developed from computer labelling systems. They build 
up records by storing information that is entered as part of the labelling process. Table 
2.35 shows that specific details used to produce labels were invariably recorded. 
However, a disappointingly low number of pharmacists indicated that they recorded 
information about the source of dispensed medicines. Such information is important in 
relation to the Consumer Protection Act 1987, and in the rare circumstances of a 
product recall. Pharmacists are liable for any licence-exempt medicinal products they 
dispense, including extemporaneous preparations and own 1nostrums. Only a minority 
of pharmacists in the survey said that they recorded details about the source of 
medicines or formulae for extemporaneous preparations in their PMR system, despite 
guidance from the NPA. They may, however, be recording this information elsewhere, 
for example in the private prescription book or a book of manufacturing records. Very
*A nostrum is a product extemporaneously prepared to the pharmacist's or patient's 
own formula.
few respondents recorded batch numbers in their records, although the benefits of 
doing so in case of product recall have been noted. 73
The majority of pharmacists do not record the supply of any non-prescription 
medicines in their PMR systems (Table 2.34). At present, there is no specific 
requirement and, in fact, it may be neither practical nor necessary to record sales of all 
non-prescription products for all patients. However, there are certain patients for 
whom such records would be useful. For example, it would be inappropriate for a 
patient, suffering from a cold, to purchase and use paracetamol tablets in addition to a 
paracetamol/decongestant cold remedy. The PMR system could warn the pharmacist 
of such potential overdose situations. A case has been described where a patient was 
admitted to hospital with hypercalcaemia due to the administration of Crampex 
tablets.74 The author of this communication noted that few patients had records for or 
reported the use of non-prescribed medicines on admission to hospital.
2.4.11 PILLS- users
Pharmacies operating the PILLS system tended to serve patients from higher SEGs 
than the sample of pharmacies as a whole (Table 2.4).
Hadley Hutt Computing Ltd had not appeared to have supplied many computer 
systems to large multiple pharmacies in the period to April 1991. In the sample of 
PILLS-users, only 4.8% of the respondents were from large multiples (cf. 29.4% in the 
main survey); the Boots and Lloyds companies have been shown to be using their own 
in-house systems. The PILLS system is typically used by a male proprietor pharmacist 
in a suburban area, dispensing 400-800 items per week. A comparison of the results 
in Tables 2.10-2.11 shows that PILLS-users are more favourably-inclined towards the 
use of PMRs than the national sample of pharmacists.
101
Figure 2.4 shows that for both of our samples o f PILLS-users (n=13, n=83) records for 
all prescriptions are maintained by about 70% of all users. This figure was 
considerably higher than for any other system supplier. Possession of a Hadley Hutt 
PILLS-system was the only factor found to influence whether records were maintained 
for all dispensed prescriptions; no other factors were found to significantly affect the 
recording of records for all patients. This finding is reinforced by the results in Table 
2.14, showing that the majority (54.9%) of PILLS-users have 5000 or more individual 
patient records. This compared with only 15.8% of the sample of all PMR users. The 
structure of the computer program determines the number of computer keyboard 
strokes necessary to switch record keeping on or off. It can be concluded that the 
method of entering patient and prescription details into the PMR system determines 
recording of records for patients. In the case of the PILLS-system, the keyboard 
operator must deliberately elect not to record a particular prescription. This shows that 
program suppliers are determining practice standards for pharmacists.
PILLS-users tended to record more information about prescribers (Table 2.21), and 
patient allergies/sensitivities (Table 2.22) than other PMR users. However, PILLS- 
users recorded significantly fewer (p<0.05) patient conditions in their records than 
users of Park Systems, In-house or AAH computers (Figure 2.9). Since the April 1991 
survey, the ability to record a wide range of patients' clinical conditions was 
incorporated into the PILLS system (August 1991), and consequently the potential 
existed for this finding to alter. The recording of patients' clinical conditions within 
PILLS systems is further discussed in Chapter 4.
A higher percentage of PILLS-users recorded counter-prescribed medicines than users 
of any other PMR system examined (Table 2.34). This finding, along with the high 
percentage of PILLS-users maintaining records for all patients, would appear to 
indicate that this system was providing those pharmacists who used it with the most 
comprehensive record keeping facility available at the time of the survey (April 1991).
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Not surprisingly, there are variations between PMR users and non-PMR users in 
labelling incomplete prescriptions (Table 2.38). However, PILLS-users are more likely 
to use the directions held in the PMR system than the users of any other system. The 
PILLS program is written such that BNF standard doses are incorporated into the drug 
data file. This is a unique feature among PMR systems. PILLS-users have the option 
of using these directions, or directions stored from a previous prescription. This may 
explain the high use of PMR held directions by PILLS-users.
2.4.12 Patient Information Leaflets
The numbers of pharmacies that produced patient information leaflets are shown in 
Table 2.39. Some pharmacies using systems other than PILLS indicated that they were 
using leaflets. These pharmacies were either involved in early use of leaflet generating 
software from Park Systems Ltd. or John Richardson Computers Ltd., or possibly 
using their own word-processed literature. It is not surprising that the advocates of 
leaflet generating systems were those who use such systems (Table 2.41).
There are other findings in the attitudes of pharmacists to leaflets that are of interest. 
Managers of large multiple pharmacies viewed leaflets more positively than other 
groups, yet this group were less likely to use the PILLS system. The use of patient 
information leaflets is reviewed in Chapter 5.
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2.5 Conclusions
1. The results of this survey show that over 61% of community pharmacies in 
England and Wales were using a PMR system in April 1991.
2. There appeared to be no significant differences in the use of PMRs by 
pharmacist proprietors and managers. We note with concern, however, that a 
very low proportion of pharmacies under locum control (ie. with no regular 
pharmacist present) maintained PMRs.
3. Pharmacists who registered after 1985 were more positive about the clinical 
advantages of PMR systems.
4. Pharmacists normally included in PMRs all the information that is required to 
produce a label for a dispensed medicine. Details, regarding the source of the 
dispensed product were rarely recorded.
5. The use of a PMR system by a community pharmacist increased the likelihood 
that a patient receives medicines labelled with appropriate dosage instructions. 
This was a consequence of the directions from a previous prescription being 
stored in the PMR system. The use of one particular PMR system, PILLS, 
appeared to increase even further the probability that the patient received 
appropriate directions.
6. Our results showed that there was wide variation in the use of PMRs by 
community pharmacists to record clinical details about patients. Some 
pharmacists recorded no details at all, whereas many others recorded a 
comprehensive range of conditions within their PMRs. By being more aware 
of patients' clinical conditions, pharmacists can contribute to improved patient
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care, for example, by advising against the supply of inappropriate medicines 
and the use of unsuitable dosage regimens.
7. Practice standards have been set by the suppliers of PMR programs. Where 
there was the facility to record clinical conditions in response to an on-screen 
prompt, a considerable number of clinical conditions was recorded. Where 
such a feature did not exist, few clinical conditions were recorded.
8. Regional variations have been identified in the recording of clinical conditions 
within PMR systems. The wide range of conditions recorded in pharmacies in 
the South West of England is probably explained by demographic factors 
related to the number of senior citizens living in this region.
9. The socio-economic group of patients served by a pharmacy influenced the 
recording of certain clinical conditions including diabetes, epilepsy and cardio­
vascular disorders. A greater percentage of pharmacies serving a DE group 
clientele recorded patients as drug addicts, than did pharmacies serving other 
SEGs. These findings indicate that it may be beneficial to target predominantly 
those pharmacies in socially deprived areas, if future Government funding is 
allocated to health promotion within community pharmacy.
10. Pharmacists who registered more recently tended to record more clinical 
conditions than those colleagues who had qualified in earlier years.
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3. Reasons For Community Pharmacists Establishing Patient
Medication Records
3.1 introduction
In Chapter 2, it has been shown that there had been a large rise in the number of 
pharmacies maintaining patient medication records (PMRs) between the end of 1989 
and April 1991. That information was obtained by means of a questionnaire sent to 
1000 community pharmacies in England and Wales, selected at random from the 
Register of Premises held by the Royal Pharmaceutical Society of Great Britain. The 
questionnaire requested information about whether PMRs were used, the systems in 
use, and the recording of details concerning patients and products.
From the results of the April 1991 study, we identified that 55.4% of the respondents 
had a computerised PMR system in April 1991. This finding contrasted with the 
previous figure of 25% of all pharmacies, excluding Boots the Chemists, given by a 
survey conducted in May 1989.26 a  further 6.1% of the respondents in the April 1991 
survey maintained a manual PMR system. One therefore can estimate that about 3500 
pharmacies introduced a PMR system between the end of 1989 and April 1991. When 
discussing those findings, we proposed the hypothesis that the provision of 
Government funding probably had encouraged community pharmacists to take up this 
aspect of the extended role. To confirm whether this hypothesis was valid and to 
elucidate what other factors if any had influenced pharmacists' decisions, we decided to 
conduct a further survey involving all those respondents who stated that they had 
installed a PMR system during 1990.
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3.2 Method
3.2.1 Equipment and Materials Used
Questionnaire forms and other project documents were produced using Microsoft 
Word for Windows on a Viglen Genie IBM-compatible computer and a Hewlett- 
Packard DeskJet 500 printer. SPSS/PC+ V4.0 was used to record results from 
returned questionnaires and for statistical analysis of the data. 53 a  Freepost licence 
arrangement with the Post Office facilitated the return of questionnaires.
3.3.2 Design of Questionnaire
The survey questionnaire (Appendix 2, page 323) was developed by considering 
factors that could have influenced a pharmacist's decision to purchase a PMR system, 
and was designed as an extension of our original national survey (Chapter 2). 
Therefore a modification to the original SPSS data definition file was written, enabling 
the new data to be cross-tabulated with results from the original survey.
Other possible factors that could have influenced a pharmacist's decision to install a 
PMR system were listed, besides the availability of Government NHS funding. These 
factors included: a desire to provide an improved clinical service, the necessity to 
update computer equipment, perceived competition from other pharmacies, and sales 
promotion by the providers of PMR systems. The pharmacists concerned were asked 
to indicate the extent to which each factor influenced their decision to purchase a PMR 
system. Seven possible reasons for installing a PMR system were listed in the 
questionnaire. Respondents were asked to rank each of these on a scale of 1 (very 
important) to 5 (not relevant / very unimportant). Such rankings produce ordinal data, 
which can be subjected to non-parametric statistical tests. An opportunity was 
provided for pharmacists to list other reasons why they had installed a PMR system. 
Respondents were also asked to indicate how they rated their PMR system on a Likert
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s e a l 5 of 1 (excellent) to 5 (poor). Finally pharmacists were invited to list any 
features that they would like to see added to their PMR systems.
The results from our original survey had shown that 224 out of a total of 740 
respondents (30.3%) installed a PMR system in 1990. Questionnaires were sent to 
each of these 224 pharmacies at the beginning of December 1991. A second copy of 
this questionnaire was sent to non-respondents as a follow-up six weeks later.
A parallel survey, using the same questionnaire was also conducted in 63 pharmacies 
which had installed a Hadley Hutt PILLS system during 1990. These pharmacies were 
those described in Table 2.13.
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3.3 Results
A total of 181 responses was received from the 224 pharmacies that were sent a 
questionnaire (80.8% response). A similar level of response rate was received from 51 
pharmacies (81.0% response) in the group of 63 users of the Hadley-Hutt PILLS 
system who were sent a questionnaire.
Responses to the request to rate each of the reasons for purchasing a PMR system on a 
scale of 1 to 5 are shown in Table 3.1 (national survey) and Table 3.2 (PILLS-user 
survey). Mean scores for the responses to each prompt were also calculated, and are 
included in these tables. Based on these mean scores, the two most important reasons 
for installing a PMR system in 1990 were the "need to provide an improved clinical 
service" and "to keep abreast of professional changes."
Additional reasons for installing a PMR system were indicated by 25 pharmacists in the 
national survey and 10 pharmacists from the PILLS-user survey. In nearly all cases, 
the reason given was access to drug interaction monitoring software.
Factors that could have influenced the reasons given by different pharmacists were 
analysed by cross-tabulating the responses in Table 3.1 against the various factors 
which had been found (Chapter 2) to influence the use of PMRs in our previous 
survey. The factors evaluated were: the region and location of the pharmacy; 
pharmacy ownership and clientele; the sex, status and year of registration of the 
pharmacist in charge; and the supplier of the PMR system. The Kruskal-Wallis one­
way analysis of v a r i a n c e ^ ,  64 was appijecj to the cross-tabulated data to determine the 
significance of variations within the ranked data.
Competition from other pharmacies was a factor which affected the decision to 
purchase a PMR system and, as shown in Figure 3.1, the perceived importance 
depended on who owned the pharmacy concerned (Kruskal-Wallis H= 12.60, corrected
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for ties, df=8, p<0.05). Figure 3.2 shows that this result is mirrored by the status of 
the pharmacist in charge of the pharmacy (//= 11.40, corrected for ties, df=8 p<0.05). 
From these results, it is apparent that managers working for multiples (2 or more 
pharmacies), especially large multiples (11 or more pharmacies), are more likely than 
independent proprietors to regard competition as an important reason for purchasing a 
PMR system.
Comparing the replies from male and female pharmacists (Figure 3.3), more of the 
latter identified competition as an important reason for installing a PMR system 
(H= 15.66, corrected forties, dfi=4, p<0.01).
The three factors that were ranked of greatest importance on the basis of the mean 
scores (Table 3.1) were those most directly related to the professional activities of the 
pharmacist. They were: the provision of an improved clinical service, enhanced 
working relationships with GPs and receptionists, and keeping abreast of professional 
changes. For two of these professional service criteria, the perception as to what 
extent the factor influenced the decision to purchase a PMR system depended on who 
owned the pharmacy. Figure 3.4 shows that pharmacists working for large multiple 
companies were less likely to consider improved relationships with GPs, or their 
receptionists, an important reason for purchasing a PMR system (H=9.97, corrected 
for ties, df==8 p<0.05). Similarly, Figure 3.5 shows that this group of pharmacists was 
less likely to purchase a PMR system to keep abreast of professional changes 
(H= 12.10, corrected forties, df=8 p<0.05).
Another finding from the survey was that, of the reasons for installing a PMR system, 
head office policy was a very important reason in the case of three categories of 
respondents: pharmacist managers, pharmacists qualifying after 1980 and female 
pharmacists. Many in these three of the pharmacist categories are likely to be
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employed by multiple groups, although no published figures are available to confirm 
this in relation to all community pharmacists.
Due to the relatively small sample size and homogeneous nature of the PILLS-user 
group, statistically significant variations within this sample were not detected. 
However, PILLS-users expressed particular satisfaction with their PMR system (Figure 
3.6).
Pharmacists were asked to rate their current systems on a scale from 1 (excellent) to 5 
(poor). Responses to this question are shown in Figure 3.6. By cross-tabulating these 
responses with pharmacy ownership, determined from our April 1991 survey, and 
applying the Kruskal-Wallis one-way analysis of v a r ia n c e ^ ,64, independent 
proprietors were shown to be more likely than managers to rate their system as 
excellent (//= 14.54, corrected for ties, df=8 p<0.05). This finding is illustrated in 
Figure 3.7
In response to the request to list features that could enhance their PMR system, 
respondents cited the following in descending order of frequency, the number of 
responses being given in parentheses: more detail on drug interactions (9), advice on 
endorsement of NHS prescriptions (5), ability to record the sale of non-prescription 
medicines (3), information about normal dose ranges (3), electronic link to the 
Prescription Pricing Authority (3), information leaflet production (2), Martindale On­
line (1), ability to record generic manufacturers (1), In te r lin k ^ , and electronic links to 
GP (1).
I l l
Table 3.1: National survey respondents' ranking of reasons for purchasing a PMR system during 1990.
<Very Important 
1
Availability of NHS remuneration 22 (12.4%) 38
Competition from other pharmacies 46 (25.4%) 49
Head office policy 49 (29.3%) 9
Necessary to update computer equipment 40 (22.7%) 51
Need to provide an improved clinical service 106 (59.6%) 49
S ales promotion 14 (8.3%) 29
To enhance working relationship with G Ps / receptionists 75(41.7% ) 55
To keep abreast of professional changes 79 (44.4%) 69
Very Unimportant
2 3 4 5
Total Mean Score
(21.4%) 62 (34.8%) 33 (18.5%) 23 (12.9%) 178 (100%) 3.0
(27.1%) 37 (20.4%) 28 (15.5%) 21 (11.6%) 181 (100%) 2.6
(5.4%) 10(6.0% ) 6 (3.6%) 93 (55.7%) 167 (100%) 3.5
(21.9%) 50 (28.4%) 19(10.8% ) 16(9.1% ) 176 (100%) 2.6
(27.5%) 16 (9%) 1 (0.6%) 6 (3.4%) 178 (100%) 1.6
(17.3%) 41 (24.4%) 29 (17.3%) 55 (32.7%) 168 (100%) 3.5
(30.6%) 34 (18.9%) 9 (5%) 7 (3.9%) 180 (100%) 2.0
(38.8%) 18(10.1% ) 6 (3.4%) 6 (3.4%) 178 (100%) 1.8
Table 3.2: PILLS users' ranking of reasons for purchasing a PMR system during 1990.
<Very Important Very Unimportant
1 2 3 4 5
Total Mean Score
Availability of NHS remuneration 7(13.4% ) 7 (13.4%) 10(19.6% ) 12 (23.5%) 15 (29.4%) 51 (100%) 3.4
Competition from other pharmacies 13 (26%) 10 (20%) 7 (14%) 7 (14%) 13 (26%) 50 (100%) 2.9
Head office policy 1 (2.2%) 1 (2.2%) 7(15.6% ) 0 36 (80%) 45 (100%) 4.5
Necessary to update computer equipment 18 (36.7%) 11 (22.4%) 8 (16.3%) 6 (12.3%) 6 (12.3%) 49 (100%) 2.4
Need to provide an improved clinical service 35 (70%) 11 (22%) 3 (6%) 0 1 (2%) 50 (100%) 1.4
S a les promotion 6 (12.5%) 11 (22.9%) 9(18.8% ) 12 (25%) 10 (20.8%) 48 (100%) 3.2
To enhance working relationship with G Ps / receptionists 19 (38.8%) 13 (26.5%) 10 (20.4%) 3(6.1% ) 4 (8.2%) 49 (100%) 2.2






Figure 3.1: The effect of pharmacy ownership on the perceived importance of competition in deciding to
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Figure 3.2: The effect of the status of the pharmacist in charge on the perceived importance of competition as a
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Figure 3.3: The effect of the sex of the pharmacist in charge on the perceived importance of competition as a






















Figure 3.4: The effect of pharmacy ownership on the perceived importance of improving relationships with GPs
and receptionists as a reason for purchasing a PMR system.
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Figure 3.5: The effect of pharmacy ownership on the perceived importance of keeping abreast of professional
changes as a reason for purchasing a PMR system.
1 2 3 4 5
<Very Important Very Unimportant>
■  Independent 
□  Small Multiple 












Figure 3.6: Pharmacists' ratings of their current PMR system.
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Figure 3.7. The effect of pharmacy ownership on pharmacists' rating of PMR system s.
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3.4 Discussion
The survey response of 81% was highly satisfactory. The results have been interpreted 
on the assumption that the 19% who did not respond would not have significantly 
affected our findings. Analysis of results before and after the mailing of reminder 
letters confirmed that the groups of early and late responders did not differ 
significantly.
A low mean score in Tables 3.1 and 3.2 represents a reason to which most respondents 
have assigned a high priority when purchasing a PMR system, whereas a high score 
represents a low priority.
It would appear that our hypothesis that NHS remuneration provided a major stimulus 
to the installation of PMR systems since 1989 is not supported by these findings. 
Clearly, the availability of a modest fee payment is a factor that has encouraged some 
pharmacists to commence using PMR systems, but the influence of this factor seems to 
have been much less than might have been expected. Only nine pharmacists, among 
our sample of 181, used manual systems; this small number of respondents indicated 
that, for them, finance was a very important reason for installing a PMR system, 
presumably because the cost of a card-file system is only a fraction of that required to 
purchase a computerised PMR system.
Competition was ranked by 46 respondents as a very important reason for installing a 
PMR system, and it is evident from Figures 3.1-3.3 that a number of factors underpin 
this response. Pharmacist managers working for large multiples appeared to view 
competition as a more important factor in this respect than their independent 
contractor colleagues. Associated with this effect, female pharmacists ranked 
competition higher than did their than their male colleagues (Figure 3.3). Some, 
though not all, of this effect could be accounted for by the fact that female pharmacists
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are more likely to be employed by multiple companies than practising as independent 
contractors. ?6
Head office policy clearly is of concern to pharmacists employed by multiple 
companies, but is not relevant to independent contractors. This resulted in a bimodal 
distribution shown in Table 3.1, where most pharmacists ranked head office policy 
either as very important or very unimportant.
The need to update computer equipment as a reason for acquiring a PMR system, was 
rated between 1 and 3 by 141 out of 176 PMR users. This, therefore, must have 
contributed to the increased utilisation of PMR systems. Most computer systems in 
daily use have a 3 to 5 year life-span. Since the introduction, in January 1984, of the 
requirement?? for community pharmacists to produce printed labels, most basic 
labelling systems would have seen about 4 to 5 years useful life by late 1989 or early 
1990. Many such systems would have been due for replacement, and the pharmacists 
concerned were probably taking the opportunity to upgrade to a PMR system from 
their basic labelling program. One of the implications of this is that one might expect 
the next major advances in the application of computer technology in community 
pharmacy practice to occur in the mid-1990s. Some possible hardware enhancements 
have been discussed in a recent article.?**
It is noteworthy that the "need to provide an improved clinical service" was the 
primary reason cited by pharmacists for the installation of a PMR system (Tables 3.1 & 
3.2). This response is reinforced by the perceived importance of a PMR system 
enabling them "to keep abreast of professional changes". These two reasons were 
assigned a ranking of 1 or 2 by about 90% of respondents.
The responses from many pharmacists indicated that sales promotion, by system 
suppliers, appeared to be an unimportant reason for acquiring a PMR system. Clearly
122
pharmacists working for multiples are required to use the system that is acquired by 
their employer, in line with company policy, and in those cases sales promotion would 
not be perceived as a major reason for the selection of a PMR system. There could 
have been some "brand loyalty" expressed by some pharmacists when upgrading 
systems; for example, users of the Richardson BBC Micro-based labelling system may 
have upgraded to the Richardson PC-based PMR system.
Enhanced working relationships with GPs or their receptionists was rated either 1 or 2 
by most respondents, and again there are some differences in emphasis between 
independent contractors and multiples. Figure 3.4 shows that independent proprietors 
are more likely to give a higher priority to this factor than pharmacists working for 
multiples, especially large multiples. The reason for this difference in response may be 
that independent proprietor pharmacists are very dependent on maintaining strong links 
with particular general practice surgeries near to the pharmacy, whereas in general this 
is less applicable to city-centre branches of multiples, due to their greater average 
distance from particular GP surgeries.
The ratings of PMR systems by their users, as shown in Figure 3.6, emphasises the 
differences between independent contractor pharmacists and those working for 
multiple companies. Generally, independent contractors will select a system that best 
meets their practice and commercial needs. Pharmacists in this group rated their PMR 
systems higher than did pharmacists who used a system provided by one of the multiple 
companies. Independent pharmacists appeared to be expressing satisfaction with 
systems that they had selected themselves, but their counterparts working for multiple 
companies expressed less satisfaction with the systems that had been selected by senior 
management. In particular, PILLS-users expressed high satisfaction with their system. 
PILLS-usqts are likely to be independent proprietor pharmacists (Section 2.4.11), and 
as such are likely to have selected the PILLS system themselves.
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The principal results from this survey have been published.79
3.5 Conclusions
1 Pharmacists have installed PMR systems primarily for reasons relevant to the 
clinical and professional services they provide.
2 Government funding has influenced the uptake of PMR usage, but only to a 
minor extent.
3 Female pharmacists, and pharmacists working for large multiples perceived 
competition from other pharmacies to be a more important reason for installing 
a PMR system than did independent proprietors and male pharmacists.
4 The need to upgrade their computer equipment at the end of its life span was 
identified by many pharmacists as an important reason for having installed a 
PMR system. As such, upgrading provided an opportunity to utilise new 
technology in practice, this may have implications for the next wave of 
computer systems coming into use after the mid 1990s, when current hardware 
will become obsolete.
5 PMR users were satisfied with the systems they used, more so in the case of 
proprietor pharmacists than managers working for multiple companies. PILLS- 
users gave their system a particularly high rating.
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4. Further Studies on the Recording of Clinical Conditions Within
Patient Medication Record Systems
4.1 Introduction
Two further studies have been conducted on the nature of the recording of clinical 
conditions within PMR systems. The first of these (Section 4.2 below) piloted a 
survey of patient conditions recorded in a sample of PMR records maintained by users 
of the Hadley Hutt PILLS system. The second study (Section 4.3 below) comprised an 
audit of clinical conditions recorded within an "in-house" PMR system used in one 
branch of a large multiple pharmacy company.
Results from the April 1991 study (Chapter 2) showed that, during the survey period 
to April 1991, there was a wide variation in the use of PMRs by community 
pharmacists to record patients' clinical details. Some pharmacists recorded no clinical 
details at all, yet many recorded a comprehensive range of patients' conditions within 
their PMRs. There was evidence that current practice standards were being set by the 
suppliers of PMR programs (Conclusion 2.5.7). It was shown that where there was 
the facility to record clinical conditions in response to an on-screen prompt, a 
considerable number of conditions was being recorded. Where such a feature did not 
exist, few clinical conditions were recorded.
The study showed that the socio-economic group (SEG) of a pharmacy's clientele 
influenced the recording of clinical conditions including diabetes, epilepsy and cardio­
vascular disorders. A greater percentage of pharmacies serving a DE clientele (those 
reliant on state benefits) recorded patients as drug addicts, than did pharmacies serving 
other SEGs (Section 2.4.3).
Another parameter which affected the recording of patients' clinical conditions was the 
year of registration of the pharmacist in charge of a pharmacy. Pharmacists who
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registered more recently tended to record more conditions than those colleagues who 
had qualified earlier (Section.2.4.4).
Regional variations were noted in the recording of clinical conditions within PMR 
systems. It is possible that the wide range of conditions recorded in pharmacies in the 
South West of England was explained by demographic factors related to the number of 
senior citizens living in that region (Section 2.4.6).
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4.2 The Recording of Patients* Clinical Conditions Within Hadley Hutt
PILLS Systems.
4.2.1 Introduction
Each of the above findings were derived from pharmacist respondents indicating those 
conditions which they recorded in their system; these resuits however, were not based 
on the numbers of actual patients recorded as having certain clinical conditions being 
recorded in the PMR system. It was decided to conduct a survey of PMR users to 
examine whether the actual numbers of patients with clinical conditions reflected the 
above findings. The Hadley Hutt PILLS system was selected as the PMR computer 
system to be examined in this study for the following reasons:
i) The response from PILLS-users had been satisfactory in the earlier surveys, 
and it was felt that a similarly good response would be obtained.
ii) Hadley Hutt Computing Ltd. were able to provide a list of all their customers, 
and were in agreement to the conduct of this survey.
iii) It is straightforward to interrogate the patient database within the PILLS 
system to obtain information about the total number of patient records, and the 
numbers of patients recorded as having clinical conditions.
A potential disadvantage of surveying PILLS-usqts was that, in the previous study, this 
particular group of PMR users was identified as one that tended to record few patient 
conditions (Figure 2.9). However in August 1991, and therefore after completion of 
the earlier study, the range of clinical conditions which could be recorded in the PILLS 
system has been considerably increased by a modification of the PILLS software. A 
major advantage of the PILLS system is that the patient and drug databases are 
interactive, thus providing the user with a warning of potential drug contraindications 
for particular specified clinical conditions, for example anti-cholinergics and glaucoma.
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Given this enhancement to the PILLS software, it was anticipated that the recording of 
patients' clinical conditions would have increased since the earlier study in April 1991.
4.2.2 Method
The list of 24 clinical conditions, included in the April 1991 questionnaire (Appendix 2, 
page 311), sent to 1000 pharmacies throughout England and Wales, was modified to 
produce a series of 29 conditions, thought likely to be recorded by PILLS-users in 
response to patients completing the PILLS leaflet number 523; which listed 112 clinical 
conditions at the time of this survey. A copy of PILLS leaflet 523 is included in 
Appendix 2 (page 327). Clinical conditions rarely encountered by the community 
pharmacist, for example sarcoidosis and Guillain-Barre syndrome were excluded from 
the series of 29 conditions.
This questionnaire requested information about the pharmacy's location, the nature of 
the socio-economic group of most of the pharmacy's clientele, and the year of 
registration of the pharmacist in-charge of the pharmacy. In addition, the questionnaire 
requested information as to whether a PILLS multi-terminal system was being used. 
The multi-user variant of the original PILLS system was marketed in late 1991, to 
enable pharmacists to locate more than one labelling and patient medication record 
computer in their pharmacy. This information about the pharmacy was requested in 
order to be able to cross-tabulate the data obtained with patient record data.
A list of all pharmacies using the PILLS system was obtained from Hadley Hutt 
Computing Ltd. All PILLS-users in Schools of Pharmacy, and those users outside the 
United Kingdom were excluded from the survey. A copy of the questionnaire shown 
in Appendix 2 (page 324) was sent to the 418 remaining PILLS-users at the beginning 
of January 1993; all non-respondents were sent a follow-up letter and a second copy of
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the questionnaire six weeks later. All coded responses from the returned 
questionnaires were entered in the SPSS-PC+ V4.0 statistics package.^
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4.2.3 Results
Completed questionnaires were received from 285 out of the 418 (68.2%) PILLS-users 
in our sample: a similar figure to our earlier response (66.9%) from this group of 
pharmacists. The results in the tables below are given with the results from the April 
1991 survey for comparison. The regional location of respondents is shown in Table 
4.1. The year of installation of respondents' PILLS systems is shown in Table 4.2.
Table 4.1 Regional location of P/LLS-usere.
Region: April 1991 survey January 1993 survey
Wales 5 (6.0%) 22 (7.7%)
London & Home Counties 20 (24.1%) 56 (19.7%)
South East 4 (4.8%) 40 (14.1%)
South West 10 (12.0%) 28 (9.9%)
North East & Yorkshire 6 (7.2%) 31 (10.9%)
Midlands 27 (32.5%) 52 (18.3%)
North West 11 (13.3%) 26 (9.2%)
East Anglia 0 9 (3.2%)
Scotland 0 14 (4.9%)
Northern Ireland 0 2 (0.7%)
Channel Islands 0 4 (1.4%)
Total 83 (100%) 281 (100.%)
Table 4.2: Year of installation of PILLS system.
April 1991 survey January 1993 survey
1987 or before 3 (3.6%) 2 (0.7%)
1988 3 (3.6%) 4 (1.4%)
1989 15(18.1%) 31 (10.9%
1990 63 (75.9%) 75 (26.7%)
1991 0 72 (25.6%)
1992 0 97 (34.5%)
Total 83 (100%) 272 (100 %)
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A PILLS multi-user system was used by 51 respondents; a single terminal system was 
used by 221 respondents, and 13 respondents did not answer this question. The 
location of pharmacies in the survey is shown in Table 4.3, with data from the April 
1991 survey shown for comparison. The main socio-economic group (SEG) of the 
pharmacy clientele is shown in Table 4.4.
Table 4.3: Pharmacy location of PILLS-users.
April 1991 survey January 1993 survey
City centre 5 (6.0%) 29 (10.2%)
Suburban 45 (54.2%) 116(41.0%)
Village/small town 27 (32.5%) 109 (38.5%)
Health centre 4 (4.8%) 22 (7.8%)
In-store 1 (1.2%) 2 (0.7%)
Other 1 (1.2%) 5 (1.8%)
83 (100%)_______________283 (100%)
Table 4.4: Main socio-economic group (SEG) of PILLS-users' clientele.
SEG April 1991 survey January 1993 survey
AB 16 (19.3%) 40 (14.1%)
C1 3 (3.6%) 11 (3.9%)
C2 5 (6.0%) 17 (6.0%)
DE 24 (28.9%) 89 (31.4%)
Mixture / unable to classify 35 (42.2%) 126 (44.5%)
83 (100%) 283 (100%)
Table 4.5 shows the year of registration of the pharmacist in charge of each pharmacy 
where the PILLS system was in use.
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Table 4.5: Year of registration of the pharmacist in charge of pharmacies where PILLS
system is in use.___________________________________________________________
Year of registration April 1991 survey January 1993 survey
1955 or earlier 2 (2.4%) 8 (2.8%)
1956-60 6 (7.3%) 16 (5.7%)
1961-65 15 (18.3%) 42 (14.9%)
1966-70 12 (14.6%) 40 (14.2%)
1971-75 8 (9.8%) 34 (12.1%)
1976-80 11 (13.4%) 51 (18.1%)
1981-85 19 (23.2%) 49 (17.4%)
1986-90 9(11.0%) 36 (12.8%)
1991-2 N/A 6 (2.1%)
82 (100%) 282 (100%)
Pharmacists were asked to disclose the total number of patient records recorded in 
their system. This value ranged from 162 to 65 534; a distribution of numbers of 
records is shown in Figure 4.1. The modal range of patient record numbers was the 
range 4 001-6 000, with a median value of 7 377. The high numbers of patient records 
stored within PILLS systems according to the earlier survey (Table 2.14) is again 
reflected in the January 1993 survey.
No patient conditions or allergies whatsoever were recorded by 145 respondents 
(50.9%). Patients’ allergies and clinical conditions were recorded by 139 respondents 
(48.8%). Of these 139 respondents, 40 only recorded drug allergies and did not record 
patients' clinical conditions. Therefore only 99 respondents (37.4%) recorded any 
clinical conditions within their patient records. The total numbers of patients recorded 
as having the selected clinical conditions in respondents' PILLS systems are illustrated 
in Figure 4.2. In these 99 pharmacies, 16 887 individual entries had been recorded for 
those 29 patient conditions selected in the questionnaire, with a mean of 170.6 selected 
conditions having been recorded across all records in those pharmacies where 
conditions were being recorded. Respondents were asked to state other conditions 
which were recorded in their records; responses were as follows: gout
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Figure 4.1: Numbers of patient records held within PILLS system s January 1993.
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(three), osteoporosis (two), Wolff-Parkinson-White syndrome, pacemaker fitted, 
children under 12, breast cancer, heart disease (one each). One respondent stated that 
he had records for 915 patients denoted as "old age pensioners."
4.2.3.1 Hypotheses Testing
Our April 1991 study had verified several hypotheses that several factors influenced 
what is recorded in PMR systems. The socio-economic group of the pharmacy's 
clientele (Section 2.4.3), the pharmacists in charge's year of registration (Section 
2.4.4), system supplier (Section 2.4.5) and the regional location of the pharmacy 
(Section 2.4.6) all influenced what was recorded.
An objective of this January 1993 survey was to verify these findings for the population 
of PILLS-users. A method of normalising the January 1993 survey results was 
developed in order to test whether these hypotheses were true for our sample of 
PILLS-users. A parameter STD was calculated as the total number of entries for those 
29 clinical conditions specified in the January 1993 questionnaire within an individual 
PILLS-user's system per 1000 patient records stored in that system. The parameter 
STD was an interval/ratio measure and could be examined using standard parametric 
statistical procedures.
A one-way analysis of variance followed by Fisher's LSD test^4 was performed on the 
January 1993 survey results to test the hypotheses that the regional location of a 
pharmacy, the socio-economic group of the pharmacy's clientele, the year of 
registration of the pharmacists in charge, and the use of a multi-user system influenced 
what was recorded. No significant effect could be detected at the 5% significance level 
for any of these factors, using STD as the representative parameter.
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Our earlier results (Table 2.27) had shown that the SEG of a pharmacy's clientele 
appeared to affect the recording of the following clinical conditions: drug 
addiction/abuse (p<0.001), mental handicap (p<0.01), cardiac disease, epilepsy, 
hypertension, diabetes, skin disorders, (all p<0.05). In the January 1993 survey, of 
these parameters, a high incidence of the recording of patients as drug abusers had 
been found in those PILLS-users serving a DE SEG (those relying on state pension or 
social security). By applying the LSD test to the January 1993 survey results, those 
PILLS-users serving a DE SEG were found to differ significantly from those P1LLS- 
users serving all other groups (p<0.05).
For our sample of PILLS-users the variation the recording of patients as drug-abusers 
was the only clinical condition for which a statistically valid variation could be 
observed across SEGs. The SEG of the pharmacy's clientele was not found to 
influence the recording of any other clinical condition. Neither the pharmacist in 
charge's year of registration nor the pharmacy's regional location were found to 




The survey response of 68.2% was similar to the 66.9% response from the April 1991 
survey of PILLS- users, and was considered satisfactory.
4.2.4.2 Patient Record Numbers
The numbers of patient records held within respondents' PMR systems was considered 
high, but is similar to our 1991 finding (Table 2.14). The very high numbers of patient 
records (20 000 and over) reported by some pharmacies (Figure 4.1) is surprising. It is 
possible that in some cases the quoted figure may be incorrect, even for very busy 
pharmacies dispensing 2000 or more prescription items each week. A number of 
possible reasons exist as to why a PMR system may contain multiple records for the 
same patient. These are as follows:
i) Retention of record under a female patient's maiden name after she has married
ii) New patient record created after a change of address
iii) Multiple records for the same patient under different variations of the same 
name eg. John Smith, Mr John Smith, John A Smith, John Andrew Smith, Mr 
John A Smith, Mr John Andrew Smith, Mr JA Smith, J Andrew Smith, Mr J 
Andrew Smith, JA Smith
iv) Creation of duplicate records. This is very possible with the PILLS system, 
especially when unique patient identification numbers are not used
v) Spelling and typing errors by prescriber, prescribers' receptionist, pharmacist 
or pharmacy assistant.
It is important that users of all PMR systems are aware of the potential hazards of 
"duplicate" records which may contain different information; and that when such 
duplicity exists, a particular record may be incomplete.
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4.2.4.3 Recording of Clinical Conditions
The low level of recording of patient conditions was both surprising and disappointing. 
There are a number of possible reasons for this low level of recording, and these are 
illustrated by many comments by respondents disclosed on the returned questionnaires. 
Three respondents stated that they were unaware of PILLS leaflet 523 which listed 
clinical conditions for patients to disclose to pharmacists. Two further respondents 
were unaware that patient conditions could be recorded within the PILLS system. 
Four respondents complained of there being insufficient time to enter clinical 
conditions into their systems. Ten respondents stated that they intended to commence 
recording clinical conditions. One stated that the recent paper by Rogers, Fletcher and 
Rees**? had prompted the recording of clinical conditions. One respondent stated that 
she had recently taken over as pharmacy manageress and that the pharmacy, previously 
under locum cover, had made very poor use of the patient records. Anecdotally, this 
supports the findings in Section 2.4.2 regarding the low use of PMRs in those 
pharmacies under locum control.
Three respondents gave more detailed and pertinent reasons for the difficulty in 
recording clinical conditions. These were as follows:
i) "The addition of conditions to a patient file has to be done with extreme 
caution, because what the patient may state may conflict with the actual 
diagnosis, or the diagnosis that the practitioner has told the patient. The 
interpretation of interactions or difficulties associated with the inclusion of a 
condition need to be dealt with (sic) extreme caution and tact. Some of the 
conditions are time-dependent and can expire, eg. pregnancy and lactation."
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ii) "Difficult to assign patients to changing conditions, eg. pregnancy. Data 
should be kept up to date under Data Protection Act Regulations. Patients 
willing to disclose selective data, eg. gout but not schizophrenia."
iii) "We generally view a patient's medication profile to arrive at our own 
judgement of which conditions, and the degree of severity which is relevant."
Two of these quotes (i & ii) discuss problems with conditions considered to be 
transient, eg. pregnancy. There is probably a case for the suppliers of PMR systems to 
provide an on-screen prompt at a specified time to check whether such a clinical state 
still applies. At the time of writing (May 1993), Park Systems Ltd. have just 
introduced such a feature into their system.
The first quote raises the problem of whether the patient's interpretation of their 
condition is the same as their prescriberis diagnosis. This is an extremely important 
issue if pharmacy records are to be relied upon to detect product contraindications. It 
is important for the pharmaceutical and medical professions to discuss how conditions 
should be recorded within pharmacy records. This subject is discussed further in the 
survey of GPs' attitudes to pharmacy-held PMRs in Chapter 9.
One PILLS-usqt felt that clinical conditions would be better recorded on smart cards. 
Certainly the use of a smart card, containing clinical details, could resolve the problem. 
However the use of smart cards in England and Wales is not being actively pursued by 
the Department of Health at present, due to the failure of the Exmouth Project to 
demonstrate any significant benefits from their use^l, although a new trial is taking 
place in Scotland.42
Clearly, from the respondents' comments in this January 1993 survey of PILLS-users 
and the low reported use of the PILLS system to record clinical conditions, there is a
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need to examine how this feature could be better utilised. One respondent stated that 
input of conditions from an on-screen menu (cf. Park Systems) would be a much better 
method of recording relevant information.
4.2.4.4 Confirmation of Earlier Hypotheses
The findings from the January 1993 survey of PILLS-users support only one of our 
earlier hypotheses, which is that the SEG of a pharmacy clientele influences the 
recording of patients as drug abusers or addicts. This survey has shown that 
pharmacies serving a DE clientele are more likely than those serving other groups to 
record drug abuse (p<0.05). This supports the finding from our initial survey in April 
1991 survey (p<0.001) that the recording of drug abuse increases as one progresses 
down the socio-economic scale.
There are two possible reasons why all other findings were not statistically supported 
by this further survey of PILLS-usqts. The very limited recording of clinical conditions 
by the majority of the respondents in this survey makes it very difficult to obtain 
meaningful comparisons, which will withstand rigorous statistical tests.
A second possible reason is that our April 1991 survey was a representative sample of 
all pharmacies using a wide variety of PMR systems, but this January 1993 survey has 
been conducted on a sub-sample, estimated to include approximately 5% of all PMR- 
users. The nature of PILLS-user respondents in the April 1991 survey has been 
described in Section 2.4.11. Tables 4.1-4.5 show that there have been no major 
changes in the nature of PILLS-users since April 1991, in terms of the factors found to 
have an influence in the April 1991 national survey: regional location, SEG of 
pharmacy clientele, and year of registration of the pharmacist in charge. In the April 
1991 study, it was shown that the sub-sample of PILLS-useis was not representative of 
the total population of PMR users (Section 2.4.11). Therefore direct comparisons
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between the national survey in April 1991 and the January 1993 survey of PILLS-users 
become very difficult. It might have been better to have conducted this later survey 
among a broader sample of PMR-users. However, that would have created additional 
problems as it is not possible to interrogate the patient databases within most suppliers' 
systems to obtain the data that was required for this survey.
It is not considered that Conclusions 2.5.8-2.5.10 have been disproved by this survey, 
given the differences between the PMR-user sub-sample in this January 1993 survey of 
PILLS-users and the sample of PMR users taken from the total PMR-user population 
in the April 1991 survey. This is despite not being able to show that the recording of 
patients' clinical conditions was influenced by the pharmacy's regional location, year of 
registration of the pharmacist in charge, or the SEG of the pharmacy's clientele, other 
than recording of drug abuse being influenced by the SEG of the PILLS-user's 
clientele.
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4.3 An Audit of Clinjcal Conditions Recorded in the PMR System at
One Branch of a Large Multiple Pharmacy.
The support of Miss Katherine Smith is acknowledged for her assistance in data- 
gathering for Section 4.3. Miss Smith undertook this work under my supervision, as 
part of an undergraduate project.
4.3.1 Introduction
The recording of patients' clinical conditions in PMR systems has been described in 
Chapter 2. One benefit of recording that information is that community pharmacists 
are better able to monitor the prescribing of both contraindicated prescribed and non- 
prescription medicines, and intervene if a particular product is unsuitable. This is 
facilitated further if a PMR computer system in use, such as the Hadley Hutt PILLS or 
Park Systems' program, can automatically detect drug-condition incompatibilities.
There were three objectives in undertaking this study. First, to assess, in some detail, 
the potential of using a PMR system to record patients' clinical conditions within a 
single community pharmacy. The second objective was to enable a comparison of the 
levels of clinical condition recording between the PILLS system and an "in-house" 
system known to be capable of recording a wide range of conditions (Figure 2.9). A 
third objective of the survey was to compare the incidence of recording of clinical 
conditions in the community pharmacy PMR system with national morbidity data. 80
4.3.2 Method
A medium-sized branch of a large multiple pharmacy company was selected for this 
survey. The community pharmacy concerned is located in the high street in a small 
town in Avon, with a population of about 20 000. A computerised PMR system had 
been in operation at this pharmacy since May 1991. It is the normal practice at this 
pharmacy to counsel patients (or their parent or representative) on the purpose of the
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PMR system, and to provide a patient questionnaire requesting details about the 
patient, their general practitioner, and any drug allergies or any chronic clinical 
conditions that they had. Details from the returned patient questionnaires are 
subsequently entered in the computerised PMR system, and the questionnaires 
archived.
All patient questionnaires returned prior to the date of this study (February 1993) were 
scrutinised and each patient's clinical conditions anonymously entered in a Microsoft 
Excel database, which enabled cross-tabulation and statistical examination of 
associated clinical conditions, using the SPSS-PC+ V4.0 statistics package.^ No 
patient names, addresses or other particulars were recorded during the survey. Patient 
medication histories were not examined.
4.3.3 Results
At the time of this retrospective survey (February 1993) there were 7429 patient 
records stored in the system. Completed questionnaires had been returned by 1895 
patients (25.5% of all patient records). The numbers of patients suffering from 
recorded clinical conditions, and allergies to penicillin and aspirin, are shown in Figure 
4.3. Several other conditions were recorded for single patients only, eg. Wolff- 
Parkinson-White syndrome, ankylosing spondylitis, carpal-tunnel syndrome and house 
dust-mite allergy. These are not shown in Figure 4.3.
Applying the test of in d ep e n d e n c e^  to cross-tabulated conditions showed that 
certain conditions were associated with each other, as follows: asthma and hay fever, 
asthma and eczema, hay fever and eczema (all p<0.001), and diabetes and cardio­
vascular disorders (p<0.01).
143
A comparison of the incidence of the recorded clinical conditions with national 
morbidity data^O is shown in Figure 4.4. If the ratio of the recording of each clinical 
condition within the PMR system matched that found in national morbidity data, the 
two lines on Figure 4.4 would overlap. Where the incidence of recorded clinical 
conditions is higher than one would expect from national data, the pharmacy plot 
would be above the plot for national morbidity data, and vice-versa.
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Figure 4.4: Percentage of patients in the medication records held at a branch of a large multiple pharmacy 
noted as having certain clinical conditions, compared with the UK population as a whole.
—  PMR system  
■" UK population
4.3.4 Discussion
Although the percentage of questionnaires returned by patients could be considered 
low, the level of reporting of clinical conditions by patients (25.5%) confirmed the 
potential for the use of PMRs in community pharmacy as a clinical database to monitor 
for contraindicated prescribed and non-prescription medicines. For example, 15.6% of 
all patients returning questionnaires claimed to be hypertensive and 14.5% claimed to 
be asthmatic. Hypertension, asthma, diabetes mellitus, epilepsy, peptic ulcer and 
glaucoma are all examples of conditions in which certain drugs are contraindicated. 
Clearly, the community pharmacist has a vital role to play in monitoring for the use of 
contra-indicated drugs. Such use of PMR systems to monitor for the use of contra­
indicated prescribed and non-prescription medicines is discussed in Chapter 7.
Figure 4.4 shows that a higher number than expected of patients at the study 
pharmacy were recorded as suffering from asthma and hay fever; indeed 89 patients 
(4.7% of those returning a questionnaire, 1.2% of all patient records) were recorded as 
suffering from both conditions. This is possibly a reflection of a high incidence of hay 
fever in the South W e s t .  72 The recording of patients suffering from eczema appeared 
low, possibly due to a low perception of the importance of this condition, especially in 
mild cases, by patients. If this was true, patients may feel that suffering from eczema 
has no relevance to their medication profile, and therefore there was no need to report 
this to their community pharmacist.
The number of patients recorded as suffering from arthritis was high, reflecting the 
large number of elderly patients who collect regular medication from this pharmacy. It 
is also possible that the high incidence of the recording of arthritis could be due to a 
high level of awareness and easy access to Rheumatology consultants at the Royal 
National Hospital for Rheumatic Duseases in Bath, which is only seven miles from the
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pharmacy concerned. For each of the other clinical conditions examined, the incidence 
of recording each condition within the PMR system was broadly as would be expected 
from national morbidity data.
For community pharmacists, there could be some advantages in conducting an audit of 
the clinical conditions recorded in their PMR systems, where such patient information 
is routinely recorded. This survey has shown that examining the profile of clinical 
conditions recorded within a community pharmacy's PMR system could provide a 
method of studying that pharmacy's client population. The information so derived 
could be used in planning future patient services and product inventories; for example, 
if the pharmacist finds that he has a large number of arthritic patients there could be a 
case for the inclusion of an appropriate range of aids for the disabled in his stock 
inventory.
4.4 General Comment
Although the records from only one branch of the large multiple pharmacy company 
were audited, these two surveys appear to confirm that the recording of patients' 
clinical conditions within PMR systems is still highly system-dependent (Sections 2.4.5 
& 4.2.4.3). However, following modification of the PILLS software there is now 
greater scope to record clinical conditions within the PILLS system than within the 
"in-house" system used by the large pharmacy multiple company, unlike the prevailing 
conditions when the original surveys were undertaken in April 1991 (Chapter 2). 
Therefore, factors in addition to the computer software must be influencing what is 
recorded. As stated in Section 4.3.2, it is normal practice within branches of the 
pharmacy multiple concerned to issue a questionnaire to patients, including a request 
for details of the patient's clinical conditions. This study has shown that, although 
only a relatively low percentage of patients returned the questionnaires, a considerable 
amount of patient data had been received by the study pharmacy and consequently
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entered into the PMR system. In contrast, several PILLS-users have stated reasons 
why the recording of patients' clinical conditions has been limited (Section 4.2.4.3). 
Clearly, there is a need to evaluate the best way for community pharmacists to obtain 
accurate and relevant information on patients' clinical conditions. Such methods would 
need to be agreed and developed with the medical profession. This is further discussed 
in Section 9.4.4.
4.5 Conclusions
1. Users of the Hadley-Hutt PILLS system tend to record few details about 
patients' clinical conditions, despite an enhancement to the PILLS software. 
Some users of this system are still unaware that clinical conditions can be 
recorded as part of a patient's record. There is a need to ensure that PMR 
systems' ability to record a patient's clinical conditions are better utilised by 
PILLS- users.
2. The recording of patients as drug-abusers by pharmacists using the PILLS 
system is dependent on the socio-economic group of the pharmacy clientele. 
The highest relative incidence of recording patients as drug-abusers was found 
in those pharmacies serving a clientele from the DE SEG.
3. Audit of patient's clinical conditions, using data held in PMRs may enable 
pharmacists to have a better understanding of their client population. This 
could have implications for the provision of improved services by community 
pharmacies.
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5. Patient Information Leaflets
5.1 Introduction
In community pharmacy practice it can be considered that patients receive information 
with dispensed products in at least one of four ways: advice from prescribers and their 
staff; directions written on the product label; verbal advice from pharmacists and their 
assistants; and from patient information leaflets. Studies have shown that patients' 
recall of spoken information is often limited, hence a need for the provision of a written 
reminder. 82 i n  this chapter, the use of patient information leaflets is described briefly 
and the results are presented of two studies on the use of information leaflets produced 
by the Hadley Hutt PILLS system.
5.1.1 The Use of Patient Information Leaflets
It is important that patients understand relevant information provided to them on 
information leaflets. Davis has shown that there is a gap between patient 
comprehension and the readability of certain patient education materials. 83
Sutton et al have shown that patients want information leaflets to include illustrations 
and simple information on side effects, interactions, dose and the effect of missed 
doses. 84 in Italy, Miselli and co-workers showed that consumers preferred 
experimental leaflets produced by a group of clinical pharmacists over standard 
package inserts approved by the Italian Ministry o f  H ealth .85 Miselli's group claimed 
that there was a need to develop an improved consumer-oriented language for widely 
used drugs.
In the UK, most of the recent work assessing patient information leaflets has been 
conducted by Professor George's research group at Southampton University.86-90 
They have shown that patients want and need more information than they received 
from doctors and p h a r m a c i s t s . 86,87 Furthermore, they showed that patients who
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received information leaflets knew more about their medicines, especially any 
associated side effects. In a survey of 3410 patients recruited at 254 pharmacies, 
Gibbs et al showed overwhelming public support for the use of patient leaflets, and 
also demonstrated significant improvements in patients' knowledge about their 
medicines. 88 in general, they found that side effects were not reported any more often 
by patients who were given leaflets than by those who were not. However, for one 
group taking P-adrenoreceptor antagonists, patients given leaflets were more likely to 
report sleeplessness, vivid dreams, itching and rashes.
The effect of patient information leaflets on compliance is unclear. Despite the 
improvements in patients' understanding of their medication, information leaflets have 
not actually been shown to improve patient compliance. In fact, anecdotal evidence 
exists to show that providing patients with information about side effects may lead to 
non-compliance with a prescribed regimenal In a survey of 1218 patients using 
inhaled bronchodilators, Gibbs could not produce evidence to show that patients who 
received information leaflets were more compliant than those control patients who did 
not. 89 in a much smaller survey of 68 patients, Dodds showed that, in the absence of 
any counselling from pharmacists, patient information leaflets improved compliance in 
patients receiving antibiotic therapy. 92
Kitching has reviewed the use of patient information leaflets. ^ 3 In his paper, he 
described the use of readability formulae and made 16 recommendations for the 
improvement of a text's comprehensibility. In addition, he listed the effects that 
typographical layout may have on well-written and readable information, making a 
further 12 recommendations on typography.
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5.1.2 Leaflets Produced by Pharmacy Computer Systems
Leaflets can normally be provided to patients in one of three ways. First, it is now 
common for original packs to contain an information leaflet. Indeed, the EEC Council 
has proposed that leaflets should be included in all original packs of products that are 
introduced or require product licence renewal after 1 January 1994. This was enacted 
by Parliament in January 1993.94 The ABPI has produced a definitive document on 
those details that should be included in patient leaflets.95 The purpose of these 
industry-produced leaflets is to reinforce and amplify information given to patients by 
pharmacists and doctors. The use of package inserts, and some of the problems 
associated with them, have been described by Griffin. 96 He identified the key problem
t
with the use of package inserts in the UK as original pack dispensing not being the 
norm. A further problem, described by Raynor, is that, since original packs should be 
dispensed intact to patients, pharmacists are not able to use their professional 
judgement as to whether the package insert is appropriate for a particular patient.97
A second type of information leaflet is that provided by pharmacists as an adjunct to 
advice. Commonly, these are non-product-specific and deal with dosage forms with 
which patients may be unfamiliar, eg. eye drops and suppositories. Typically, these 
leaflets will contain illustrations on how to use a particular dose form.
The third method of supplying leaflets to patients is by means of the pharmacy 
computer system, a method pioneered by Hadley in the mid-1980s in the UK.98 Chir 
1991 survey identified that three UK suppliers of pharmacy computer systems (Hadley 
Hutt, Park Systems and John Richardson Computers) offered leaflet production as an 
optional feature on their system (Section 2.4.12). In Chapter 6, it will be shown that 
many pharmacy computer systems used in the USA have a facility to produce patient 
information leaflets (Table 6.4). A recent paper has described the use in Finland of a 
computer-based drug information system £Z£/.99 This system integrates with
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software used to process prescriptions, and is capable of producing leaflets about the 
effects, adverse effects and proper use of dispensed medicines.
5.2 Assessment of the Readability of Leaflets Produced by the Hadley 
Hutt PILLS System
5.2.1 Methods of Assessing Readability
Certain patient information leaflets have been criticised for being either too simple or 
too complex. 89 jn particular, original-pack leaflets enclosed with oral contraceptives 
have been singled out for criticism.89,90 Such leaflets have been described as being 
written in a style, and with such detail, that only a biological sciences graduate could 
understand them.90 George stated that leaflets should be written using simple words 
and avoiding jargon.
Readability is the measure of the ease (or level of difficulty) with which a text can be 
read and understood. *00 Several readability indices exist to assess numerically the 
readability of a text. Readability indices are usually based on regression formulae.93 
Examples are the Flesch Formula (Flesch Reading Ease Score), the Dale-Chall Formula 
and the SMOG grading. 32 One of the most commonly quoted formulae is the Flesch 
Reading Ease score* 01, which is calculated on a scale of 0 (very difficult) to 100 
(very easy), and is calculated using the following equation:
Reading Ease = 206.8 - 0.846W - 1.015S
where W=Number of syllables per 100 words, S=Average number of words per 
sentence.
The interpretation of calculated Flesch Reading Ease scores is shown in Table 5.1.
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Table 5.1: Interpretation of Flesch Reading Ease scores.^
Reading ease score Verbal description of 
score
Estimated percentage who would 
understand document with given 
score:
Aged 25+ Aged 75+
90-100 Very easy 97 91
80-90 Easy 95 88
70-80 Fairly easy 90 77
60-70 Standard 90 77
50-60 Fairly hard 77 50
30-50 Difficult 31 17
0-30 Very hard 7 3
5.2.2 Method
This study involved a comparison of Flesch Reading Ease scores for Hadley Hutt 
PILLS leaflets with patient information leaflets supplied with equivalent products from 
different drug manufacturers. Although similar methods* 00 have been applied to the 
readability of patient education materials, no studies of the readability of pharmacy 
computer-produced materials have been reported in the literature.
Flesch Reading Ease scores were calculated manually by recording the average 
numbers of words per sentence and number of syllables from a sample of 100 words on 
each patient information leaflet. Average syllable numbers were recorded for five 100 
word samples; and the average sentence length was calculated by dividing the total 
number of words in the leaflet by the number of sentences.
The accuracy of this simple method of calculating Flesch Reading Ease scores was 
checked by the use of two computer packages: Microsoft Word and Grammatik IV 
(Reference Software). Hadley Hutt Computing Ltd supplied a computer disk 
containing ASCII files of 10 PILLS leaflets. Flesch Reading Ease scores were
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calculated by each package, as well as by the manual method described above. A 
comparison of the figures generated by each method is shown in Table 5.2. While 
there was some variation between the three sets of figures, the results were considered 
sufficiently consistent to proceed with the computerised methods of calculation. 
Similar results were obtained by Baker when comparing manual methods with 
computerised calculations performed by two software packages, RightWriter 3.0 and 
Grammatik El. 100
Table 5.2: Comparisons of reading ease scores for PILLS leaflets using three different 
methods of calculation.
Flesch reading ease scores
Drug leaflet Manual Microsoft Word Grammatik IV
Topical corticosteroids 68 61.7 62
Buccal nitrates 65 73.2 69
Migril 70 51.7 62
Vaginal nystatin 60 54.8 61
Nalidixic acid 70 73.0 74
Piroxicam 71 64.7 67
Calciferol 62 64.2 70
Naltrexone 65 64.9 67
Quinoderm 58 61.7 68
Vitamins A and D Capsules 68 66.9 67
Mean 65.7 63.7 66.7
Standard deviation 4.5 6.7 4.1
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5.2.3 Results and Discussion
A comparison of manually calculated Flesch Reading Ease scores for 21 manufacturers' 
original pack leaflets and equivalent PILLS leaflets is shown in Figure 5.1.
Flesch Reading Ease scores for the original pack leaflets ranged from 46-81 
(mean=70.2, std deviation=6.78). Figure 5.1 shows that all the original pack leaflets 
examined, except a package insert for Trinordiol produced by Wyeth, had a Flesch 
Reading Ease score of 60 or above. Using Table 5.1 to interpret these results shows 
that 90% of the adult population aged over 25, and 77% of the population aged over 
75 would have been expected to understand such leaflets. However, only 31% of the 
population aged over 25, and 17% of the population aged over 75, would have 
understood the Trinordiol leaflet. The companies ICI and Servier produced leaflets 
with the highest scores of 80 or over. At this score, the leaflets should be understood 
by over 90% of the population aged over 75. These readability results reflect those 
from a recent study of industry-produced l e a f l e t s .
The score of all PILLS leaflets was at least 60, ranging from 62-80 (mean=70.1, std. 
dev.=5.15). This implies that the leaflets produced by the PILLS system would be 
understood by 90% of the population over 25, and 77% of the population over 75. 
PILLS leaflets produced more consistent scores than original pack inserts, which is not 
surprising given that PILLS leaflets are derived from a single source, whereas the pack 
inserts come from different manufacturers.
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5.3 The Effect of Information Leaflets on Compliance
5.3.1 Introduction
As discussed in Section 5.1.1, there has been little published evidence to demonstrate 
that information leaflets actually improve patient compliance, though Raynor has 
described how a patient reminder chart has been shown to improve compliance J03 
These reminder charts were computer-generated automatically as part of the labelling 
process within a hospital pharmacy department. The charts gave information on the 
name(s) of patients' medication, doses and the times at which medication should be 
administered. However Raynor's charts did not provide information on therapeutic and 
side effects of prescribed medication.
There have been no published reports of the effects of pharmacy computer-produced 
patient information leaflets on compliance. It was decided, therefore, to conduct such 
a survey on a pilot scale examining the effect of PILLS leaflets on the compliance of 
patients receiving short courses of antibiotics for acute illness. It was felt that 
relatively large numbers of patients would be seen in community pharmacies over a 
period of six weeks in the winter months, thus facilitating data collection.
For the purpose of our study, patients were regarded as "compliant" if they completed 
their full course of antibiotics, and took the medication at an appropriate time in 
relation to food. Non-compliant patients were regarded as those who did not complete 
the prescribed course of antibiotics or took them at the wrong time in relation to food, 
for example taking oxytetracycline with meals.
5.3.2 Method
This study was undertaken with the assistance of Miss Karen Harris MRPharmS who 
designed the questionnaire and analysed the data as her final year undergraduate 
project.
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Two community pharmacies operating the Hadley Hutt PILLS system were selected 
for this survey: a health-centre consortium pharmacy in Glastonbury, Somerset; and a 
suburban independent pharmacy in Plymouth, Devon. Both had participated in the 
earlier survey of PILLS users (Section 2.2.4), and the pharmacists in charge had 
indicated a willingness to participate in further research projects. A questionnaire was 
developed (Appendix 2, page 328), requesting the following information from patients: 
the name of their prescribed antibiotic; details of any side effects they experienced; 
when they took their medication in relation to meals; their age and sex; whether they 
received an information leaflet; and, if so, whether they had read and had felt they 
understood it.
Two hundred colour-coded questionnaires were sent to each pharmacy along with 200 
Freepost envelopes. A covering letter was sent to each pharmacy requesting the co­
operation of employed pharmacists. The instructions provided asked participating 
pharmacists to give a questionnaire to each patient over 16, who had a prescription 
dispensed for any antibiotic listed in Section 5.1 of the British National Form ulary.81 
The Plymouth pharmacy was advised to hand out a green form and Freepost envelope 
to those receiving a PILLS leaflet and counselling with their antibiotic and an orange 
form with a Freepost envelope to those control patients receiving counselling only. 
The Glastonbury pharmacy followed the same principle using beige and purple forms. 
Pharmacy staff were instructed to continue the project for four weeks commencing 20 
January 1992; data was collected for a further four weeks, ie. eight weeks from the 
beginning of the survey. Forms returned after that date were excluded from analysis.
Cross-tabulated responses from the completed questionnaires were examined using the 
SPSS/PC+ V4.0 statistics package, and the x^ test of independence.^*^
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5.3.3 Results and Discussion
All 200 questionnaires were given to patients by the Plymouth pharmacy, and 197 
questionnaires were given out by the Glastonbury pharmacy. A total of 167 completed 
questionnaires was received: 81 from Plymouth and 86 from Glastonbury. This 
represented an overall 42.1% response, which was slightly lower than anticipated. A 
disadvantage of the anonymous nature of this survey was that non-respondents could 
not be followed up. Of the 167 respondents, 85 (50.9%) had received a PILLS leaflet, 
and a further 28 (16.8%) had received a manufacturer's original pack insert. One or 
more suspected adverse drug reactions (ADRs) was suffered by 69 patients (41.3%)
The effect of the various examined parameters on patient compliance is shown in Table 
5.3. Significant findings (p<0.05) are shown in bold type.
Table 5.3: Effects of patient information leaflet provision and ADRs upon compliance 
of male and female patients receiving antibiotic therapy.2_________________________
Patient group/category: Compliant: Non-compliant:
Receipt of any product information leaflet 106 (93.8%) 1 (6.2%)
Non-receipt of any product information leaflet 48 (88.9%) 6(11.1%)
Receipt of PILLS leaflet 79 (92.9%) 6 (7.1%)
Non-receipt of PILLS leaflet 75(91.5%) 7 (8.5%)
Male patients 62 (95.4%) 3 (4.6%)
Female patients 92 (90.2%) 10 (9.8%)
ADRs suffered by patient 59 (85.5%) 10 (14.5%)
No ADRs suffered by patient 95 (96.9%) 3 (3.1%)
^The figures quoted are numbers (and percentages) of patients in each category who 
complied or did not comply.
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The only factor which was found to have any influence on patient compliance was the 
incidence of ADRs. Thus, patients who considered that they experienced one or more 
side effects at the time of taking their antibiotics were significantly (x^—7.4, df=l, 
p<0.01) more likely not to comply with their prescribed regimen. Further tests 
were performed on cross-tabulated data to examine the possible associations of, first, 
leaflet provision and, second, the concurrent administration of other medication with 
the incidence of ADRs. Of the total 113 patients who received an information leaflet, 
52 (46.0%) claimed to suffer an ADR whereas only 17 (31.5%) of the 54 patients who 
did not receive an information leaflet claimed to suffer an ADR. Of the 76 (45.5% of 
the total respondents) who were concurrently taking other medicines, 37 (48.7%) 
claimed to suffer side effects as a result of their antibiotic, compared with only 35 
(38.5%) of the 91 (54.5% of all the respondents) who were not taking other medicines. 
Despite the apparent influence of patient information leaflets and other concurrent 
medication on the incidence of ADRs, these results were not significant at the 5% 
significance level.
The results from this limited study of patients receiving information leaflets provides 
some support for previously published work, although one cannot draw many 
conclusions from a survey with a less than 50% response. One has no way of knowing 
how the 57.9% of patients who did not respond behaved in taking their antibiotics. It 
is quite possible that those who did not respond (and who therefore did not comply 
with their questionnaire instructions) were less likely to comply with their prescribed 
regimen.
The results in Table 5.3 support previous work**9 showing that the provision of patient 
information leaflets does not improve patient compliance. Conversely, our results do 
not show that the provision of patient information leaflets has an adverse effect on 
patient compliance. The only factor that influenced patient compliance according to 
our survey was side effects produced by prescribed medication. This finding has
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implications for prescribes, in that it is recommended, where practicable, they do not 
prescribe medication associated with a high incidence of side effects, for example the 
new macrolide clarithromycin should be regarded as preferable to the older drug 
erythromycin.
Gibbs et al presented conflicting evidence about whether issuing patients with 
information leaflets that provide detailed information about side effects causes them to 
report a higher incidence of ADRs. 88 While not statistically significant in our survey, 
the results might indicate that the use of patient leaflets does indeed increase the 
reporting of adverse effects. It is possible that detailing side effects to patients may 
cause them to attribute side effects to their medication, whereas the same symptoms 
might have been attributed to other causes if no such leaflet had been read by the 
patient. Further work is needed in this area, with a larger patient cohort to determine 
whether the provision of information on side effects does in fact cause patients to 
experience more adverse drug reactions. Such a survey should be carefully controlled, 
whenever possible, to exclude patients taking other medication.
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5.4. Conclusions
1. Use of the Flesch Reading Ease formula, to calculate readability scores for both 
industry-produced and pharmacy-generated patient information leaflets, 
showed that most leaflets currently in use would be understood by a large 
majority of the adult population. However, one leaflet (Trinordiol) examined 
was unlikely to be understood by a majority of the population, due to the 
complex presentation of the information.
2. This limited study appears to show that patient information leaflets have a 
neutral effect on patient compliance.
3. These results show that patients who suspect that they have had ADRs as a 
result of prescribed antibiotic therapy are less likely to comply with their 
prescribed medication than those who had no suspected ADRs.
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6. A Comparison of Patient Medication Record Systems Used bv 
Community Pharmacists in the UK and USA
6.1 Introduction
During the course of the research described in this thesis, it became apparent that 
major differences existed between PMR systems in the nature of the information 
provided to pharmacists about potential drug interactions. This problem is discussed in 
detail in Chapter 8. Its was, therefore, considered essential to examine the sources of 
pharmaceutical information for those PMR systems that had the largest market share in 
the UK (Figure 2.3). Furthermore, it was considered to be advantageous to compare 
PMR systems used in the UK, with those in another English-speaking country with a 
tradition of PMR use in community pharmacy. The USA was selected for this 
purpose.
The purpose of this study was to compare and contrast pharmacy computer systems 
available in the UK and USA, with particular reference to those facilities that aid the 
community pharmacist in his clinical role. The sources of pharmaceutical information 
used to compile each system’s database(s) have been noted, as well as the extent of 
referencing of the information that is provided to the pharmacist, for example on 
potential drug interactions. Other criteria discussed include: the ability of systems to 
report product information; how potential drug interactions are presented; whether 
information was provided on patient conditions; and the use of patient information 
leaflets. This survey was not intended to be a fiill evaluation of the functionality of the 
hardware and software of each PMR system.
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6.2 Investigative Methods 
6.2.1 Postal Survey (June 1992) of Suppliers of USA Pharmacy 
Computer Systems
An issue of the American pharmacy computing journal ComputerTalk was examined to 
obtain the names and addresses of 27 listed pharmacy computer system suppliers in the 
U S A .  104 £ ach identified supplier was sent a postal questionnaire (Appendix 2, page 
329) requesting information on: the type and supplier of the database(s) used within 
the system; drug use and dosage, adverse drug reactions; drug interactions, the 
recording of patient conditions and allergies; residential care and management 
information facilities.
Subsequent to the questionnaire survey, further details and demonstration software 
were requested from two suppliers of pharmacy databases in the USA: First Data Bank 
and Medi-span.
6.2.2 Examination of UK Systems
Each of the five systems identified as having the largest market shares in the UK in 
April 1991 (Figure 2.3) is available in the teaching laboratories of the School of 
Pharmacy and Pharmacology, University of Bath. The various factors examined in the 
survey of USA suppliers could therefore be investigated by use of the software in the 
laboratory.
A recent paper had discussed the inclusion of patient coding methods (Sectionl.5) 
used in a number of those computer systems used in general medical practice. 105 
Enquiries were made as to which, if any, patient coding method was used in the AAH 
Meditel, VAMP, M-Tec and Genisyst systems used by GPs.
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6.3 Results and Discussion
Of the 27 identified USA suppliers, only 13 (48.1%) responded by sending a completed 
questionnaire or information brochure. This was a slightly disappointing response, 
though perhaps not surprising given the location of the potential respondents, and their 
lack of a clear motive to reply. In the cases of non-response, the article in 
ComputerTalk^  was scrutinised to extract relevant information from the published 
tables of data. Information obtained from the published tables, the returned 
questionnaires and suppliers' literature is shown in Tables 6.1-6.5.
The 27 identified USA suppliers are listed in Table 6.1, along with the type of database 
used (where this could be ascertained), the database supplier and whether a standard 
coding system was used for patient details. More suppliers employed a relational 
database structure than a flat-file structure, the former enables more flexible use of 
software, with the option of integrating third party databases, for example product 
information and features for processing insurance claims. The two principle data 
suppliers were found to be First Data Bank (Hearst Corporation) and Medi-span. The 
only patient coding system found in the USA systems was ICD-9 (International 
Classification of Diseases 9th edition). There is no standardised patient coding systems 
in use in UK pharmacy systems, though ICD-8 (International Classification of 
Diseases 8th edition) featured in the VAMP system used in UK general medical 
practice. The Read clinical coding system (Section 1.4) was implemented in the AAH 
Meditel and M-Tec systems; the suppliers of the Genisyst and VAMP systems 
indicated that they planned to include Read coding during 1993.
Table 6.2 shows comparisons between USA and UK systems in the provision of 
product information by the software. In general, more specific product information 
was provided by the USA systems, although the Philex database in the AAH LINK 
system provides "data sheet" style information on drug side-effects. The Hadley Hutt 
PILLS system provides information on the signs and symptoms of adverse effects by
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means of information leaflets (Section 5.1.3). Information on normal dose ranges was 
provided by some of the USA and UK systems, including the AAH LINK and Hadley 
Hutt PILLS systems; the latter providing this data at the point of labelling.
Drug interaction monitoring was a feature of all the USA and UK systems examined 
(Table 6.3). The number of levels of severity of interaction ranged between one and 
five; with the USA systems tending to feature a higher number of levels. Drug 
interaction information was either provided by a data supplier, or developed in-house, 
or in consultation with a University School of Pharmacy. All of the USA systems 
provided literature references for drug interactions; whereas the Hadley Hutt PILLS 
system was the only UK system to do so. Reference sources used by pharmacy 
computer suppliers are described in detail in Section 8.1.
The recording of patients' clinical conditions has been discussed in Sections 2.3.3 and 
4.1; the ability of systems to utilise this feature is shown in Table 6.4. She systems 
(3PM McKesson, Etreby, RenLar Systems, Reynadyne Data Systems, Hadley Hutt 
PILLS and Park Systems) cross-referenced the databases for patient condition and for 
drugs, thus enabling automatic monitoring for contraindicated medication. All the 
USA suppliers who responded to the questionnaire stated that drug allergies could be 
recorded within their systems. With the exception of the Hadley Hutt PILLS system, 
the ability of UK systems to record patients' drug allergies was limited. Patient 
information leaflets, providing information on dispensed medicines, were available on 
all USA systems, and three UK systems. Two of the USA systems and one UK system 
provided patient leaflets on certain medical conditions, in addition to the information 
about dispensed products.
In the USA, software vendors sell products intended for pharmacists' use in residential 
care establishments, often in association with a portable computer which can be taken 
from the pharmacy into the residential care establishment.^ Such computer systems
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can be brought into the establishment by the pharmacist, who is then able to provide a 
clinical service, monitoring for drug interactions and contraindications. A similar 
system, Littlefoot, was launched in the UK in April 1993 by Surgichem Ltd. for use in 
conjunction with their Nomad monitored dosage system. At the time of this survey 
(June 1992), facilities for the management of monitored dosage dispensing, albeit 
dispensary-based, were included in the Hadley Hutt PILLS system, and were options 
available on the John Richardson and Park Systems' programs. All the systems 
examined also provided pharmacy management support, eg. stock control and 
prescription pricing.
6.3.1 Pharmacy Database Vendors in the USA
The information in Table 6.1 show that at least 17 out of the 27 USA computer 
suppliers used data from either First Data Bank or Medi-span. In the USA, the 
pharmacy systems were structured in a more modular manner than those in the UK. 
With the exception of the AAH LINK system, all drug file, pricing and interaction data 
in the UK were produced in-house, either with or without consultancy support. In the 
USA, pharmacy computer vendors sell programs that process database information 
that has been licensed by one or more third-party data-providers, eg First Data Bank 
and Medi-span.
6.3.1.1 First Data Bank
Both First Data Bank and Medi-span supplied product information and demonstration 
software. First Data Bank's National Drug Data File (NDDF) appeared to be more 
comprehensive than any comparable UK database. This system enabled dosage and 
frequency of administration to be checked, and issued a warning if they were 
unsuitable. Patient conditions and allergies could be recorded, and cross-referenced to 
the product database. References were provided for all information.. Interactions
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were given five priority levels, which is one more than the nearest UK equivalent 
(Exeter Data Base Systems’ Interlex [Section 8.1.6.2]).
A support system for clinical drug decision-making (Rx Triage) was included as part of 
First Data Bank's drug interaction monitoring software, providing information on how 
pharmacists should manage potential drug interactions when they are presented. An 
example is given in Figure 6.1.
Figure 6.1: Example of the drug interaction between anti-coagulants and salicylates 
as flagged by the Rx  Triage system
Anti-coagulants + Salicylates
*
Interaction: 1 - Most significant
*
How is salicylate used?
Salicylate use: Action:
1. Anti-platelet effect Intentional interaction: monitor patient.
2. Analgesia or anti-pyretic Can acetaminophen (paracetamol) be used
instead?
3. Anti-inflammatory Use non-salicylate instead.
The demonstration software from First Data Bank enabled patient information leaflets 
to be examined. These were somewhat less detailed than those produced by the 
Hadley Hutt PILLS system (Section 5.1.3).
6.3.1.2 Medi-span
Medi-span's Drug Therapy Screening System (DTSS) has been rated better than Rx 
Triage in its ability to detect potential drug interactions.**^ As well as recording
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product information, the DTSS system enabled the recording of patient's allergies and 
previous adverse reactions. The system could be utilised to predict other drugs to 
which a patient may also experience an adverse drug reaction. Patient, product and 
food databases were cross-referenced, and all interactions were referenced. This is in 
significant contrast to most systems used in community pharmacy in the UK. Five 
drug interaction warning levels were provided on this system, but the user had the 
opportunity to screen for, and only consider, the most serious level(s) if he so wished. 
A novel feature of this system was the derivation of the interaction warning level by a 
consideration of an interaction's predicted severity, likely frequency and documentation 
level (ie. the number of literature citations).
Patient education leaflets, to aid compliance with dispensed medicines, were produced 
by the DTSS system.
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Table 6.1: USA pharmacy computer suppliers, the database type and supplier, and 
patient coding system employed (where this could be determined).
Type Supplier(s) Coding
3PM McKesson Corp. Flat File In-house
system
Bluff Creek Systems - Medi-span -
BSI Business Systems Inc. - Medi-span -
Cardinal Health Systems Inc. Relational First Data Bank, Medi-span -
ComCoTec Inc. - - -
Compute-Rx Inc. Flat File First Data Bank -
Condor Corporation Relational First Data Bank I CD-9
DAA Enterprises Inc. - - -
Dagar Software Development Corp. - Medi-span -
Delphi Associates, Inc. - - -
Digital Simplistics Inc. Fiat File First Data Bank ICD-9
Etreby Computer Company, Inc. Relational In-house ICD-9
Foundation Systems Inc. - Medi-span -
General Computer Corporation Flat File First Data Bank, MONITORx ICD-9
Health Business Systems Inc. - First Data Bank -
Healthcare Computer Corporation - - -
Interactive Systems & - First Data Bank -
Management Corporation 
National Data Corporation - First Data Bank -
pc 1 professional systems, Inc. - Medi-span -
PharmaSoft Services - - -
QS/1 Data Systems - - -
RenLar Systems, Inc. Relational Medi-span ICD-9
Response - Medi-span -
Reynadyne Data Systems Inc. Relational First Data Bank ICD-9
Synercom Computers, Inc. - - -
Transaction Data Systems, Inc. - - -
Zadall Relief (Drug Store Systems) - First Data Bank -
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Table 6.2: Information availability on dose and adverse drug reactions in USA and UK pharmacy systems.
USA systems:
Dosing ADRs Severity Incidence Signs & Symptoms Consideration of allergies, overdose 
and toxic effects
3PM McKesson Corp. YES YES YES YES YES YES
Cardinal Health Systems Inc. YES YES YES YES YES NO
Compute-Rx Inc. YES YES NO NO YES NO
Condor Corporation NO YES YES NO NO YES
Digital Simplistics Inc. NO YES YES NO YES NO
Etreby NO NO NO NO NO NO
General Computer Corporation NO YES NO NO NO YES
RenLar Systems, Inc. NO YES YES NO NO YES
Reynadyne Data Systems Inc. YES NO NO NO NO NO
UK systems:
AAH LINK YES YES YES NO NO NO
Chemtec Alchemist 3000 NO NO NO NO NO NO
Hadley Hutt PILLS YES leaflets leaflets NO leaflets NO
John Richardson Computers NO NO NO NO NO NO
Park Systems NO NO NO NO NO NO
Table 6.3: The provision of drug-interaction information by USA and UK pharmacy systems: number of interaction levels, background 
information, database and references used.___________________________________________________________________________________
Drug
Interactions






3PM McKesson Corp. YES 5 Univ. Michigan YES Facts & Comparisons**®®
Bluff Creek Systems YES ? Medi-span YES Hansten**®7 Facts & Comparisons
Cardinal Health Systems Inc. YES 3 First Data Bank & Medi-span YES Hansten, USP Dl108
Compute-Rx Inc. YES 3 First Data Bank YES Hansten
Condor Corporation YES 5 First Data Bank YES Hansten. Facts & Comparisons
Digital Simplistics Inc. YES 3 Medi-span YES Hansten. Facts & Comparisons
Etreby YES 5 In-house YES Hansten. Facts & Comparisons
General Computer Corporation YES 3 MONITORx YES
QS/1 Data Systems YES ? YES Hansten, USP Dl, EDI109
RenLar Systems, Inc. YES 5 Medi-span YES Hansten
Reynadyne Data Systems Inc. YES 3 First Data Bank YES Hansten
Transaction Data Systems, Inc. YES ? First Data Bank
Zadall Relief (Drug Store Systems) YES ?
UK systems:
AAH LINK YES 4 Exeter Data Base Systems NO
Chemtec Alchemist 3000 YES 3 In-house NO
Hadley Hutt PILLS YES 2 In-house YES BNF81, Stockley69, USP Dl
John Richardson Computers YES 1 In-house / Stockley NO
Park Systems YES 3 Liverpool School of Pharmacy NO
Table 6.4: The recording in pharmacy computer systems, of patient conditions, allergies, effects on clinical tests (eg. urine analysis)
and cross-referencing between patient and drug databases; the production of information leaflets on dispensed products and a patient's
conditions.
Patient Information:




3PM McKesson Corp. YES YES YES YES YES NO
Cardinal Health Systems Inc. unknown unknown unknown unknown YES YES
Compute-Rx Inc. YES NO YES YES YES NO
Condor Corporation YES NO YES NO YES NO
Digital Simpiistics Inc. YES NO YES NO YES NO
Etreby YES YES YES YES YES NO
General Computer Corporation YES NO YES YES YES NO
RenLar Systems, Inc. YES YES YES YES YES NO
Reynadyne Data Systems Inc. YES YES YES NO YES YES
Zadall Relief (Drug Store Systems) unknown unknown unknown unknown YES NO
UK systems: 
AAH LINK YES NO NO NO NO NO
Chemtec Alchemist 3000 v. limited NO limited NO NO NO
Hadley Hutt PILLS YES YES YES NO YES YES
John Richardson NO NA penicillin only NO YES NO
Park Systems YES YES limited NO YES NO
Table 6.5: Residential care facilities and management information provided by USA and UK suppliers of pharmacy computer systems.
Residential Care Management Information
USA systems:
Regimen Review Utilization Review Stock Control Usage Enquiry Pricing
3PM McKesson Corp. YES YES YES YES YES
Cardinal Health Systems Inc. NO NO YES YES YES
Compute-Rx Inc. YES YES YES YES YES
Condor Corporation YES YES YES YES YES
Dagar Software Development Corporation YES YES unknown unknown unknown
Digital Simplistics Inc. YES YES YES YES YES
Etreby YES YES YES YES YES
General Computer Corporation NO YES YES YES YES
National Data Corporation YES YES unknown unknown unknown
RenLar Systems, Inc. YES YES YES YES YES
Reynadyne Data Systems Inc. 
UK systems:
NO NO YES YES YES
AAH LINK NO NO YES NO YES
Chemtec Alchemist 3000 NO NO YES NO YES
Hadley Hutt PILLS YES YES YES YES YES
John Richardson Option Option YES NO YES
Park Systems Option Option YES YES YES
6.3.2 Drug-Food Interactions
Some of the USA systems featured drug-food interaction software. This tends not to 
feature on UK systems, except within the patient advice printed on information leaflets. 
However, all of the UK systems that were examined produced BNF additional labels**! 
detailing whether products should be taken with food or on an empty stomach.
6.3.3 Third Party Links
Each of the UK systems examined permitted the use of a modem link to 
pharmaceutical wholesalers for the purposes of stock ordering. Most of the USA 
pharmacy computer systems also possessed a facility to pass details about supplied 
products to insurance companies funding drug costs; this contrasts with the UK where 
direct links between community pharmacies and the Prescription Pricing Authority 
have not yet evolved.
6.4 Conclusions
1 This survey has shown that the key patient-oriented functions of pharmacy 
computer systems, enabling prescription labelling, updating of medication 
records and drug interaction monitoring are broadly similar in the UK and 
USA.
2. The principal variation between UK and USA systems lies in the provision of 
clinical data. Most UK systems use data that had been gathered by the 
supplier; whereas in the USA, pharmacy computer system suppliers use data 
which has been compiled by companies specialising in clinical data provision.
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7 The Clinical Application of Patient Medication Records and the
Assessm ent of Benefits to Patients
7.1 Introduction
The original aim of our research into the use of patient medication records (PMRs) 
was to assess the clinical impact of PMRs on community pharmacy practice. One of 
the principal objectives was to test a hypothesis that the use of PMRs held in 
community pharmacies provides an improvement in patient care, through interpretation 
of PMR data by the pharmacist who subsequently advises the patient and/or the 
prescriber. During the study reported in this Chapter, cases are considered where the 
use of PMR systems potentially enhanced patient care and altered treatment outcome.
The modem role of the community pharmacist has two core activities; these are the 
supply of prescription and non-prescription medicines, and the associated provision of 
information and advice to patients and prescribers with, or without, the supply of a 
product. The provision of advice encompasses cases where the pharmacist offers a 
response to patients' symptoms. Before supplying a medicinal product to a patient, a 
pharmacist has a professional duty of care to ensure that the product is both safe and 
appropriate for use as determined by therapeutic knowledge and legislation at any 
given time.
One use of PMRs is to ensure that patients do not receive medication when it is 
contraindicated or inappropriate^; for example, a non cardio-selective beta-blocker 
may induce bronchospasm in an asthmatic patient. ^ 6 Similarly, it may be inappropriate 
to supply certain non-prescription medicines to patients suffering from certain medical 
conditions; for example, sympathomimetic decongestants may be hazardous in patients 
with cardiovascular disease.^
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Drug interactions, ranging in significance from some merely of pharmacological 
interest to others that are life-threatening, may occur with medicines that are 
prescribed or those purchased without a prescription. It is a routine, but essential, role 
of the pharmacist to monitor for the situation when two interacting medicines are 
prescribed on a single prescription. A logical extension to this is where a pharmacist, 
through the maintenance of prescription records, is able to monitor for interactions 
between newly-prescribed medicines and those which were dispensed previously. 
Computerised PMR systems can automatically examine records for potential 
interactions faster than a community pharmacist using manual records and reference 
books. We have shown that this is a prime reason for pharmacists having purchased 
computerised PMR systems (Chapter 3)79 Pharmacists can also use PMRs to check 
the appropriateness of patient-requested or counter-prescribed medicines, where the 
potential for important drug interactions is considerable; for example, ibuprofen can 
raise the plasma level of lithium to a level at which toxic side effects may occur.$9
Prescription forms presented in a pharmacy may contain clinical errors and omissions, 
other than those referred to above. The wrong drug may be prescribed, or the wrong 
strength, dose, or patient's name may be stated on the prescription form. Such errors 
are likely to arise as a result of administrative errors within the surgery. Prescriptions 
may be written so that they do not comply with the requirements of the Medicines Act 
1968 and the Misuse of Drugs Act 1971. Such errors, although reported by 
respondents, were not considered within the scope of this study and were therefore 
excluded from the results.
Under Regulations made in 1979, pharmacists have been able, in an emergency, to 
supply prescription-only medicines without a prescription form. * ^  To do this, certain 
requirements must be fulfilled in order to comply with the requirements of the 
Medicines Act 1968. The use of PMRs normally would facilitate the administration of
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emergency supplies, by providing a record of previous dispensing of the product(s) 
requested by patients or prescribers.
Strand et al have discussed the need for hospital-based clinical pharmacists to 
document their activities, * * * A number of papers have been published describing such 
documentation of clinical interventions made by hospital pharmacists. One study, 
based on the use of a system for coding intervention data used a mainframe computer 
was used to store and process alpha-numeric codes representing clinical pharmacists' 
i n t e r v e n t i o n s .  Catania et al have discussed the cost-savings generated by the 
activities of clinical pharmacists in a 324-bed non-profit community hospital in 
C a l i f o r n i a . They were able to demonstrate average net cost savings of $3739 per 
month, over a four-year period from 1986-90. Brown has published a paper 
discussing the clinical merit of hospital clinical pharmacists intervening to initiate or 
discontinue drug therapy. H4 It was shown that 27 out of 106 clinical interventions 
made by the pharmacists concerned, during the experimental period, were judged to 
have been of "very significant benefit” or "significant benefit" to patients. In 
comparison, only two cases were judged to have been detrimental to patients. 
Problems associated with documenting clinical pharmacy interventions in the hospital 
setting have been described, emphasising the need to record those interventions with 
the greatest clinical significance. 115 A description of a computerised system to record 
hospital pharmacists' clinical interventions has been described by Schumock et al. 116
Hospitalisation as a result of the consequences of drug interaction has been 
described. 117 In the United States, Rupp has published work evaluating the 
community pharmacist's role in correcting prescribing errors. ** 8-122 Qne paper* *** 
described the nature of prescription errors encountered by the community pharmacist. 
These included errors of omission (51%), such as incomplete prescription details, and 
errors of commission (29%), such as incorrect drug strength. Remaining errors 
included drug allergies and drug interactions. In his subsequent paper* *9, he
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estimated the monetary values of intervening to deal with such problematic 
prescriptions. The average cost per prescription of the pharmacist's time in conducting 
the intervention was estimated to be $1.75, whereas the value of the pharmacist's 
intervention, as determined by the avoidance of medical care (visits to a physician) was 
estimated to be $7.15. A further p a p e r ^ O  described the results of a project where 
community pharmacists in the United States and Canada were encouraged to 
spontaneously document and report any reactive interactions made by pharmacists. In 
that paper prescribers' errors of commission were found to be the most frequently 
reported problems. The two drug groups most frequently associated with these 
reactive interventions were anti-infective agents (22.6%) and hormones (8%). Rupp 
described the purpose of the traditional collaboration between physician and 
pharmacist in the delivery of care as being "to combine the unique knowledge and 
competencies of each to achieve optimal outcomes in, and for, the patient. "121 A 
central responsibility of the pharmacist in this role is to screen new prescription orders 
to ensure that the prescribed therapy is safe and appropriate. In a later p a p e r 122 he 
proposed a value of $122.98 per "problematic prescription", as being the cost of 
avoidance of medical care, had the pharmacist not intervened. This value equated to 
$2.32 per each new prescription order. The considerably higher figure produced in 
this paper, was higher than that in his earlier p a p e r d u e  to the consideration of the 
high cost of hospitalisation that would have been required had some of the pharmacist 
interventions not been made.
There have been no published reports to-date of similar studies in the UK, although 
Maguire and Lowrie have described the nature of some prescribing errors encountered 
in p r a c t i c e .  ^23 Neville et al have developed a system for classifying prescription 
errors in general practice; in so doing emphasising the key role that community 
pharmacists could play in influencing prescribing practice. 124 vitillo and Lesar have 
described ways in which prescribing errors can arise. 125 Examples of "assumption" 
errors included co-prescribing of drugs which interact, and writing a prescription on
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the wrong patient's chart. Documented "selection” errors included the prescribing of 
inappropriate antibiotics, or the mis-selection of products by name, eg. Zostrix cream 
instead of Zovirax cream. Lastly, "capture" errors included the prescribing of 
incorrect dosage regimens. It is possible that audit of the community pharmacist's 
clinical work, through routine documentation of clinical interventions might prove 
beneficial both for litigation-defence and for justifying increased professional 
remuneration. Payne et al have described the use of a PMR system in one community 
pharmacy to identify missing details on repeat prescriptions. *26
In the following study we have examined records made by community pharmacists 
when they have made interventions in practice. Despite the necessity for pharmacists 
to maintain various statutory records, it is not normal practice in the United Kingdom 
for them to document of prescribing errors and interventions. During this study 
(Autumn 1991- Spring 1993) the PILLS system was the only computerised system 
available in the UK that provided a facility to record any type of pharmacist 
intervention. The PILLS system requires the operator to record, in the database, their 
actions when faced with a probable drug interaction or recognised contraindication. 
For example, the operator could enter that the prescriber confirmed that the co­
administration of two interacting drugs was intended; or, in other circumstances, that a 
patient no longer suffers from a particular clinical condition. The Alchemist 3000 
system (Chemtec Systems Ltd.) requires the user to enter a password when presented 
with a potential drug interaction flagged at the highest level of significance.
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7.2 Method
7.2.1 Equipment and Materials Used
All documentation was produced using Microsoft Word for Windows on a Viglen 
Genie PC, and a Hewlett-Packard DeskJet printer. Microsoft Excel and SPSS-PC+ 
were used for storing and analysing data. Completed record forms were returned 
under a Freepost arrangement with the Post Office.
7.2.3 Selection of Pharmacies
The starting point for this study was the distribution of the postal questionnaire 
(Appendix 2, page 311) sent to 1000 community pharmacies in England and Wales, 
selected at random from the Register of Premises of the Royal Pharmaceutical Society 
of Great Britain. That questionnaire (described in Chapter 2) not only presented a 
series of questions requesting comprehensive information about the uses of PMR 
systems, but also concluded with an invitation to the respondent to take part in a 
further long term research programme. Respondents could either respond with a yes 
or no response, or request further information. All respondents who did not respond 
negatively were sent an information letter giving details of the nature of data to be 
recorded, and a response slip to be returned if they wished to proceed with the 
continuing programme.
All pharmacists who, at that stage, still wished to continue were sent a package 
containing several blank forms for recording clinical intervention events. Freepost 
envelopes, instructions on how to complete the record forms and a sheet containing 
sample entries.
7.2.4 Design of the Clinical Intervention Event Record Form
The purpose of the clinical intervention event record form was to provide a simple, 
rapid method for community pharmacists to log their intervention activity. A copy of
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the record sheet is shown in Appendix 2, page 331. Each record sheet provided a 
space for the four digit identity code used in the initial survey questionnaire to identify 
the pharmacy concerned, thereby ensuring anonymity of the collected data. The record 
sheet provided six columns in which pharmacists entered data as illustrated in Figure 
7.1.












In the first column pharmacists recorded the date the intervention was made. A code 
for the type of intervention was entered in the second column. Codes were provided 
as shown in Table 1, to minimise the amount of writing when completing the form.
Table 7.1: Clinical intervention event category codes.
C1 Contraindicated prescribed drug
C2 Contraindicated OTC drug
E Emergency supply of prescription-only medicine
11 Drug interaction between two drugs on presented prescription
12 Drug interaction with a drug previously dispensed
13 Drug interaction with OTC medicine
M1 Prescription error-incorrect drug on presented prescription
M2 Prescription error-incorrect strength on presented prescription
M3 Prescription error-incorrect dose on presented prescription
M4 Prescription errors incomplete/incorrect patient details 
eg. Mr Jones' Tablets on Mrs Jones' prescription.
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The third column enabled pharmacists to enter the drug(s) associated with the 
intervention event. The patient group, if known, was noted in the fourth column, using 
single letter abbreviation as shown in Table 7.2.
Table 7.2: Patient at-risk groups and associated codes.
A Asthmatic
B Breast-feeding
C Cardiovascular disease inc. cardiac failure, hypertension, clotting disorders
D Diabetic
E Expectant mothers, pregnant
F Fits, epileptic
G Geriatric, elderly patients
H Hepatic impairment
I Immunosuppressed
M Mentally ill, psychiatric






Y Young patient (paediatric, under 12)
N Not listed above, miscellaneous.___________________________________________
The fifth column was used to show whether a PMR system was used during the 
intervention and the sixth column provided a space for explanatory notes.
7.2.5 Pilot Study
Before general distribution to the participating pharmacists, the use of the record sheet 
was tested, for a six week period, in the geographically-closest community pharmacy 
taking part in the programme. No problems were encountered and it was decided to 
proceed with data collection.
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7.2.6 Phase I Study: Data Collection and Processing
Record sheets were returned by each participating pharmacy every six weeks, over the 
18-month period September 1991-February 1993. A postal reminder was sent when a 
pharmacy did not return a sheet within two weeks of the due-by date. The data from 
each record sheet were entered in a database created using Microsoft Excel. The 
following were recorded in the database for each event: a code representing the 
relevant pharmacy, the intervention category, the drug(s) involved and their British 
National Formulary (BNF) code, the patient group, whether a PMR was used, and any 
explanatory notes required.
The database was constructed to facilitate data manipulation, including ordered sorting 
by any of the columns on the record sheet. The database permitted the recording of up 
to three drugs associated with each clinical intervention event. Any product associated 
with an event was recorded using its generic name, except proprietary combination 
products with no generic equivalent, for example, Kalten. The data were transferred 
to the statistics program SPSS-PC+ for statistical analysis.
7.2.7 Phase II Study: Survey in Branches of a Multiple Pharmacy 
Company
One purpose of the study described above (Section 7.2.6) was to determine whether it 
could be shown that pharmacists' use of PMRs improved patient care. The aim was to 
analyse results from a group of pharmacies in the original sample that used PMRs, in 
parallel with a control group which were using simple labelling systems only. During 
the initial stages of the project a problem was encountered in the selection of 
pharmacies taking part in the programme: substantially fewer pharmacies without 
PMRs wished to take part than those using PMRs. Therefore an additional survey was 
undertaken in parallel in 30 branches of a multiple pharmacy company: 15 branches 
using a PMR system were requested to record clinical intervention events for three six- 
week periods, alongside 15 branches using a simple labelling system as a control
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group. Each group contained pharmacies matched in size, location and the number of 
prescription items dispensed.
For the purposes of both the Phase I and Phase II studies, "computerised PMR-users" 
were considered as those pharmacies in which patient medication records were stored 
on a computer. "Non-computerised PMR-users" were considered as those pharmacies 




7.3.1.1 Pharmacies Participating in Phase I Survey
Results from the original survey (April 1991) showed that 253 respondents were 
interested in taking part in a further research programme. Of these, 42 eventually 
agreed to participate. During the early stages of data collection, the number of 
pharmacies continuing to provide fell to 28. Characteristics of these pharmacies, and 
the pharmacists in charge, are given in Tables 7.3-7.5, using the categories previously 
defined in our original questionnaire (Appendix 2, page 311).
Table 7.3: Ownership of the pharmacies participating in the survey.
Independent 9
Small multiple (2-10 pharmacies) 7
Large multiple (11 or more pharmacies) 12








Table 7.5: Use of patient medication record system in pharmacies in the survey.
Manual system 3
Computer 19
No system used 6
System in use at the outset of the survey were John Richardson, Park systems, AAH 
Link and Mawdsley-Brooks and in-house systems, used by large multiple companies. 
One non-PMR user purchased a Chemtec system during the study. All the PMR 
systems were installed between 1987 and 1991, and 16 systems had been installed 
since 1989.
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7.3.1.2 Clinical Intervention Events
By the end of the survey in February 1993, a total of 1862 clinical intervention events 
had been recorded and entered into the Excel database. The number of interventions 
reported per pharmacy ranged between one and 473. Thirteen pharmacies ceased to 
provide regular data reports the last eight months of the survey, hence a low number of 
reported events from some contributors. At no stage during the experimental period 
did, the proportion of prescriptions associated with a documented clinical intervention 
event exceed 2% of the total number of dispensed prescription items. Figure 7.2 
shows the number of events reported during each six week period.
Figure 7.2: Number of clinical intervention events during each six 
week data collection period.
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Of the 1862 recorded events, 1457 (78.2%) took place in pharmacies using a 
computerised PMR system, 111 (6%) in pharmacies using a manual system, and 294 
(15.8%) in those pharmacies not maintaining PMRs. Due to the number of pharmacies 
in this survey, and the variety of computer systems used, it was not possible to detect 
significant differences between each system. A patient medication record was used in 
1234 (66.3%) of the interventions. The use of PMR systems in association with 
clinical intervention events is shown in Table 7.6. The number of intervention events
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in each pre-defined category of event is given in Table 7.7. Table 7.8 shows the 
frequency of patient at-risk groups occurring within the data.
Table 7.6: The use of PMR systems in association with clinical intervention events 
(percentages of totals in brackets).
PMR type:
Computer Manual None Total
PMR Used: Yes 1168(80.2) 66 (59.5) 0 1234 (66.3)
No 289 (19.8) 45(40.5) 294(100) 628 (33.7)
Total 1457 (100) 111 (100) 294(100) 1862 (100)
Table 7.7: Number of clinical intervention events within each category of event, 
related to whether a PMR system was used (percentages of totals in brackets).______
Intervention category PMR used PMR not 
used
All events
Prescription error-incorrect strength 263 (21.3) 103 (16.4) 366 (19.7)
Prescription error-incorrect dose 186 (15.1) 96(15.3) 282 (15.7)
Interaction between a previously dispensed
medicine and a newly-prescribed medicine 259(21.0) 19 (3.0) 278 (14.9)
Prescription error-incorrect drug 162 (13.1) 110(17.5) 272 (14.6)
Interaction between two drugs on a
presented prescription 100(8.1) 97 (15.4) 197 (10.6)
Contraindicated prescription medicine 98 (7.9) 47 (7.5) 145 (7.8)
Prescription errors incomplete/incorrect
patient details 44 (3.6) 66 (10.5) 110(5.9)
Emergency supply 68 (5.8) 38 (6.1) 106(5.7)
Contraindicated non-prescription medicine 24 (1.9) 42 (6.7) 66 (3.6)
Interaction with a non-prescription
medicine 28 (2.3) 7(1.1) 35 (1.9)
Miscellaneous, not listed above 2 (0.2) 3 (0.5) 5 (0.3)
Total 1234 (100) 628 (100) 1862 (100)
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Table 7.8: Frequency with which patient at-risk groups occur within clinical 
intervention event data (percentages off totals in brackets)._______________
PMR used PMR not 
used
All events
Geriatric 411 (33.3) 101 (16.0) 512 (27.5)
Cardiovascular disease 231 (18.7) 72(11.5) 303 (16.3)
Asthmatic 129 (10.5) 65 (10.4) 194 (10.4)
Young patient 31 (2.5) 94 (15.0) 125 (6.7)
Diabetic 55 (4.5) 16 (2.6) 71 (3.8)
Mentally ill 39 (3.2) 20 (3.2) 59 (3.2)
Expectant mother 15(1.5) 30 (4.9) 45 (2.4)
Fits, epileptic 29 (2.4) 5 (0.8) 34(1.8)
Parkinson's disease 19(1.5) 3 (0.5) 22(1.2)
Peptic ulcer 13(1.1) 5 (0.8) 18(1.0)
Skin diseases 7 (0.6) 11 (1.8) 18(1.0)
Thyroid disorders 11 (0.9) 4 (0.6) 15 (0.8)
Ophthalmic disorders 9(0.7) 6(1.1) 15 (0.8)
Breast-feeding 2 (0.2) 3 (0.5) 5 (0.3)
Renal impairment 4 (0.3) 1 (0.2) 5 (0.3)
Immuno-suppressed 2 (0.2) 1 (0-2) 3 (0.2)
Hepatic impairment + immuno-suppressed 1 (0.1) - 1 (0.1)
Not listed, miscellaneous 226 (18.3) 191 (30.5) 417 (22.4)
Total 1234 (100) 628 (100) 1862 (100)
Applying the x^ test of independence^^ to the results in Table 7.8 showed that the use 
of a PMR system was less likely to result in patients being classified as miscellaneous 
(pO.OOOl).
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Table 7.9: BNF classifications and Department of Health prescription data, for products associated with clinical intervention events in this 
study.
BNF classification Occasions when a product within BNF % of total number of % 1990 total NHS Factor a
category has been associated with a clinical 
intervention event
products(a) prescriptions (b)
Gastro-intestinal system 102 3.98 7.96 0.50
Cardio-vascular system 657 25.63 17.23 1.49
Respiratory system 319 12.45 8.80 1.41
Central nervous system 450 17.56 19.78 0.89
Infections 347 13.54 12.13 1.12
Endocrine system 132 5.15 4.35 1.18
Obstetrics, gynaecology & urinary-tract 211 8.23 2.63 3.13
Malignant disease and immunosuppression 12 0.47 0.30 1.56
Nutrition and blood 52 2.03 3.50 0.58
Musculoskeletal and joint diseases 155 6.05 5.40 1.12
Eye 31 1.21 2.56 0.47
Ear, nose and oropharynx 23 0.90 1.22 0.74
Skin 53 2.07 9.58 0.22
Immunological products and vaccines 8 0.31 0.32 0.98
Unclassified 11 0.43 0.81 0.53
Totals 2563 100.00 96.57
Of the 1862 documented clinical intervention events, 17 (0.9%) were associated with 
groups of three products, 683 (36.7%) were associated with a combination of two 
products and 1162 (62.4%) were associated with individual products. A total of 2563 
products were associated with the 1862 events. The BNF classifications of the 2563 
products involved in these 1862 clinical intervention events are shown in Table 7.9. In 
11 cases the BNF classification could not be applied to the product, for example, 
homoeopathic preparations.
Table 7.9 shows the number of products in each BNF classification, together with the 
percentage of the total 2563 products that each BNF group represented. These 
percentages are then compared with data supplied by the Department of Health 
(personal communication) which have been interpreted to give total prescription 
numbers for products in each BNF category for 1990. The Department of Health have 
not used the BNF classification to date, but instead have used a similar system of 
prescribing by therapeutic class. These figures do not add up to 100% since some 
listed products are not in the BNF, for example X-ray contrast media.
Comparing the frequency with which products were associated with intervention 
events, with prescription data from the Department of Health enabled us to standardise 
our findings. A factor, alb, was calculated to illustrate those pharmacological groups 
of drugs which were particularly prone to intervention event association. If this 
calculated factor a/b equalled one, the frequency of reported interventions with a 
particular group of drugs would be exactly in proportion to the number of times such 
drugs were prescribed. If a/b was greater than one, the number of reported 
interventions associated with that category of drugs was higher than one might expect. 
Pharmacological groups with a high a/b factor were those used in obstetrics, 
gynaecology and acting on the urinary-tract. Drugs acting on the skin had a low a/b 
factor.
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Those drugs most often associated with the reported clinical events are listed in Table
7.10.
Table 7.10: Drugs most frequently associated with clinical intervention events.
Number % Number %
of events occurrence of events occurrence
Amoxycillin 87 4.67 Propranolol 30 1.61
Atenolol 82 4.40 Theophylline 28 1.50
Salbutamol 75 4.03 Aspirin 26 1.40
Logynon 62 3.33 Captopril 25 1.34
Digoxin 49 2.63 Temazepam 25 1.34
Beclomethasone 46 2.47 Diltiazem 24 1.29
Nifedipine 46 2.47 Phenytoin 23 1.24
Erythromycin 44 2.36 Indomethacin 22 1.18
Penicillin V 44 2.31 Prednisolone 22 1.18
Microgynon 30 40 2.15 Ciprofloxacin 21 1.13
Co-proxamo! 39 2.09 Frusemide 21 1.13
Enalapril 37 1.99 Isosorbide mononitrate 20 1.07
Co-amilofruse 35 1.88 Paracetamol 20 1.07
Ibuprofen 35 1.88 Co-amilozide 19 1.02
Warfarin 35 1.88 Cimetidine 19 1.02
Pseudoephedrine 34 1.83 Verapamil 19 1.02
Diclofenac 32 1.72
A cross-tabulation of the clinical intervention event categories (Table 7.1) and the 
patient at-risk groups (Table 7.2) with which they were associated is shown in Table
7.11. Points of particular note in Table 7.11 are: the association of asthmatic patients 
with contraindicated prescribed products (Cl) and emergency supplies (E); the 
association of patients with cardio-vascular conditions (C) with contraindicated non- 
prescription products (C2) and drug interactions (11-3); the association of diabetic 
patients with contraindicated prescribed products (Cl); and a high number of drug 
interactions (11-3) potentially affecting elderly patients (G). The high incidence of
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incorrect strength (M2) and incorrect dose (M3) interventions with both geriatric (G) 
and young patients (Y) is of note.
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Table 7.11: Cross-tabulation of at-risk patient groups and clinical intervention 
categories. Figures of particular note in bold type._______________________
Asthmatic 44 7 29 7 18 2 27 47 6 6 1 194
B rea s t-fee d in g 2 1 - - 2 - - - - - - 5
Cardio-vascuiar disease 16 17 29 52 29 13 30 68 33 16 - 303
Diabetic 23 2 4 2 2 23 3 10 2 - 71
E x p e c ta n t 10 10 1 3 - 5 6 8 2 - 45
Fits, ep ileptic 2 - 7 5 7 1 4 5 3 - - 34
Geriatric 8 6 17 53 65 13 89 120 109 30 2 330
H epatic-im pairm en t - - - - 1 m - - - - - 1
Im m u n o -su p p re sse d - - 1 - - m - 1 1 - - 3
M enta lly ill - - 1 13 7 9 15 9 4 1 59
O phtha lm ic d isorders 1 5 - - - 2 6 - 1 - 15
P arkin son 's  d ise a se - - - 1 2 2 3 12 2 - 22
R e n a l im pa irm en t - 1 - - - 1 1 2 - - - 5
S k in  d is e a s e s 1 1 1 1 7 2 3 2 - 19
Thyroid p a tien t 1 - 1 - - - 11 2 - - 15
P ep tic  U lcer 11 4 1 - - 1 1 - - - - 18
Young patient 16 7 2 3 - 16 28 38 14 1 125
N o t listed, m isc e lla n eo u s 10 5 12 57 145 4 56 49 48 31 - 417
Total 145 66 106 197 278 35 272 366 282 110 5 1862
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7.3.2 Phase II Study: Multiple Pharmacy Company Survey Results
Of the 15 pharmacies selected as a control group of non-users of PMR systems, one of 
those which responded was found to be maintaining manual records. This pharmacy 
only documented two clinical intervention events, and therefore, did not bias the 
results to any significant extent.
Over the 18 week period of study, completed clinical intervention record sheets were 
received from 16 pharmacies operating a PMR system (7 computerised PMR-users and 
9 non-computerised PMR-users), representing 50% of the total selected sample. Not 
all of the participating pharmacies returned three completed record sheets; 13 sheets in 
total were received from the PMR-users and 20 from the non PMR-users.
A total of 159 clinical intervention events was recorded. Of these 159 events, one 
event (0.6%) was associated with a group of three drugs, 65 (40.9%) were associated 
with a combination of two drugs and 93 (58.5%) were associated with individual 
drugs.
Table 7.12 shows the incidence of the use of PMRs associated with clinical 
intervention events in those pharmacies participating in the Phase II survey. A 
comparison with Table 7.6 shows that the percentage results are not dissimilar to those 
obtained in the Phase I survey.
Table 7.12: Phase II Study: Cross4abulation of the use of the PMR and the type of 
system in use in the selected branches of the multiple pharmacy company 
(percentages of totals in brackets).
Was PMR used? Computer
PMR type: 
Manual None Total
Yes 77(72) 1 (50) 0 78 (49.1)
No 30 (28) 1 (50) 50 (100) 81 (50.9)
Total 107 (100) 2(100) 50 (100) 159 (100)
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Table 7.13: Phase II Study: Number of events being associated with each clinical 
intervention category for PMR computer-users and non-PMR computer-users 
(percentages of totals, in brackets)._____________________________________________
Intervention category PMR Non-PMR All
computer- computer- respondents
users users
Prescription error-incorrect strength 18(16.8) 12 (23.1) 30 (18.9)
Prescription error-incorrect dose 12(11.2) 4 (7.7) 16(10.1)
Interaction between a previously dispensed
medicine and a newly-prescribed medicine 32 (29.9) 0 32 (20.1)
Prescription error-incorrect drug 10 (9.3) 4 (7.7) 14 (8.8)
Interaction between two drugs on a
presented prescription 15(14.0) 8 (12.5) 23 (14.5)
Contraindicated prescription medicine 4 (3.8) 0 4 (2.5)
Prescription errors incomplete/incorrect
patient details 3 (2.8) 11 (21.2) 14 (8.8)
Emergency supply 9 (8.4) 11 (21.2) 20 (12.6)
Contraindicated non-prescription medicine 4 (3.4) 1 (1.9) 5 (3.1)
Interaction with a non-prescription
medicine 0 1 (1.9) 1 (0.6)
Total 107 (100) 52 (100) 159 (100)
The incidence of each type of clinical intervention event is shown in Table 7.13, for 
both PMR computer and non-PMR computer users. Likewise the frequency of 
patient-at-risk groups associated with each event is shown in Table 7.14.
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Table 7.14: Phase II Study: Frequency of patient at-risk groups being associated with 
clinical intervention event data for PMR computer-users and non-PMR computer-users 







Geriatric 26 (24.3) 4 (7.7) 30 (18.9)
Cardio-vascular disease 24 (22.4) 10 (19.2) 34(21.4)
Asthmatic 8(7.5) 6(11.5) 14 (8.8)
Young patient 3 (2.8) 3 (5.8) 6 (3.8)
Diabetic 4(3.7) 2 (3.8) 6 (3.8)
Mentally ill 5(4.7) 3 (5.8) 8 (5.0)
Expectant mother 1 (0.9) - 1 (0.6)
Fits, epileptic 4(3.7) 1 (1.9) 5 (3.1)
Parkinson's disease 2(1.9) - 2(1.3)
Skin diseases - 3 (5.8) 3(1.9)
Peptic ulcer 1 (0.9) - 1 (0.6)
Thyroid disorders 1 (0.9) 1 (0.6)
Ophthalmic disorders 1 (0.9) - 1 (0.6)
Breast-feeding - - -
Renal impairment 1 (0.9) - 1 (0.6)
Hepatic impairment - - -
Immuno-suppressed - - -
Not listed, miscellaneous 26 (24.3) 20 (38.5) 46 (28.9)
Total 107 (100) 52 (100) 159 (100)
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7.4 Discussion
7.4.1 Phase I Study
7.4.1.1 Design of the Clinical Intervention Record Sheet
In practice, the record sheet worked well and only three events could not readily be 
classified under the coding system. These were the processing of a totally illegible 
prescription form, and the use of PMRs in specific two events - an accidental nifedipine 
overdose and a suspected adverse drug reaction with pseudoephedrine.
The record sheet encouraged the recording of one patient condition, where applicable. 
This produced some disadvantages, which had not been foreseen when designing the 
form. Some patients have multiple disease states and may be at risk from drug therapy 
for more than one reason. For example, an epileptic patient with a prosthetic heart 
valve, who receives warfarin, phenobarbitone and phenytoin, is at a considerable risk 
from multiple drug interactions. If this patient is also hypertensive, then non- 
prescription systemic sympathomimetics are contraindicated. In some cases, it is 
possible that pharmacists attributed the patient to one at-risk group when the code for 
another group may have been equally or more appropriate.
The recording of patients as "geriatric'' occurred in 330 (26.3%) of the database 
events, despite many of these patients obviously having other disease states. This was 
particularly the case when PMRs were used (33.3%) (Table 7.8). There are two 
possible explanations for this high percentage. First, "geriatric" is a term which is not 
clearly defined, and some respondents may have regarded all patients over 60 or 65 as 
geriatric. A second possible explanation is that pharmacists are paid to keep records 
for the elderly and the confused. It may, therefore, be in a pharmacist's financial 
interest to designate a patient as geriatric, where possible.
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7.4.1.2 Response
A response of only 28 participating pharmacies was disappointing (Section 7.3.1). 
Many potential participants were deterred by the need to record interventions on a 
regular basis, over a long period of time. In particular, pharmacists qualifying before 
1986 were much less disposed to participate than their colleagues who had registered 
more recently. The year of registration as a pharmacist again appears to influence a 
practising community pharmacist's clinical role (Chapter 2). The reasons for this are 
complex, but may relate to a stronger self-perception among younger community 
pharmacists of a clinical role that has been developed by undergraduate education, and 
the participation or otherwise in postgraduate continuing education.
The mixture of independent and multiple pharmacies did not differ significantly (x^ 
analysis) from the 744 pharmacies that participated in our original survey.
7.4.1.3 The Use of PMR Systems
The low number (six) of respondents not using a PMR system initially hindered 
comparisons, since a much larger group of 15-20 pharmacies ideally would be needed 
as a control. This problem was overcome by undertaking the Phase II study. On 
reflection, it is not surprising that the number of non-users participating in our study is 
low, since it is probable that those pharmacists who were interested in clinical patient 
care, and therefore interested in taking part in a survey on the subject, have already 
purchased a computerised PMR system.
Only three of the participants were using a manual record system. Despite the small 
number, this group provided a valuable contrast with users of computerised systems 
when examining the percentage of intervention events during which the PMR system 
was used (Table 7.6). Where the pharmacy possessed a computerised PMR system, 
the system was used for 80.2% of the recorded interventions. With a manual system,
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this figure fell to 59.5%. These findings are significantly different (x^=39.62, d£=l, 
p<0.0001). Within our limited sample size, this shows that computer-based PMRs are 
more intensively used than manual card-index systems. The interactive nature of some 
PMR systems, eg. Hadley Hutt and Park Systems is surely advantageous in that drug 
and patient databases constantly cross-reference and warn pharmacists when potential 
problems arise. The relatively small sample size did not permit meaningful analysis of 
differences between various computer systems in widely varying practice settings.
7.4.1.4 Patient At-risk Groups
The possibility that pharmacists may record patients as geriatrics, when it may be more 
appropriate to associate them with particular disease states has been discussed above 
(Section 7.4.1.1). Table 7.8 shows that patient at-risk groups associated with a high 
frequency of clinical intervention events are those suffering from cardiovascular 
disease, asthma and diabetes. Excess morbidity may be associated with the use of 
contraindicated drugs in these patient groups. Both the supply of inappropriately 
prescribed medication and the sale of contraindicated non-prescription medicines are 
likely to have adverse effects in these patient groups.
It is a legal requirement under the Medicines Act 1968 for prescribers to indicate the 
age of children under 12 when prescribing prescription-only medicines. However, 
Rogers et al have reported that this requirement is not always complied with. 127 The 
results in Table 7.8 show that young patients are at risk from prescribed overdoses. 
Clearly, it is of benefit to this group of patients if, by maintaining medication records, 
pharmacists are able to prevent morbidity associated with prescribed overdoses, 
particularly when there is no indication of the child's age on the prescription form. 
Our findings support the work published by Paes in Holland, which showed a high 
frequency of inappropriate doses being prescribed for children. 128
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Pharmacists are able to claim a fee for maintaining records for elderly and confused 
patients. Results demonstrated in this study present a strong case for the provision of 
fees for keeping records for other at-risk patient groups.
7.4.1.5 Prescription Errors
Table 7.7 shows the variety of events in the database. Over 50% of the events 
consisted of the wrong drug, strength or dose being written on a prescription form. In 
the case of strengths and doses, many examples were omissions rather than errors. 
Where an incorrect drug was prescribed, another drug from the patient's records at the 
general practice surgery had sometimes been prescribed in error, thus inconveniencing 
both patient and pharmacist during the provision of repeat medication. However, in 
many instances serious harm to the patient could have resulted. For example, the use of 
PMRs by pharmacists prevented the incorrect dose of digoxin being dispensed on 17 
occasions: 15 incorrect strengths and two incorrect dose frequencies, and a morphine 
overdose was detected by a pharmacist albeit not using a PMR system. On two 
occasions, a potentially serious overdose of theophylline or a theophylline derivative 
was prevented in a paediatric patient. In 1992, the Committee on Safety of Medicines 
has recently advised on the appropriate use of the non-sedating histamine Hj-receptor 
antagonists terfenadine and astemizole.129 Following the publication of that advice, 
11 potential overdoses of terfenadine and one of astemizole were reported. 
Predictably, other drugs known to have a narrow therapeutic index were prescribed in 
error in terms of excessive dose: lithium (twice), carbamazepine, phenytoin and 
primidone. Recombinant human erythropoietin is used to treat anaemia associated 
with erythropoietin deficiency in chronic renal failure. 81 It may be prescribed on a 
complex dosage regimen, with potential for the prescribing or dispensing of an 
incorrect strength. On two occasions, the use of a PMR system by pharmacists 
prevented the supply of incorrect strengths of the erythropoietin products Eprex and 
Recormon to renal patients.
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Incorrect use of a general medical practice computer system produced a prescription 
for Co-proxamol Tablets, 11 pm, which was intercepted by a pharmacist without the 
use of patient records. This example illustrates the fact that pharmacists almost 
certainly will notice obvious errors, and probably detect prescribed overdoses, both 
without the use of PMRs. However, especially where drugs have a low therapeutic 
index, the use of a PMR system is likely to prevent incorrectly prescribed strengths 
being dispensed to patients, thus enhancing patient outcomes, e.g. in the case of the 
digoxin examples.
It is the opportunity to intervene when the wrong drug is prescribed that particularly 
justifies the use of PMRs. The use of computerised systems helped to prevent the 
dispensing of the non-steroidal anti-inflammatory drug Rheumox (azapropazone) 
instead of the homoeopathic product Rhus Tox on three occasions where a doctor's 
receptionist had misinterpreted a doctor's handwriting. In a similar example, the 
proton-pump inhibitor Losec (omeprazole) was prescribed instead of the loop diuretic 
Lasix (frusemide); again this was due to a probable misinterpretation of handwriting at 
the surgery. Three examples were recorded of quinidine salts being prescribed in place 
of quinine salts; in each of these three cases, mis-selection of a drug on a prescriber's 
computer screen was the cause of the error.
This survey illustrated a very alarming type of prescription error, which the PMR-user 
is well-placed to prevent. Many general practitioners are now changing their 
prescribing policies, in that they now prescribe by generic drug name when possible, 
whereas formerly the proprietary brand name was normally used on prescription forms. 
There is a risk of error when the same drug is prescribed generically in addition to a 
prescription by proprietary name. This may happen when a patient's drug regimen is 
reviewed, for example, if repeat prescription items are changed from proprietary to 
generic name and the original proprietary products not deleted. Such errors may not
203
be detected by the patients, because proprietary and generic examples of the same 
medicine may differ in appearance, as well as by name. Two examples of this type of 
error were detected in our survey. In the first example, Univer and verapamil were 
prescribed together when a doctor switched to generic prescribing without removing 
the proprietary product from the patient's current record. This error could have caused 
severe hypotension, heart block or even accidental death through ventricular 
fibrillation. In the second example, Melleril and thioridazine were co-prescribed. 
These errors also illustrated the need to maintain correctly computerised records at the 
general practice surgery.
Errors due to the use of the wrong approved-name of generic combinations with the 
Co- prefix were detected in three cases relating to the analgesic combinations Co- 
proxamol (dextropropoxyphene and paracetamol), Co-codamol (codeine and 
paracetamol) and Co-dydramol (dihydrocodeine and paracetamol). In other examples, 
the diuretic combinations Co-amilozide (amiloride and hydrochlorothiazide) and Co- 
amilofruse (amiloride and frusemide) were transposed. This is evidence that the Co- 
prefix in approved names causes confusion; vigilance is therefore required when 
pharmacists are presented with prescriptions for such products. This evidence 
confirms Lawrie's concerns. *30
Another example, where a computerised PMR system prevented the possibility of 
iatrogenic illness, was a patient suffering from angina who required isosorbide 
dinitrate, but was prescribed the anti-tubercular drug isoniazid in error. Another 
patient needing co-proxamol was prescribed captopril. One patient, suffering from 
angina requiring the calcium-channel antagonist Tildiem (verapamil) was prescribed 
the histamine Hj-receptor antagonist Triludan (terfenadine). Other potentially serious 
errors detected by the use of a PMR system were the prescribing of the tricyclic anti­
depressant clomipramine instead of the histamine H]-receptor antagonist 
chlorpheniramine, and a hay fever sufferer requiring the corticosteroid nasal spray
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Dexarhinaspray being prescribed the vasopressin analogue Desmospray. Another 
example where a patient could have suffered, through a hand-writing error, was the 
prescription of the anti-thyroid drug carbimazole when the anti-epileptic 
carbamazepine was required. Loss of epileptic control could have had serious 
consequences for this patient, and possibly for others if that patient held a driving 
licence.
Of the serious errors detected without the use of a PMR, the prescribing of the major 
tranquilliser pimozide instead of pizotifen for the prophylaxis of migraine, was of 
particular note. The use of a PMR system alerts pharmacists to these major errors 
before the patient may be aware that anything is wrong. Such errors are much less 
likely to be identified without the use of a PMR system. If prescription forms 
containing such errors are to be intercepted without the use of a PMR system, then 
reliance is placed on the pharmacist's personal knowledge about a patient, or on a 
patient's ability to detect the error. Clearly, PMRs will only be an effective safeguard 
where patients regularly visit the same pharmacy. This point, of course, is a very 
strong argument in favour of either patient registration with a particular pharmacy or 
the community pharmacist having access to a patient's medication histoiy through a 
modem link or by means of a smart card.
The classification M4 in Table 7.1 covered incorrect patient details. Nothing of 
unusual note was found with this group of interventions. The correct standard 
procedure of checking a patient's name and address against a prescription should filter 
out such errors in any case. The fact that 110 such prescription errors were 
documented reinforces the need for pharmacists and their staff to be vigilant through 
the use of systematic procedures when receiving prescription forms.
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7.4.1.6 Drug Interactions
Potential drug interactions accounted for 510 (27.3%) of the recorded interventions. 
Interactions with previously dispensed medicines were noted in 278 of the 510 cases; 
of these only 19 were identified without the use of a PMR. The patient's therapy was 
altered as a result of the pharmacist's intervention in 30 of these 278 cases (10.8%), as 
documented in Appendix 3. This illustrates a raison d'etre for the use of PMRs. It is 
very difficult to monitor for the possibility of drug interactions with previously 
dispensed medication without the use of records. A pharmacist must first enquire 
about other medicines that are being taken, then find a reference source to check for 
potential interactions. Assuming that a patient takes all their prescriptions to the same 
pharmacy, and that full records are maintained by that pharmacy, a computerised 
system with software for drug interaction monitoring will automate this task. The 
results suggest that pharmacists not using PMR systems are putting patients at risk 
from drug interactions. Taking this point further, one could argue that pharmacists 
could be considered negligent by not using PMRs if harm came to a patient as a result 
of a preventable drug interaction. It has been shown that drug interaction monitoring 
software is not widely used by GPs, despite widespread computerisation. 131,132 This 
places further responsibility on the community pharmacist.
Of the 387 cases where a PMR was used to establish a drug interaction, 136 examples 
involved drugs which affect the cardiovascular system. This therapeutic category 
produced several examples which illustrate some of the advantages and pitfalls of using 
PMRs. Co-amilofruse when taken with the angiotensin-converting enzyme inhibitor 
captopril may lead to hyperkalaemia^^; in this instance, the pharmacist recommended 
the substitution of co-amilofruse with frusemide, which the GP accepted. In a similar 
example, the potassium supplement Slow K  was discontinued when treatment with 
captopril was initiated. In many examples therapy was not altered because patients 
were said to be stable, albeit often on hazardous combinations of drugs, eg. digoxin 
and verapamil.^^ One can regard the figure of 10.8% change in therapy in two ways.
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On a national level, if this figure was applied to all significant interactions detected by 
pharmacists' PMR systems, the clinical contribution of community pharmacists in this 
area could be viewed as considerable. Conversely, the percentage may be regarded as 
low; which could be due to many pharmacists not being sufficiently assertive towards 
GPs, or because some pharmacists are unaware of the potential consequences of 
interaction, or possibly a result of GPs' ignorance. This is a subject worthy of further 
research.
Interactions between broad-spectrum antibiotics and previously-prescribed oral 
contraceptives were found 128 times in the database: this was the most common 
potential drug interaction. This finding corresponds, in part, with the work published 
by Rupp, which showed that anti-infective agents and hormones are the drug groups 
most frequently associated with intervention events. *20 While the true significance of 
the interaction between broad-spectrum antibiotics and oral contraceptives is 
unclear^, the high frequency illustrates the need for pharmacists to record the supply 
of oral contraceptives, and to provide appropriate advice when dispensing broad- 
spectrum antibiotics. Women of child-bearing age are not usually considered an "at- 
risk" group, unlike diabetics or asthmatics, nor have they been considered to warrant 
special attention in the context of pharmacy-maintained records, unlike the elderly or 
confused. However, the level of intervention reporting observed in this study shows 
that comprehensive records are required, even if the only requirement for medication in 
this group may be short-term anti-bacterial therapy. Other interactions recorded 
included several cases of drugs affecting liver microsomal enzymes, eg. erythromycin, 
phenytoin and cimetidine.
The 197 cases of two interacting drugs, both written on the same prescription form 
(event code II), produced similar examples of potential drug interactions to those 
cases listed above. Fifteen cases (7.6%) of the 197 resulted in the patient's medication 
being altered. These included a prescription for the monoamine-oxidase inhibitor
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phenelzine and the tricyclic antidepressant amitriptyline where, after consultation with 
the prescribes amitriptyline was not dispensed. A further 15 (7.6%) of the 197 
examples in the II interaction group involved the macrolide antibiotic erythromycin, 
including two cases of a potential terfenadine-erythromycin interaction. Erythromycin, 
through inhibition of hepatic microsomal enzymes, reduces the metabolism of many 
drugs, including w arfarin. 81 Despite being a well-documented interaction, one GP 
refused to monitor a patient's prothrombin time when recommended to do so by the 
pharmacist who noticed a potential interaction between warfarin and erythromycin.
The final group of interactions considered was the group coded 13, involving non- 
prescription medicines. Together with the contraindicated non-prescription medicines, 
coded C2, only 101 cases were recorded. Either there has been considerable under­
reporting of this type of intervention, or the pharmacists in our survey were giving little 
consideration to the problems associated with non-prescription medicines. Our earlier 
survey showed that only 35.5% of our sample of 744 pharmacists ever recorded any 
non-prescription products in their PMR system (Table 2.34).65 However may 
interventions related to non-prescription medicines were significant. In this present 
study, 41 examples were associated with the non-supply of sympathomimetic 
decongestants to patients with cardiovascular diseases. There were also four notable 
examples of requests for hyoscine-containing products (e.g. Kwells) for glaucoma 
sufferers. Anti-cholinergic drugs, eg. hyoscine are contraindicated in patients with 
closed-angle glaucoma.
In view of the current trend to make certain prescription-only medicines available 
through pharmacies without prescription, the low reporting of both the recording of 
the supply of, and the documentation of interaction with non-prescription medicines is 
of some concern. Community pharmacists probably need to have a greater awareness 
of the potential for drug interactions with non-prescription medicines that are sold to 
patients.
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7.4.1.7 Problems With Drug Interaction Monitoring Software
Two examples of incorrect information being produced by PMR systems were noted. 
Loop diuretics, for example, bumetanide, increase the nephrotoxicity of cephalothin, an 
obsolete first generation cephalosporin. 133 However, one large multiple pharmacy 
company's system classified all cephalosporins as interacting with all loop diuretics; 
and as a result a false interaction was indicated between Burinex K  and cephalexin, the 
outcome of which was that antibiotic therapy was stopped prematurely. This example 
demonstrates the need for drug-specific interactions to be distinguished from 
interactions between pharmacological classes of drugs, when programming drug 
interaction databases.
All drug interaction software, currently available in the UK, monitors for the possibility 
of interaction by examining pairs of drugs in turn, for example four drugs prescribed 
concomitantly will be examined as a permutation of six drug pairs. Our results 
included a report of an interaction between frusemide and digoxin. However, when 
the pharmacist concerned investigated this, he found that the patient was also taking 
Slow K  which would overcome the potential problem of hypokalaemia caused by the 
loop diuretic. The combination of frusemide and digoxin was therefore acceptable 
given the concurrent administration of Slow K. Systems must be developed in future 
to consider the suitability of a patient's total combination of current medication in one 
examination process.
7.4.1.8 Emergency Supplies
Emergency supplies were recorded 106 times, the most common example being 
salbutamol which was requested on 25 (23.5%) occasions. Miscellaneous products 
acting on the cardiovascular system were requested 36 times. The use of a 
comprehensively maintained PMR system can enable the pharmacist to fulfil his
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professional and legal obligations when making emergency supplies at the request of a 
patient.
7.4.1.9 "Problem" Categories of Medicines
Table 7.9 shows a summary of the BNF classification of all products associated with 
the interventions recorded in the database, together with prescribing frequency derived 
from data supplied by the Department of Health. The Table shows a calculated factor 
alb which is the percentage frequency, a, with which a drug in a particular BNF 
category of drug occurs in our database, divided by the percentage frequency, b, of all 
NHS prescription items for that given category during 1990. For example, an alb ratio 
greater than 1.25 indicates that a particular category of drugs has presented over 25% 
more problems than would be anticipated. The purpose of our factor a/b was to 
standardise our findings against national dispensing figures. Our recording of a large 
number of interactions between antibiotics and oral contraceptives is reflected in an alb 
ratio of 3.13 for drugs classified as "obstetrics, gynaecology and urinary tract," 
encompassing Chapter 7 of the BNF which includes oral contraceptives. The high alb 
ratio of 1.56 for malignant disease and immuno-suppression may be spurious, due to 
the low number (seven) of intervention events reported for this group. However, this 
finding could be a reflection of the highly toxic nature of many of the drugs included in 
this category of the BNF.
The most notable from these figures are the drugs affecting the cardiovascular and 
respiratory systems, both of which presented in a number of different types of 
intervention. The cardiovascular drugs have considerable potential for 
pharmacodynamic interaction, which is reflected in our results. The frequent problems 
involved in the medication of asthmatic patients are also reflected in our data. For 
example, there are many potential drug interactions with theophylline and its 
d e r i v a t i v e s . 1% Problems exist with both contraindicated prescription and non­
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prescription medicines, for example, propranolol and ibuprofen, both of which may 
induce bronchospasm. Requests for emergency supply of bronchodilators are common, 
due to the unpredictable nature of mild acute asthmatic attacks in many patients.
The low ratio a/b of 0.22 for dermatological products reflects few contraindications 
and a low potential for interaction with topically administered drugs.
Application of our calculated ratio alb could prove useful in education of health 
professionals about the potential for, and incidence o£ adverse reactions, interactions, 
and potential prescribing errors. An important advantage of this parameter in 
evaluating the effects of these medication problems is that it normalises the results with 
respect to the extent to which a particular category of drug is used. In this study, we 
have considered the use of the ratio a/b based on broad complete BNF categories. In 
future work, the ratio a/b could be used to compare BNF sub-categories, for example, 
beta-blockers and ACE-inhibitors.
7.4.2 Phase II Study
The response from the pharmacies in the Phase II study was disappointing. Only 16 
(53.3%) of the possible 30 pharmacies returned any completed forms. All non­
respondents were contacted again and reminded to return data. Reasons given for not 
making a return included being too busy, or giving this task a low priority. It is 
probable that the explanation for the poor response was that this group of 30 
pharmacists could be regarded as "conscripts” rather than "volunteers", unlike those 
participating in the main survey.
Where PMR systems were available, the proportion of clinical intervention events 
associated with PMR use was 72% for computerised systems and 50% for manual 
systems (Table 7.12). This compares with 79.8% and 48.8% respectively from the
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main study (Table 7.6). Despite the low numbers in the large-multiple pharmacy 
group, the results are very similar.
The poor response and low number of returned clinical intervention event record sheet 
made a rigorous statistical analysis of the results impossible. However, important 
trends can still be observed. Table 7.13 shows that 107 events were recorded by 
computerised PMR-users on 13 record sheets, i.e. a mean of 8.2 events per six-week 
form. In comparison, 52 events were recorded by non-computerised PMR-users on 20 
record sheets, i.e. a mean of 2.6 events per form. Thus, clinical intervention among the 
group of computerised PMR-users would appear to be considerably higher than in the 
control group of non-computerised PMR-users.
The nature of the events recorded in the Phase II study is shown in Table 7.13. Most 
of the interventions associated with non-computerised PMR-users involved incorrect 
prescription details (Ml-4). No interactions with previously dispensed medication 
were reported by the non-computerised PMR group. In contrast, interactions with 
previously dispensed medication accounted for 29.9% of the interventions in 
pharmacies running the computerised PMR system. This result accords with, and 
reinforces, the finding for the same intervention category in the national survey (Table 
7.7).
Patients' clinical conditions associated with intervention events are shown in Table 7.14 
for the Phase II survey. This may be compared with Table 7.8 for the Phase I study. 
The results for PMR-users are similar in each case. The six patient groups which 
feature predominantly in both tables are: those with cardio-vascular disease, geriatrics, 
asthmatics, the mentally ill, diabetics and young patients. Pharmacists receive fee 
payment if they keep records for 100 elderly and confused patients. 60 All groups of 
pharmacists in these two studies also reported a relatively high number of clinical 
interventions associated with four other patient groups. On the basis of these results a
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case could be made for widening the scope of this fee payment provision to include 
patients with cardio-vascular diseases, asthmatics, the young and diabetics.
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7.5 Conclusions
1. This study has shown the important benefits of community pharmacists 
monitoring patients' therapy and intervening when appropriate. The survey has 
also demonstrated the feasibility of documenting such interventions in a busy 
community pharmacy.
2. Community pharmacists using computer-based PMR systems intervene 
more frequently than their colleagues using manual card-index systems.
3. NHS remuneration to pharmacists for maintaining records for the elderly and 
confused needs to be extended. Other patient groups are also at special risk 
from drug-related morbidity. The nature of interventions made by pharmacists 
demonstrates the need to maintain records for those patients with 
cardiovascular disease, asthmatics, diabetics and the young. Consideration 
should be given to the introduction of an ethical requirement for pharmacists to 
utilise PMRs for these and other defined groups of patients.
4 PMRs are of particular benefit in monitoring for potential drug interactions
between previously-dispensed and newly-prescribed medication. Where 
interacting drugs are prescribed for a patient but not on the same prescription 
form, pharmacists not using PMR systems may be exposing their patients to 
risk from adverse drug interactions.
5. A potential problem of inadequate performance of drug interaction monitoring
software has been detected. Deficiencies have been brought to our attention 
where systems failed to consider a patient's medication as a whole, and where 
non-existent interactions were reported.
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6. A factor a/b has been calculated to reflect the frequency, normalised against 
national prescription data, with which therapeutic classes of drugs have been 
associated with clinical interventions. Use of the calculated factor a/b enabled 
the prediction of those therapeutic categories of drugs like to present potential 
adverse drug problems. Pharmacists must remain especially vigilant when 
dispensing such medicines, which include drugs used in malignant disease and 
oral contraceptives.
7. This study has highlighted the importance to the patient of the pharmacist 
having access to complete patient medication records at the time of dispensing 
a prescription or supplying a non-prescription medicine. Optimum benefit to 
patients would be achieved if they were required to register with a particular 
pharmacy, or if their pharmacist had access to comprehensive patient 
medication data on a smart card or via a modem link to computer records 
stored elsewhere.
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8. Problems Associated With Drug Interaction Monitoring Software
8.1 Introduction
The issue of false positive drug interaction warnings being reported by pharmacy 
computer systems has been raised in Section 7.4.1.7. As part of the study into 
pharmacists' use of PMR systems to monitor for potential drug interactions, a serious 
problem was uncovered whereby a computer system used by a large multiple pharmacy 
company reported an interaction between all loop diuretics and all cephalosporins. 
This is an example of one type of error that can occur with drug interaction monitoring 
software. The other type of error is a false negative report, when a computer system 
fails to detect a potential drug interaction that actually exists. Both types of error are 
illustrated diagrammatically in Figure 8.1.
Figure 8.1: Diagrammatic representation of errors presented by drug-interaction 
monitoring software.
Interaction exists
Interaction ✓ False negative Interaction
detected False positive ✓ not detected
Interaction non-existent
Given that many pharmacists stated the need for the availability of drug interaction 
monitoring software as a prime reason for installing PMR systems (Section 3.3), it is 
surely reasonable for them to expect that the system they purchase or lease has drug 
interaction software that functions reliably. Indeed, in the Royal Pharmaceutical 
Society's guidelines on the use of pharmacy computer systems, it is recommended that 
"information should be obtained from a reputable source with a guarantee that it is 
regularly updated." * 34
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8.1.1 What is a Drug Interaction?
Stockley has defined a drug interaction as "a modification of the effect of one drug by 
the prior or concomitant administration of another. "59 A fuller description has been 
given by Maurer and Bartowski as fo llow s^ : "A drug interaction is considered to be 
the modification of one drug by prior or concomitant administration of another." In 
order to observe a clinically significant drug interaction there must be an alteration of 
the expected pharmacological outcome of individual drugs when used in combination. 
If the resultant response is greater than the sum of their separate actions then 
potentiation has occurred, while if the overall result is less than expected this 
development can be regarded an antagonism." Drug interactions can be conveniently 
divided into those affecting the pharmacokinetics of a drug and those that affect the 
pharmacodynamic responses. 136
Drug interactions can be regarded as encompassing three distinct groups of problems: 
drug-drug interactions; drug-food interactions; and drug-clinical-condition interactions. 
Drug-food interactions have not been considered as part of this research project, and 
the use of PMR systems to monitor for drug-patient-condition interactions (ie. 
contraindications) has been described in Chapter 7. In the following examination of 
drug interaction monitoring software, only drug-drug interactions have been 
considered.
8.1.2 The Availability of Drug Interaction Information to Community 
Pharmacists and General Medical Practitioners
Primary information sources on potential drug interactions include the following: 
published research papers; published clinical reports, for example a recent report on a 
probable terfenadine-itraconazole interaction^; letters to professional journals; 
manufacturers' data sheets; and Current Problems, issued by the Committee on Safety 
of Medicines.
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Community pharmacists and GPs have available to them a variety of reference sources 
to check for potential drug interactions, in addition to the possible use of a computer 
system. Probably, the most widely used paper-based information source on drug 
interactions in the UK is Appendix 1 of the British National Formulary^, which is 
published twice-yearly. Drug interaction information is also provided in each monthly 
issue of MIMS (Monthly Index of Medical Specialities).*^ Each of these 
publications is received by large numbers of community pharmacists and GPs. Many 
UK community pharmacies will have an up-to-date edition of the comprehensive text 
Martindale.*33 Specialist drug interaction texts are also available, including
Stockley's book Drug Interactions59, and in the United States two loose-leaf volumes 
containing drug interaction literature. 106,109 Other secondary literature-based 
sources of drug interaction information include published reviews, for example those 
covering specific pharmacological classes*^’*39, therapeutic groups*^, and 
recently-documented interactions 141-143, although such sources are usually less 
readily available to community-based practitioners, within their practice environment. 
The results of a survey investigating GPs' use of drug interaction information sources 
are presented in Section 9.3.
8.1.3 Secondary Reference Sources on Drug Interactions
A description of the modus-operandi of four paper-based drug interaction reference 
sources is given below.
8.1.3.1 The British National Formulary
The BNF^l is jointly published, twice a year, by the British Medical Association and 
the Royal Pharmaceutical Society of Great Britain, and includes an appendix providing 
brief drug interaction information which is cross-referenced. Interactions are classified 
at two levels of importance. Certain interactions are highlighted, indicating that they
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are potentially hazardous or that combined administration of two drugs should be 
avoided. Others are stated as not usually having hazardous consequences.
The BNF is compiled under the auspices of the Joint Formulary Committee, currently 
chaired by Professor CF George FRCP. The inclusion of drug interaction information 
is co-ordinated by the Executive Editor, currently Mrs Anne Prasad FRPharmS. Drug 
interaction information sourced from the pharmaceutical industry, published papers, 
other secondary reference sources and clinical reports, is reviewed by members of the 
Executive Committee, with expert opinion being sought from outside specialists. In 
the case of each new suspected drug interaction, or the review of a previously included 
interaction, expert advice is normally sought from a clinical pharmacologist, recognised 
for her work in the field. In addition, expert advice is sought from a specialist clinical 
practitioner working in the field concerned, for example a consultant cardiologist 
would normally advise on suspected interactions between two cardiovascular drugs.
8.1.3.2 Martindale: The Extra Pharmacopoeia
Published by the Pharmaceutical Press, and currently in its 30th edition, 
M artindale 133 has recently been published every four to seven years. Consequently, 
the paper-based version of Martindale cannot be considered as an adequate reference 
source for up-to-date drug interaction information, except perhaps for a short period 
after publication. An on-line, computerised version of Martindale is available, and is 
continuously updated; 1^4 a CD-ROM based version is also available. Martindale 
differs significantly from the BNF, in that only published papers are included in the 
drug interaction monographs. In contrast to the BNF independent expert clinical 
opinion on drug interactions is neither sought nor included.
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8.1.3.3 Drug Interactions (Stockley)
The second edition of this specialist text on drug interactions was published in 1991.59 
The first edition was published in 1981. This book is a result of the work of Dr Ivan 
Stockley, a recognised expert on drug interactions. It is a compendium of monographs 
on drug interactions, for which there have been published reports. An opinion of the 
significance of each potential interaction is provided. While, comprehensive in its 
nature, the infrequent publication of this work renders it out-of-date soon after 
publication.
Boehringer Ingelheim Ltd., with Stockley's guidance, publish a chart-based information 
system (Drug Interaction Alert) for doctors and pharmacists.^ it is not 
comprehensive, but provides an aide-memoire giving information about interacting 
drug pairs. The chart indicates whether drug effects are likely to be increased or 
decreased, as a result of a drug interaction, whether an interaction may be dangerous, 
or whether a toxic reaction is produced. Interactions are given three levels of 
significance: those of major or potentially serious significance; those of moderate or 
minor significance; and those of unclassified importance.
8.1.3.4 Evaluations of Drug Interactions
Evaluations of Drug Interactions (EDI) 109, published by Professional Drug Systems 
Inc., is similar in its philosophy to Drug Interactions.59 Primarily intended for use in 
the USA, and endorsed by an American Pharmaceutical Association (APhA) Scientific 
Review Panel, EDI has two important advantages over Drug Interactions. First, it is 
in loose-leaf format and bimonthly updates are issued to subscribers of the volume. 
Second, information is sourced from a number of academics and practising 
pharmacists. Drug interaction information is reported by consultant contributors and 
reviewed by an inter-disciplinary review panel and by the APhA Scientific Review 
Panel. Judgements on the inclusion and rating of monographs are made on the basis of
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levels of documentation, likely prevalence, and predicted severity. Interactions are 
ranked, based on these factors, from one (highly clinically significant) to four (not 
clinically significant). EDI is used as a reference source by Hadley Hutt Computing 
Ltd. for their PILLS system (Section 2.4.11).
8.1.4 The Development of Drug Interaction Monitoring Computer 
Software
The use of a program, written in the FORTRAN language, to store and retrieve drug 
interaction information was described by Lowenthal.145 The use of computer 
algorithms, based on the use of BNF drug classifications to determine drug-drug 
interactions has been described by workers at Liverpool University. 146 Their work 
considered "interaction groups", based on BNF classifications. Such a method of 
classifying drug groups, on its own, is insufficient to produce reliable drug-interaction 
monitoring software, since such BNF-based interaction groups are not usually drug- 
specific because they take no account is made of the effect of a drug's structure. The 
example of drug interactions with the histamine ^-antagonists cimetidine and 
ranitidine (Figure 8.2) illustrates this point.
Figure 8.2: Structures of two histamine H2~receptor antagonists, cimetidine and
ranitidine.
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Cimetidine inhibits the cytochrome P450 in the liver microsomal enzyme system, 
whereas ranitidine, and the other histamine H^-receptor antagonists famotidine and 
nizatidine do n o t .  147 Cimetidine is bound to cytochrome P450 and forms a stable 
complex, preventing the access of other agents to the cytochrome P450 enzyme 
system. It has been proposed that the particular ability of cimetidine to inhibit the 
hepatic metabolism of other drugs may be due to the imidazole ring in its structure. *48 
This structural feature is not shared by ranitidine or the other histamine H2-receptor 
antagonists famotidine and nizatidine. Therefore drug interaction groups used to code 
for interactions with histamine H2-receptor antagonists must take account of 
differences in each drug's activity, produced as a function of chemical structure, and 
not simply rely on the BNF classification 1.3.1 "Histamine H2-receptor antagonists."
The use of Prolog to produce a drug-to-drug interaction package has been described 
by Pinciroli and P o z z i . 1 4 9  Gardner and Rizack have used a Prolog knowledge base, 
which consisted of two databases: the first of drug interactions, and the second of drug 
chemical names and s t r u c t u r e s . * ^  They used this knowledge base to examine the 
relationship between interacting drugs and their chemical components. The problems 
of interfacing a drug interaction monitoring program to pre-existing medical records 
has been described by D oling* He used a Pascal program to store medical records in 
a dBase-compatible format (Ashton-Tate Ltd.), which was then linked to a 
commercially available drug interaction monitoring program. Some pharmacy 
computer programs store their drug-product data in a dBase-compatible format, for 
example, the Nomad program produced by Surgichem Ltd.
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8.1.5 Evaluation of Drug Interaction Monitoring Software
The value of a computer application is usually dependent on the program's ability to 
store, process, and retrieve information in a format that is useful to the computer 
user. * 52 Jo  date, there has been no published work in the UK evaluating the ability of 
pharmacy computer systems to detect drug interactions, although Stevens and Crabbe 
discussed the nature of interactions detected in a community pharmacy over a one- 
month period by the Interlex system, used as part of the AAH LINK system.28 The use 
of hospital-based drug interaction monitoring software in the USA has also been 
described. ^
A number of papers have been published as a result of work in the USA, examining the 
abilities of various software packages to detect potential drug interactions. Poirier and 
Guidici have evaluated 11 American drug interaction monitoring programs. 1 54-164 
When evaluating each program, they considered ease of installation, learning and use; 
documentation; and the provision of technical support. The ability to detect ten 
potential drug interactions was tested. A final paper was published summarising and 
comparing each s y s t e m .  *63 Fox published a paper evaluating three systems in 
1991152^  and, most recently, Jankel and Speedie evaluated and compared she systems, 
concluding that for those interactions examined, the Medicom Micro Plus system 
(PDS Inc.) was the most reliable. *66 The ability to detect drug-food interactions has 
also been evaluated in one paper. 167
8.1.6 Sources of Drug Interaction Information Used by UK Pharmacy 
Computer Systems Suppliers
In commenting on the RPSGB guidelines on pharmacy computer u s e *  34, Strickland- 
Hodge has summarised the criteria essential for an effective drug interaction system.^? 
These were as follows:
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i) The system should recognise proprietary and generic drug names and be able to 
identify individual drug constituents within compound preparations.
ii) Drug interaction information should be obtained from a reputable source.
iii) Drug interaction information should be updated on a regular basis in electronic 
form.
iv) The pharmacist should be able to set the time period over which the patient 
record is searched for interactions and this period should extend up to two 
years if required.
Interaction reference sources that were cited within the five systems with the largest 
UK market shares in April 1991 (Figure 2.3) are described below.
8.1.6.1 John Richardson Computers Ltd.
The drug interaction information within the Richardson system has been compiled by 
Richardson staff with input from Dr Ivan Stockley. Recently, the VADIS database has 
been included with this system. 168 The Richardson system does not provide any 
ranking of the significance of reported drug interactions.
8.1.6.2 AAH UNK
The AAH LINK system uses the Philex and Interlex databases produced by Exeter 
Data Base Systems Ltd. The LINK system gives interaction guidance to pharmacists 
as in Figure 8.3.
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Figure 8.3: Drug Interaction Guidelines Given to Pharmacists by the AAH UNK
Computer System.
Key: **** Most Severe * Least Severe 
Suggested Action:
**** Hold script and contact GP
*** Dispense script but inform GP 
** Dispense script & counsel patient
* No specific guidelines - actions dependent on circumstances
8.1.6.3 Park Systems Ltd.
Interaction information within the Park Systems program is provided by staff from the 
School of Pharmacy, John Moores University, Liverpool. Interactions are designated 
"1: Major", "2: Moderate" or "3: Minor", in decreasing order of significance.
8.1.6.4 Hadley Hutt Computing Ltd. PILLS System
The PILLS system cites drug interaction information from the following sources: BNF 
(Section 8.1.3.1); Drug Interactions', the British Medical Journal, drug 
manufacturers; Adverse Drug Reaction Bulletin, produced by the Adverse Drug
Reaction Research Unit at Shotley Bridge General Hospital, Consett, Co. Durham,
UK; USPDI*08; Evaluations o f Drug Interactions (Section 8.1.3.4). *09 Each drug 
interaction warning brought to the user's attention is referenced to one of these 
sources. Interactions are classified by the PILLS system as either "Probable" or 
"Possible" : the former being those rated as being of greater significance.
8.1.6.5 Chemtec Systems Ltd.
The Alchemist 3000 system includes interaction information from the following 
sources: Hansten & H o r n  107, BNF^l, M artindale^ and the Pharmaceutical 
Journal. Interactions are ranked as follows, in decreasing order of significance:
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dangerous, moderate, minor. The user has the facility to switch off the lower levels of 
significance, but those interactions ranked as dangerous require the pharmacist to enter 
a password in order to proceed.
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8.2 Method
The study on clinical interventions made by community pharmacists (Chapter 7) 
produced a total of 510 reported drug interactions (Table 7.7), of which 364 occurred 
during the period August 1991 - July 1992. Of these 364 reported incidents, 168 were 
duplicate interactions which had each occurred on more than one occasion. Therefore, 
at the time of the following study on drug interactions (July-August 1992) there were 
196 reported discrete drug interactions contained within database of the clinical 
intervention events. Each of these interacting drug pairs was input to the five PMR 
computer systems described in Section 8.1.4, and any computer output was noted. At 
the same time, each interacting drug pair was examined in four published reference 
sources: B N F^, Stockley's Drug Interactions^, M artindale^, the ABPI Data Sheet
Compendium. 169
8.3 Results
The reporting of drug interactions by each of the five PMR computer systems and four 
published reference sources is shown in Appendix 4 (page 338). The data are 
presented in order of the numerical BNF classification of the first drug of each 
interacting pair, italics being used to identify branded combination products, without 
an equivalent generic description, for example, Sotazide.
An examination of the results in Appendix 4 shows that the systems and reference 
sources employed are far from consistent in reporting potential drug interactions. Of 
the published reference sources, the BNF and Drug Interactions included the greatest 
number of reported interactions; and, of the computer systems the Richardson system 
reported far fewer interactions than any of the other four PMR systems. It is of note 
that the Hadley Hutt PILLS system most closely follows the guidance on drug 
interactions given in the BNF.
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8.4 Discussion
Some reasons for discrepancies between the systems are described below, with 
appropriate illustrative examples, from the results of the clinical intervention study 
(Chapter 7), where appropriate. Interactions that are discussed in the following text 
are highlighted in bold in Appendix 4, page 338.
8.4.1 Inappropriate Drug Groupings
The problem of false positive drug interaction reports has been introduced in Section 
7.4.1.7, with reference to the incorrect grouping of all cephalosporins which caused a 
PMR system to report a non-existent interaction between cephalexin and Burinex K  
(bumetanide & potassium chloride). In fact, cephalothin is the only cephalosporin 
which interacts with loop d i u r e t i c s .  133
A further report on the inappropriate use of interaction groups occurred with the non­
steroidal anti-inflammatory drug ibuprofen. One pharmacist, using the Park Systems 
program reported a detected drug interaction between ibuprofen and warfarin. As a 
result, the general practitioner ceased the patient's ibuprofen treatment. The literature 
shows considerable evidence for the potentiation of warfarin by ketoprofen, mefenamic 
acid, tiaprofenic acid, suldinac and piroxicam, possibly through the displacement of 
warfarin from plasma proteins by the NSAID m o le c u le s .  59 In addition, indomethacin 
has been shown to reduce platelet aggregation, thereby prolonging bleeding if it 
occurs. In contrast, ibuprofen, diclofenac, fenbufen, naproxen and tolmetin have been 
shown not to interact with warfarin.59,109
Of the computer systems examined, Park Systems' program ranked the possible 
ibuprofen/warfarin interaction as a major interaction, the Alchemist 3000 program 
ranked it as a moderate interaction, and the PILLS program ranked it as a probable 
interaction. Neither the Richardson nor AAH LINK programs detected an interaction.
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It would appear that the Richardson and AAH LINK programs correctly considered 
each NSAID as a separate entity as far as interactions are concerned; whereas the 
other programs incorrectly are using a global interaction group to include all NSAIDs.
8.4.2 Programming Omissions
The interaction between digoxin and amiodarone is well d o c u m e n t e d . 5 9 , 1 0 8 , 1 3 3  
Serum digoxin levels may double after administration of amiodarone, leading to 
possible toxicity. This interaction was ranked as being of at least moderate 
significance by all PMR systems, except Park Systems' program. All of the published 
reference sources listed in Appendix 4 included this interaction. The absence of this 
interaction from Park Systems' program is probably an error of omission.
Administration of potassium salts to patients taking ACE inhibitors may cause 
hyperkalaemia.81 One pharmacist reported an interaction between Potassium Citrate 
Mixture BP and captopril. This interaction was found in all the published reference 
texts (Section 8 . 1 . 3 ) ,  and was detected by each of the computer systems, with the 
exception of the Chemtec Alchemist 3000 program. Further investigation of the 
Alchemist 3000 program showed that it also failed to detect interactions between ACE 
inhibitors and NSAIDs, although these were detected by the AAH LINK, Park Systems 
and PILLS programs.
Internal audit of the drug databases by the company concerned, together with external 
audit by appropriate experts would help to eliminate such non-complex errors within 
the product files.
8.4.3 Obscure Interactions
One pharmacist, using a Richardson computer system, documented a drug interaction 
between co-amilofruse (amiloride & frusemide) and phenytoin. None of the other four
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systems under examination detected this interaction. The interaction was not 
documented within the BNF or ABPI Data Sheet Compendium. However, there are 
literature reports describing a possible mechanism, whereby jejunal absorption of 
frusemide is reduced by p h e n y t o i n . 5 9 , 1 0 9  Effects of this interaction on patients, 
though, are not considered to be serious. ^
Two papers were published in 1984 describing three serious cases of Stevens-Johnson 
syndrome attributable to the concurrent administration of captopril and 
a l l o p u r i n o l .  170,171 These papers have been used to justify the inclusion of this 
particular interaction in Stockley's book^, and presumably also within the Richardson 
system. This interaction was documented in M artin d a le l-^  and the ABPI Data Sheet 
C o m p e n d i u m ,  169 but not the BNF. 81 No computer system, other than the 
Richardson detected this interaction.
8.4.4 Drug File Deficiencies
Problems can arise as a result of the drug files in computer systems not being 
maintained up-to-date. The vasodilator doxazosin (Cardura) is licensed for the 
treatment of hypertension, and was introduced to the UK market in October 1989, but 
it is not included in the current edition of Drug Interactions.^ An interaction 
between doxazosin and co-amilozide (amiloride & hydrochlorthiazide) was reported by 
a pharmacist using an AAH LINK system. This was ranked as a "two-star” interaction, 
with a warning of possible increased postural hypotension caused by the diuretics. The 
BNF listed this interaction as potentially hazardous. The same warning was reported 
by the Hadley Hutt PILLS system. However, the Chemtec system ranked this 
interaction as being of only minor significance; whereas the Richardson and Park 
Systems' programs did not warn of any interaction. In this example, three different 
answers were provided by the computer systems, and one text (Drug Interactions) was 
shown to be out-of-date. This shows potential deficiencies in the ability of computer
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systems to present dat^ i on new drugs. Another example of the same type of problem 
is the interaction between lithium and paroxetine (<Seroxat), a new anti-depressant, 
marketed in the UK in February 1991. Again, paroxetine is not listed in Drug 
Interactions $9 it was not included in Park Systems' program, which therefore could 
not check interactions for this product. The AAH system rated the interaction as a 
"one-star" interaction, and thus of little significance. The BNF described the 
interaction as potentially hazardous, as a result of raised plasma lithium levels. Again, 
the PILLS system matched the BNF warning, and the Chemtec Alchemist 3000 
program ranked the interaction as of moderate significance. Although both lithium and 
paroxetine were on the Richardson system's drug file, no interaction was indicated 
between the two drugs. This example illustrates a considerable discrepancy across the 
range of interaction reference sources, both for computer systems and published texts. 
The lithium and paroxetine interaction has only recently been included in EDI (June 
1993).
Other potential problems exist within drug databases as a result of discontinued 
products. If a computer supplier deletes a product from their drug file, users of their 
system may not detect potential drug interactions when remaining stock is dispensed 
after the product's discontinuation, for example Navidrex K, discontinued in November 
1991. Navidrex K  had been deleted from the Alchemist 3000 program prior to the 
time of this study (July-August 1992) Reported interactions between this product and 
indomethacin therefore could not be checked.
Non-prescription medicines, traditionally referred to as "over the counter" products are 
not always included in the drug files of pharmacy computer systems. Examples that 
could not be investigated using some of the computer systems were Cymalon, Mucron, 
and Benylin Day and Night. Each of these products contains drugs with significant 
pharmacological activity (sodium citrate, paracetamol and phenylpropanolamine), and 
has the potential to interact with other compounds. The potential for interactions with
231
non-prescription medicines (Table 7.7) again highlights the dangers if pharmacists do 
not make records of the supply of non-prescribed medication (Sections 2.3.4 & 
2.4.10).
8.4.5 Incorrect Pharmaceutical Form
Drug interactions may, in certain cases, depend on the pharmaceutical form of one or 
more interacting drugs. This point is illustrated by the example of glyceryl trinitrate 
(GTN), which is commonly prescribed as a sublingual or buccal tablet used for the 
relief of acute angina. It is also used in a transdermal delivery system for angina 
prophylaxis. Drugs which reduce saliva production, for example, anti-cholinergics and 
tricyclic antidepressants, reduce the sublingual and buccal absorption of GTN. 
However, such drugs would not be expected to reduce transdermal drug delivery. In a 
study of PMR systems to examine the ability of drug interaction monitoring software 
to detect interactions with drugs acting on the cardiovascular system, some systems 
failed to differentiate between different dosage forms. *^2 it Was found that the 
interaction between GTN sublingual tablets and tricyclic antidepressants was detected 
by all of the systems tested except the Richardson system. However, when GTN 
transdermal patches were entered into the AAH LINK system, the system still 
responded that the above drugs would "cause a decrease in GTN dissolution in the 
mouth." The Park Systems and Chemtec Alchemist 3000 programs both gave similar 
warnings. Only the Hadley Hutt PILLS system differentiated between the dosage 
forms.
8.4.6 Literature Interpretation
An interaction alert between doxycycline and carbamazepine was documented by a 
user of an "in-house" system. This interaction has been shown to decrease the 
doxycycline half-life for patients receiving long term carbamazepine. 1 ^  The effect is 
documented as potentially hazardous (failure of antibiotic therapy) in the BNF, and
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was found in the all the other examined reference texts. The Richardson system did 
not detect the interaction; the PILLS system stated that it was a ’’Possible” interaction 
(ie. of low significance); Park Systems' program rated the interaction as level "2” (ie. of 
moderate significance; yet the AAH LINK system rated this as a "three-star" 
interaction. This is an example of how a well-documented interaction can either be 
overlooked, or interpreted in a number of different ways by the program suppliers.
A second example of this type of problem is the interaction between diltiazem and 
aminophylline. Stockley^^ states that this drug combination can be used safely despite 
a 12-21% decrease in theophylline clearance after the administration of diltiazem; 
however references cited in EDI show that the mechanism of this interaction is very 
u n c l e a r .  109 The interaction between theophylline and diltiazem is shown as potentially 
hazardous in the BNF. Therefore the secondary literature reference sources for this 
interaction are somewhat inconsistent. Consequently, it is not surprising that the 
computer systems were inconsistent in the reporting of the interaction between 
diltiazem and aminophylline. The Richardson system did not report any interaction, 
possibly as a result of Stockley's advice. The AAH LINK system ranked this a "three- 
star" interaction; Park Systems a level "1" interaction (ie. major); Alchemist 3000 a 
moderate interaction; and PILLS a "Probable" interaction, reflecting the BNF.
8.4.7 How Could Drug Interaction Reporting by Pharmacy Computer 
Systems be Improved?
The examples of reported interactions, in Appendix 4, show many inconsistencies both 
between published reference sources and reports from pharmacy computer systems. It 
is quite possible that a pharmacist could use two sources, eg. Drug Interactions^ and 
the Richardson computer system, and not be alerted to an interaction using either; yet 
another pharmacist using two different sources, for example the BNF and the PILLS 
system, may detect interactions using both. This is what would happen in the case of
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diltiazem and aminophylline. Where there are conflicting reports in the literature, there 
will always be the potential for inconsistencies between computer programs. However 
where this is the case, the software should be programmed to indicate any divergence 
of opinion as to the importance of any particular interaction to the user, better enabling 
him to obtain the optimal patient outcome.
Most UK pharmacy computer systems, unlike some used in the USA, provide users 
with very little referenced information about drug interactions (Table 6.3). A fuller 
explanation of potential interactions, and citation of key references, would probably be 
of benefit to users and patients under their care.
During the clinical intervention survey (Chapter 7), some respondents stated that GPs 
occasionally refused to alter patients’ therapy when confronted with alleged drug 
interactions, due to differences in the perceived importance of those interactions by 
pharmacist and doctor. Community pharmacists' use of computer systems to monitor 
for potential drug interactions has been shown to be higher than GPs’ use 26,131,132 
It would surely be of benefit to patients if the pharmaceutical and medical professions 
agreed on common reference sources for drug interactions. Partly with this in mind a 
survey of GPs' use of interaction reference sources has been conducted; the results are 
presented in Section 9.3.
8.4.8 "Ternary Systems"
All of the interactions shown in Appendix 4 can be considered as "binary” interactions, 
involving two interacting drugs. The author proposes the development in 
pharmaceutical and medical computer systems of what would be called "ternary 
systems." Models illustrating ternary interactions are shown in Figure 8.4.
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Figure 8.4: Software models for the proposed mternary system* drug-interactions.
a) Digoxin <-> Frusemide b) 4-Quinolones <-> NSAIDs
t I
Potassium Epilepsy
As part of the clinical intervention survey (Chapter 7), an interaction between loop 
diuretics and digoxin was reported. When the pharmacist further investigated this, it 
was found that the patient concerned was also taking a potassium supplement, thus 
reducing the concern about the interaction (Section 7.4.1.7). This is an example where 
drug interaction software cannot, at present, process more than two drugs at any one 
time.
Drug interaction monitoring software that detects the likelihood of adverse drug 
interactions in those sub-population as particular risk have not yet been detected. 1^1 
Rarely, 4-quinolone antibiotics, for example ciprofloxacin may precipitate seizures in 
epileptic patients: the probability of this adverse drug reaction is increased if NSAIDs 
are administered c o n c u r r e n t l y .  1^3 This is an example of where a patient's clinical 
condition may determine the validity of a potential drug interaction. These two 
examples show the need for enhanced drug interaction monitoring software, capable 
of processing more than two factors at any one time. The use of decision-making and 
support packages using "expert system” software is likely to facilitate this at some 
point in the future. Expert systems are described as computer systems that are capable 
of performing at or near to the levels of an expert in a particular f i e l d .  1^4 Although not 
yet used in pharmacy practice, expert systems have been used in medicine. 175-177
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8.5 Conclusions and Recommendations
1. This analysis of nearly 200 potential drug interactions, using five drug 
interaction monitoring programs, has shown that there is considerable 
inconsistency between the systems in their ability to detect drug interactions. 
This lack of consistent performance can be due to several factors: consideration 
of general pharmaceutical classes of compounds as opposed to individual drug 
entities; frank programming omissions; incomplete or out-of-date drug files; 
and lack of consideration of pharmaceutical form and route of administration.
2. Internal audit of the drug databases by the software supplier concerned, 
together with external audit by appropriate experts would help to eliminate 
non-complex errors within the product files, for example due to typing 
mistakes.
3. Complex interaction problems, involving three or more drugs will require the 
use of more advanced software, possibly using "expert system" techniques, to 
enhance patient outcome.
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9. General Medical Practitioners* Views on Patient Medication
Records in Community Pharmacy
A survey has been conducted to examine general practitioners' (GPs) views on 
community pharmacists' use of PMR systems. In particular, opinions were solicited on 
whether pharmacists should maintain PMRs, and if so, for which patient groups. 
Community pharmacists' use of patient information leaflets has been described in 
Chapter 5 and in this survey GPs were asked whether they approved of pharmacists 
issuing PILLS type patient information leaflets to patients, and whether they 
considered that the use of such leaflets affected patient compliance.
Problems associated with the use of drug interaction monitoring software, and 
discrepancies between literature-based and computer-based reference sources have 
been described in Chapter 8. The study presented in this chapter has examined GPs' 
use of available reference sources on drug interactions, and whether they welcome 
information from community pharmacists on potential drug interactions arising from 
prescribed medication.
9.1 Introduction
9.1.1 General Practitioners' Use of Computer Systems
GPs have been encouraged by Government to use computer systems since the early 
1980's. In June 1982 the "Micros for GPs" scheme was announced by the Department 
of Industry, now the Department of Trade and Industry. This scheme helped 150 
general practices to install computers designed for the registration of patients, the issue 
of repeat prescriptions and the screening and recall of patients. The final report on the 
scheme identified that the main benefits of computers in general medical practice were 
not in the day-to-day routine of practice administration, but rather in the aggregation 
and analysis of information.
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Further financial support for GPs' use of computer systems came from the 
pharmaceutical industry during the mid-1980's.^® Ciba-Geigy provided subsidised 
software to GPs in 1986, and systems were provided to GPs at no cost by VAMP and 
AAH Meditel in 1986, in exchange for the return of prescribing data, which could then 
be traded to marketing organisations and the pharmaceutical industry. The VAMP and 
AAH Meditel schemes ceased in 1991 due to lower than expected financial returns 
from the data collected by these two organisations. 1 ^ 9
In 1987 the Government White Paper Promoting Better Health made direct reference 
to the benefits of practice computers^, as did the White Paper Working fo r Patients 
in 1989.180 jn contrast, apart from payments for the maintenance of PMRs, 
community pharmacists have received no financial support from Government or the 
pharmaceutical industry towards the capital and running costs of computer systems.
Since April 1991, GPs have been able to elect to become "fund-holders”, whereby they 
control their own financial budgets enabling them to "buy” services for their patients. 
The survey reported here examines whether being a fund-holder influenced GPs' use of 
computer systems or their attitudes towards community pharmacists' use of systems. 
Similarly the attitudes of dispensing doctors (Section 1.2) have been examined, as have 
the influences of the location in which a GP practises and his year of registration as a 
doctor. In our earlier study, community pharmacist's year of registration has been 
shown to influence PMR use and attitudes towards PMR systems (Section 2.4.4), 
whereas pharmacy location had no significant influence (Section 2.4.7).
It was thought that more-recently registered GPs would be more positive in their 
attitudes towards the community pharmacist's clinical role, given that their 
postgraduate clinical training will have involved exposure to clinical pharmacy in the 
hospital setting. It was felt that the location in which a GP practises could influence 
attitudes towards the clinical role of the community pharmacist. There are two
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possible reasons for this: first, rural GPs are more likely to dispense medicines than 
their non-rural colleagues, which can lead to generally poor working relationships or 
disputes between community pharmacists and dispensing doctors* ^ 1; second, from the 
author's management of four pharmacies and experience in several others, relationships 
between the general practitioner and community pharmacist tended to be better in 
small to medium-sized towns than in suburban or city centre locations.
9.1.2 General Practitioners1 Perceptions of the Community Pharm acists 
Clinical Role
Professional relationships between GPs and community pharmacists have been 
discussed in the Nuffield Report, which stated that the co-operation shown between 
hospital practitioners was rarely reflected in the community.* The report then 
progressed to state how the development of closer relationships between GPs and 
community pharmacists would be in the interests of patients and could lead to a more 
efficient use of resources within the NHS.
In a recent paper (1992), Spencer and Edwards described the results of a survey of 
general practitioners' attitudes to the community pharmacist's extended r o l e .  ***2 High 
levels of support were found among GPs for an increased role for community 
pharmacists in three areas: managing minor illness, advising general practitioners about 
cost effective prescribing, and reporting adverse drug reactions. There was little 
support found among GPs for pharmacists' involvement in screening for raised blood 
pressure and blood lipid levels. Support for pharmacists supervising repeat 
prescriptions was mixed. Spencer and Edwards felt that at a local level relationships 
between the professions were good, though closer co-operation and better 
communication might help to extend the quality of advice given to patients.
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In New Zealand in 1991, Ellis et al conducted a survey on general practitioners' views 
of the community p h a r m a c i s t .  183 High support was found among GPs for the 
community pharmacist's traditional roles of dispensing and providing advice to patients 
on minor illnesses. Respondents also felt that it was appropriate for community 
pharmacists to advise medical practitioners on drug usage and information. However, 
they did not welcome the provision to patients of information about previously 
diagnosed conditions. In this context it should be noted that the Hadley Hutt PILLS 
system used in the UK (Section 5.1.3) can provide information leaflets on several 
clinical conditions.
Blenkinsopp et al have described development of liaison groups between GPs and 
community pharmacists as a novel way of facilitating communication between the two 
professions serving the same patient c o h o r t .  184 As part of their study, two research 
groups have been set up to examine the feasibility of collaboration between GPs and 
community pharmacists in monitoring patients suffering from asthma.
In the survey described here, the aim was to make both quantitative and qualitative 
assessments about GPs' opinions on the community pharmacist's role in maintaining 
PMRs, together with the associated roles of providing patient information leaflets and 
advising prescribers on potential drug interactions.
240
9.2 Method
9.2.1 Equipment and Materials Used
Questionnaire forms and other project documents were produced using Microsoft 
Word for Windows on a Viglen Genie IBM compatible computer and a Hewlett- 
Packard DeskJet 500 printer. SPSS/PC+ V4.0 was used to record results from 
returned questionnaires and for statistical analysis of the data. A Freepost licence 
arrangement with the Post Office facilitated the return of questionnaires.
9.2.2 Design of Questionnaire
This survey considered those factors that could possibly influence a GP's attitudes 
towards pharmacists' involvement in maintaining medication records. These were 
envisaged to include the location of the GP's workplace; whether he was a fimd-holder; 
the GP's length of experience, represented by his year of registration as a doctor; 
whether he belonged to a dispensing practice; and the degree to which he used a 
computer system for clinical purposes.
A questionnaire was developed to gather responses from GPs as to whom they thought 
should hold patients' medication records; which patient groups pharmacists should 
maintain records for; whether pharmacists should include clinical conditions in PMRs; 
whether pharmacists should provide information to patients using computer-generated 
information leaflets; to what extent pharmacists' advice on drug interactions was 
welcome; and those reference sources which a GP used if he suspected the existence of 
a potential drug interaction.
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The questionnaire was piloted among a sample of 20 GPs in the 3Guildford area, and 
their comments were taken into account in making minor changes to the questionnaire; 
in particular the length of some questions was reduced and the typeface was altered to 
produce a final questionnaire printed on fewer pages.
A covering letter, a copy of the final questionnaire (Appendix 2, page 333) and the 
PILLS leaflet on penicillins were sent to a total of 1257 GPs (579 in Avon, 678 in 
Devon) in April 1993. A Freepost envelope was enclosed for the return of the 
completed questionnaires. Non-respondents were sent a reminder and a second copy 
of the questionnaire after a six week period.
^Guidford was chosen as it was an area that would not be included in the final survey. 
Also, the author was familiar with this location, and was aware that the sample would 
be likely to contain a representative mixture of GPs, including some who provided a 
dispensing service for their patients.
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9.3 Results
Completed questionnaires were received from 811 GPs (383 from Avon, 423 from 
Devon, and five unidentifiable due to their identity codes being obliterated by the 
respondents). Information was also provided that two GPs were on long term sickness 
leave; two were on sabbatical; two had relocated; and three only provided a family 
planning service. Another GP wrote a letter detailing his considered reasons for not 
responding to the questionnaire. An overall response of 64.5% was therefore achieved; 
the response from Avon (66.1%) being slightly higher than that from Devon (62.4%). 
A profile of the respondents is shown in Table 9.1.
763 (94.1%) of the respondents worked in a computerised practice. GPs use of 
computer systems is shown in Table 9.2.
The responses in Table 9.2 were cross-tabulated with the practice profile data from 
Table 9.1, and analysed using the x^ test of independence. ^ 3>^  City centre
practitioners were shown to be less likely to work in computerised practices than those 
elsewhere (x^=18.3, df=4, p<0.01); 87.7% of GPs working in city centre areas were in 
computerised practices. A computer system was used by 98.9% of fund-holding GPs, 
in contrast to 92.6% of non-fund-holders (x^=10.6, df=l, p<0.01). Fund-holding GPs 
were also more likely to use their computer system to monitor for potential drug 
interactions than non-fund-holders (57.1% of fund-holders, 47.0% of non-fund- 
holders, x^=5 82, df=l, p<0.05); and to use their systems to view clinical data on 
patients (82.0% of fund-holders, 71.0% of non-fund-holders) (x^=8.92, df=l, p<0.01). 
Finally, 59.2% of fund-holders possessed a modem and communications software, 
compared with 39.4% of non-fund-holders (x^=22.1, df=l, p<0.0001).
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Table 9.1: General medical practitioner practice profiles.
FHSA:
Avon Devon Not identified Total
Practice location: City centre 70 (18.5%) 58 (13.9%) 2 130 (16.2%)
Suburban 164 (43.3%) 73 (17.5%) 2 239 (29.8%)
Small town 88 (23.2%) 188 (45.0%) 276 (34.4%)
Rural 34 (9.0%) 80 (19.1%) 1 115(14.3%)
Other 23 (6.1%) 19 (4.5%) 42 (5.2%)
Fund-holder: Yes 87 (22.7%) 102 (24.2%) 1 190 (23.5%)
No 296 (77.3%) 319 (75.8%) 4 619 (76.3%)
Dispensing practice: Yes 36 (9.4%) 77 (18.3%) 1 114(14.1%)
No 346 (90.6%) 343(81.7%) 4 693 (85.9%)
Year of registration: 1962 or earlier 41 (10.8%) 56 (13.2%) 97 (12.0%)
1963-72 116(30.4%) 109 (25.8%) 2 227 (28.1%)
1973-82 168 (44.1%) 179 (42.3%) 3 350 (43.3%)
1983-92 56 (14.7%) 79 (18.7%) 135 (16.7%)
Cross-tabulation of the responses, followed by x^ analysis showed that rural GPs were less likely to be fund-holders than those GPs practising 
elsewhere (x^=25.9, dfi=4, pO.OOOl). 51.3% of those GPs classed as "rural” were dispensing doctors, this differed significantly from all other 
practice locations (x^= 181.1, df=4, p<0.0001).
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Table 9.2: General practitioners' use of computer systems.
FHSA:
Computerised practice:
Use of computer system to 
monitor for drug interactions:
Use of computer system to 
view clinical patient data:
Use of computer system to 
view clinical drug data:













Devon Not identified Total
395 (93.4%) 5 763 (94.1%)
28 (6.6%) 48 (5.9%)
187 (47.5%) 3 377 (49.5%)
207 (52.5%) 2 384 (50.5%)
296 (74.7%) 4 563 (73.8%)
100 (25.3%) 1 200 (26.2%)
251 (63.7%) 5 488 (64.0%)
143 (36.3%) 274 (36.0%)
162 (41.8%) 3 332 (44.4%)
226 (58.2%) 2 415 (55.6%)
Dispensing doctors were more likely to use their computer systems to monitor for 
potential drug interactions (68.5% dispensing doctors, 46.2% non-dispensing doctors) 
(X^=18.4, df=l, p<0.0001); and to possess a modem and communications software 
(61.9% dispensing doctors, 41.5% non-dispensing doctors) (x^=15.3, df=l,
p<0 .0 0 0 1 ).
GPs who registered before 1962 were less likely to work in a computerised practice 
than their more-recently registered colleagues (x^=15.0, df=3, p<0.01).
GPs' responses to the question "Who do you think should keep patients' medication 
records?" are shown in Table 9.3.
Table 9.3: General practitioners' responses to the question "Who do you think should 
keep patients' medication records?"__________________________________________





Twenty nine respondents indicated that other persons or groups should hold patients' 
medication records. Where specified, these included carers, hospitals, nursing and 
residential homes, and the ambulance service. The only significant factor influencing 
respondents' views on PMR retention was whether the GP was a dispensing doctor 
Only 42.9% of dispensing doctors stated that pharmacists should hold PMRs, in 
contrast with 61.7% of non-dispensing doctors (x^=14.1, df=l, p<0.001).
Significant trends were shown in the effect of the GPs' year of registration on their 
views of whether patients (p<0.001) and pharmacists (p<0.01) should hold PMRs. 
This is illustrated in Figure 9.1.
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Figure 9.1: The effect of GPs' year of registration on their opinion whether patients and 
pharmacists should retain patient medication records.
1962 or earlier 1963-72 1973-82
Year of registration
1983-92
□  Pharmacist retention H  Patient retention
The next question (Q9) on the questionnaire presented the hypothetical situation where 
the FHSA, or some other authority, held patient records; GPs were asked which 
professional groups should have access, appropriate to their role, to patient records. 
Responses to this question are shown in Table 9.4.
Table 9.4: GPs' agreement with selective access to FHSA-held records by primary 
health care professions.





Of those 46 respondents stating that "Others" should have selective access to FHSA- 
held patient records, ten stated hospital doctors, five community nurses, three 
chiropodists, three hospital pharmacists, two the ambulance service, and one 
physiotherapists. Nine respondents explicitly stated that the FHSA should not hold 
patient records under any circumstances. Reasons given were lack of security and 
confidentiality and that it was not the role of the FHSA to keep such patient data.
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Only 42.0% of rural GPs felt that pharmacists should have selective access to patient 
records, in contrast with 61% of GPs in city centre, suburban and small town locations, 
(^2 = 1 9  4 , p<0.001). This finding matched the views of dispensing doctors; of
whom 45 .9% were in favour of pharmacists having selective access to patient records, 
in contrast with 59.5% of non-dispensing doctors (x^=7.2, df=l, p<0.01). Dispensing 
doctors (23.4% were in favour) were also less likely than non-dispensing doctors 
(33.4% were in favour) to accept that ophthalmic opticians should have access to 
FHSA-held patient data (x^=4 35, df=l, p<0.05).
GPs who registered before 1962 were less likely than their more-recently registered 
colleagues to agree with pharmacists having selective access to FHSA-held patient 
records. This is illustrated in Figure 9.2.
Figure 9.2: The effect of year of registration on whether GPs considered community 







1983-921962 or earlier 1963-72 1973-82
Year of registration
Patient registration with a pharmacy was considered beneficial for all patients by 115 
respondents (14.4%), compared with 574 (72.1%) who supported this for selected 
patient groups. Registration with a pharmacy was considered of no benefit to any 
patients by 107 (13.4%) respondents. A greater diversity of opinion occurred with 
GPs from Devon, and those practising in rural areas. These groups tended to show
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greater preferences either for registration of all patients, or no patient registration at 
all. Dispensing and non-dispensing doctors did not differ significantly in their views. 
Five respondents expressed concern that any registration scheme would have to have 
adequate provisions for rota duties and emergency dispensing.
GPs were presented with a list of candidate groups of patients with clinical disorders, 
and asked to state whether they agreed that pharmacists should keep medication 
records for these patients. Responses are shown in Table 9.5.
Table 9.5: GPs( agreement with pharmacists keeping PMRs for selected patient 
9 r9 »Ps -____________________________________________________________________
Confused patients 689 (85.8%)
Elderly 640 (79.7%)




Patients with renal or hepatic impairment 513 (64.0%)
Ostomy patients 440 (54.8%)
Patients with cardiac disorders and/or hypertension 430 (53.0%)
Patients with a history of peptic ulceration 342 (42.6%)
HIV positive / AIDS patients 240 (30.0%)
GPs in Avon (26.3%) appeared to be less likely than those from Devon (33.3%) to 
favour pharmacists keeping records for HIV positive / AIDS patients, (x^=4-6, df=l, 
p<0.05), although the FHSA in which respondents practised did not influence the 
agreement with pharmacists keeping PMRs for any other patient groups. GPs 
practising in rural areas were less likely than their colleagues practising elsewhere to 
favour pharmacists keeping PMRs for the following patient groups: epileptics 
(p<0.01); the confused, the elderly, diabetics, asthmatics, those with a history of ADR, 
and those patients with renal or hepatic failure (all p<0.05). Similarly, dispensing 
doctors were less likely than their non-dispensing colleagues to favour pharmacists
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keeping PMRs for the following patient groups: diabetics, epileptics and those with 
cardiac disorders and/or hypertension (all p<0.01); the elderly, asthmatics, and those 
patients with renal or hepatic failure (all p<0.05).
42 respondents listed other patient groups that they believed should be included in 
pharmacists PMRs (Table 9.6).




All those on multiple medication 12
Those on anti-coagulants 11
Long term mentally ill 8
Those on steroids 5
Those on benzodiazepines 5
Handicapped / blind 3
Patients with allergic conditions 3
Pregnant women 3
Skin disorders 2
Those on anti-depressants 2





Patients on azathioprine 
Patients on lithium
Patients with gastro-intestinal disorders 
Residential / nursing home patients 
Rheumatology patients 
Temporary residents
Those taking HRT or oral contraceptives____________
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A majority of respondents (454, 57.6%) were in agreement with pharmacists including 
patients' clinical conditions within PMRs. However, dispensing doctors (48.2%) were 
less likely to favour the recording of clinical conditions than non-dispensing doctors 
(58.9%), (x^=4-47, df=l, p<0.05). The GPs' year of registration as a doctor also 
influenced opinions on whether clinical conditions should be encompassed within 
PMRs (x2=8.51, df=3, p<0.05), with more-recently registered GPs favouring the 
inclusion of clinical conditions. This is illustrated in Figure 9.3.
Figure 9.3: The effect of GPs' year of registration on agreement with the inclusion of 









Three GPs expressed specific concerns about the recording of clinical conditions 
within PMR systems. One was concerned about breaches of confidentiality; another 
felt that conditions should be recorded within GPs' computer systems, but not within 
pharmacists' systems; the third felt that large multiple pharmacy groups would be able 
to afford better systems than independent pharmacies.
Those respondents who agreed with the inclusion of patients' clinical conditions within 
PMR systems were then asked a further question on how such clinical details should be 
incorporated. The responses to this question are shown in Table 9.7. None of the 
practice parameters from Table 9.1 influenced respondents' opinions on the recording 
of patients' clinical conditions.
68.964.762.2
1983-921962 or earlier 1963-1972 1973-82
Year of registration
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Table 9.7: GPs* opinions on how pharmacists should incorporate patients1 clinical 
conditions within PMR systems. The figures give numbers of respondents (and 
percentage of total) agreeing with each listed method.________________________
By inference, using patients' medication profiles 39 (8.8%)
Asking patients, using a confidential questionnaire form 137 (30.9%)
Through formal contact with GP and/or practice staff, with assurance 
of confidentiality
176 (39.6%)
A combination of any of the above 84 (16.9%)
Some other method 8 (1.8%)
Total: 444 (100%)
Of the 454 respondents who agreed with pharmacists' including clinical conditions 
within PMRs, 10 did not indicate how they considered this should be achieved. Eight 
GPs stated that some other method of including clinical conditions was preferable; of 
these, four respondents (all from Devon) stated that the use of smart cards (Section 
1.5.1) was the most appropriate method. One further respondent stated that computer 
systems used by pharmacists and GPs should be linked (Section 1.5.2). A suggestion 
was made, by one GP, that prescriptions should indicate the condition for which a 
product was prescribed, especially for chronic conditions.
Table 9.8: GPs opinions on whether pharmacists should provide HILLS type patient 
information leaflets
In favour of Not in favour Statistics
leaflets of leaflets
All GPs: 623 (79.9%) 157 (20.1%)
GPs in Avon 304 (83.5%) 60 (16.5%) *2=5.3, df=1, p<0.05
GPs in Devon 316 (76.9%) 95 (23.1%)
GPs registering before 1963 67 (72.8%) 25 (27.2%)
GPs registering between 1963-72 167 (76.6%) 51 (23.4%) *2=18.4, df=3, p<0.001
GPs registering between 1973-82 267 (78.8%) 72(21.2%)
GPs registering between 1983-92 120 (93.0%) 9 (7.0%)
252
GPs were presented with a Hadley Hutt PILLS leaflet on penicillins and asked to state 
whether they considered that pharmacists should provide such information leaflets to 
patients. Furthermore, the questionnaire solicited respondents' opinions on their 
perceptions as to the effect of such leaflets on patient compliance. GPs' opinions on 
the provision of leaflets are shown in Table 9.8. The question about whether 
pharmacists' use of patient information leaflets would influence compliance was 
answered by 770 respondents, of whom, 373 (48.4%) believed that the use of leaflets 
would improve compliance, 33 (4.3%) stated that the use of leaflets would have no 
effect on compliance, 118 (15.3%) believed that pharmacists' use of leaflets would 
worsen compliance, 246 (31.9%) were unsure of the effects of leaflets. Additional 
comments by certain GPs were largely critical; these are discussed in Section 9.4.8.
The next series of questions in the questionnaire concerned the recording of non­
prescribed medication within PMRs. 229 (29.1% of those responding) felt that 
pharmacists should record the sale of all non-prescription medicines. A further 116 
(14.7% of those responding) felt that pharmacists should record the sale of those 
medicines recently transferred from prescription-only to pharmacy-sales status, for 
example hydrocortisone 1% cream and clotrimazole pessaries. Relatively few GPs 
(119, 15.2% of those responding) felt that pharmacists should keep records of the 
supply of non-prescription medicines for all patients. This figure rose to 308 (39.2% 
of those responding) in agreement with record keeping for certain patient groups only; 
this particular figure was influenced by the GP's year of registration. Those registering 
in 1973 or later were more likely to favour (43.6%) a selective form of record 
retention for non-prescribed medicines than those doctors qualifying in 1972 or earlier 
(32.6%), (x^=13.1, df=3, p<001). Finally, 206 (26.2% of those responding) stated 
that the recording of the supply of non-prescription medicines should not be a role for 
the community pharmacist.
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GPs' responses to how often they welcomed information from community pharmacists 
about potential drug interactions is shown in Figure 9.4.
Figure 9





0% 20% 40% 60% 80% 100%
□  Always ■  Often ■  Som etim es □  Rarely □  Never
The only parameter which appeared to have any influence on GPs' attitudes to 
pharmacists providing them with warnings about potential drug interactions was the 
year of registration. This is discussed in Section 9.4.7.
GPs were then asked to state those reference sources that they would normally use if 
they suspected a potential drug interaction. Their responses are shown in Table 9.9.
Of the 23 respondents who stated that they use reference sources other than those 
listed in the questionnaire, four cited Beeley's pamphlets Safer Prescribing^ ^ 6 four 
cited Martindale (Section 8.1.3.2)^^, and two cited drug companies. One cited 
Professor Inman in Southampton, one a clinical pharmacologist, one a local hospital 
consultant, and another his practice colleagues.
.4: How often GPs welcome information about potential 
drug interactions from pharmacists.
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Table 9.9: GPs' normal reference sources when dealing with a potential drug 
interaction. _________________________
No. using source 
(% of total respondents)
BNF81 743 (92.2%)
ABPI Data Sheet Compendium169 417 (51.7%)
Their practice computer system 235 (29.2%)
Hospital pharmacy / district drug information centre 198 (24.6%)
MIMS138 191 (23.7%)
Local community pharmacist 135(16.7%)
Regional drug information centre 79 (9.8%)
Drug Interactions69__________________________________________________52 (6.5%)
Some interesting findings were obtained by performing cross-tabulations between the 
reference sources in Table 9.9 and the practice parameters in Table 9.1, followed by a 
test of in d ep en d en ce.6 6 *6^ stockley's book69 was used by 8.3% of the 
respondents from Devon compared with 4.5% from Avon, (x^=4.8, df=l, p<0.05). 
38.3% of fimd-holders used their practice computer system for monitoring for 
potential drug interactions compared with 26.5% of the non-fund-holders, (x^=9.8, 
df=l, p<0.01).
A number of trends were observed with GPs' year of registration. These are shown in 
Table 9.10. Differences between dispensing and non-dispensing doctors are shown in 
Table 9.11.
255
Table 9.10: The influence of GP's year of registration on their use of sources of 
information when dealing with potential drug interactions. (Percentage using stated 
source shown)____________________________________________________________
Year of registration
1962 or 1963-72 1973-82 1983-92 Statistics
earlier df=3
MIMS138 34.4 34.4 19.1 10.4 X2=37.1,
p<0.0001
ABPI Data Sheet Compendium 57.3 63.8 49.1 34.3 X2=31.4,
p<0.0001
BNF 87.5 89.7 92.9 97.8 72=10.8,
p<0.05
Local community pharmacist 26.0 17.9 13.7 16.4 X2=8.4,
p<0.05
Table 9.11: Differences between dispensing and non-dispensing doctors on the use of 
sources of information when dealing with potential drug interactions. (Percentage 





ABPI Data Sheet Compendium 63.7 49.8 X2=7.5,
p<0.01




Their practice computer system 37.2 27.9 X2=4.1,
p<0.05
Local community pharmacist 9.7 18.0 X2=4.7,
p<0.05
In reply to a specific question the BNF was regarded as the standard reference source 
by 759 GPs (95.8% of those responding). Of the 33 respondents who did not agree 
that the BNF should be taken as the standard reference source on drug interactions, 15 
stated that the ABPI Data Sheet Compendium should be standard, three each stated
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regional and district hospital drug information, two stated Stockley's book^  (one with 
the condition that it should be updated quarterly), and two stated the need for regular 
drug information updates in suitable electronic form.
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9.4 Discussion
The response to the questionnaire used in this survey was slightly lower than the 
surveys described in Chapters 2, 3 and 4, which were conducted with community 
pharmacists. However, the response of 64.5% was not dissimilar to a survey 
ascertaining GPs' attitudes to an extended role for community pharmacists, which 
attained a response of 68.4%. *82
9.4.1 General Practitioners' Computer Use
In this survey, 94.1% of the respondents stated that they worked in a computerised 
practice. This figure is higher than two surveys published in 1991. Goves et al 
estimated that 67% of all patients in Wales were served by a computerised practice. * 3 1 
Rogers and Fletcher showed by means of a survey of GPs practising in Bath and 
Bristol, that 84% worked in a computerised practice.*^ The new NHS contract for 
GPs allows them to receive bonus payments for achieving targets in patient monitoring 
(for example blood pressure) and immunisation. Greater use of computer systems to 
store patient data is likely to assist GPs to achieve such targets.
Use of the various features available in general practice computer systems has 
increased since 1991, although it appears that these systems are still not being used to 
their full potential (Table 9.2) The recording of patients' clinical details has not altered 
significantly over the last two years: 73.8% of respondents in this survey used their 
system to view patients' clinical records, compared with 76%* 31 and 65% *32 ‘m the 
earlier studies. The number of practices possessing a modem has increased 
considerably. In 1991, only 9.1% of those practices sampled by Goves et al had a 
modem* 3*; in the present study 44.4% of the sample of GPs worked in a practice that 
had a modem.
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There was low usage of computer systems to monitor routinely for potential drug 
interactions between prescribed medicines: 20% in our 1991 s u r v e y !  ^2 and 49.5% in 
this survey. Only 29.2% of the respondents stated that th y would use their computer 
system to check a suspected drug interaction (Table 9.9) The reasons for this low 
reported use are not clear, although some GPs expressed irritation with information 
provided by their computer systems. One GP complained that interaction information 
provided by his system was not sufficiently drug-specific, a problem that has been 
discussed in Section 8.1.4. Another GP was irritated by repetitive warnings being 
issued by his system.
A further reason for the apparent low use by GPs of their drug interaction monitoring 
software is possibly that the use of computerised systems for drug interaction 
monitoring is viewed as a "dispensing" function. Support for this may be offered by 
the fact that dispensing doctors were more likely to use their computer system in 
monitoring for potential drug interactions than non-dispensing doctors.
9.4.2 Fund-Holding GPs
It is noteworthy that fund-holding GPs were shown to be more likely than non-fund- 
holding GPs to possess and make greater use of their computer systems, through 
monitoring for potential drug interactions, viewing clinical data on patients and use of 
a modem.
9.4.3 Retention of Patient Data
GPs traditionally have maintained patients' medical records, and so it is not surprising 
that a large majority of the respondents stated that prescribers should keep patients' 
medication records (Table 9.3). The figure of 91.6% takes into account a small 
number of GPs who felt that only they, and not dentists (who are also prescribers) 
should keep patients' medication records. The high number of respondents (73.7%)
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expressing the opinion that patients should have responsibility for retaining their own 
records included one who pointed out that many patients effectively retain a 
medication record by means of a repeat prescription card. However, relying on this 
alone will not usually permit the recording of "one-off* prescription items, for example 
short courses of antibiotics for acute infections, nor non-prescription medicines. One 
respondent from a Devon coastal resort commented that "patients should be 
encouraged to record prescribed and OTC products on hand-held records." This 
respondent emphasised the benefit of this method for holidaymakers. This group of 
patients are likely to present at pharmacies, requesting emergency supplies of 
prescription-only medicines; present at GPs* surgeries in need of primary medical care; 
and also present in hospital as a casualty patient or an emergency admission. In all of 
these circumstances, some form of patient-held medication record would be useful for 
a rapid assessment of the patient's medication profile.
A majority (59.1%) of respondents felt that pharmacists should keep PMRs. A similar 
percentage of respondents (57.4%) stated that community pharmacists should have 
selective access to FHSA-held records. However, it is of concern that over 40% of 
respondents appeared not to recognise a role for community pharmacists in 
maintaining medication records or having access to patients' medication details. 
Reasons for this may include an incomplete knowledge of the pharmacist's education 
and training, a lack of appreciation of what the community pharmacist actually does, 
and fear of community pharmacists extending their role. Comments from the returned 
questionnaires that may support this limited appreciation were:
i) "Pharmacists require a very much increased clinical knowledge."
ii) "As far as I am concerned, the role of the pharmacist is in dispensing only, 
which includes checking for drug interactions and warning of side effects. I
260
worry about attempts to extend the pharmacist's role into other areas as they 
are not trained in diagnosis."
Another possibility is that GPs are not convinced of the benefits to patients of 
pharmacy-held PMRs. This view is perhaps valid since there has been little published 
work in the UK to demonstrate the benefits of PMRs to patients and the NHS. In 
particular, there have been no published reports extending work to include patient 
outcome. One GP stated "any system must demonstrate definite benefits and not 
generate extra paperwork." Four GPs commented that pharmacy PMRs would create 
"unnecessary duplication" of data. Such views are likely to persist until such a time 
when the value to patients of community pharmacists' clinical interventions have been 
more widely demonstrated.
Some of the general comments on pharmacists' use of PMRs were positive. One GP 
stated that pharmacists should have access, via computer-link, to all patient records. 
Two further respondents commented that pharmacist-maintained PMRs could be used 
to facilitate a system of repeat dispensing by community pharmacists, whereby patients 
could have medication dispensed monthly by the pharmacist, returning to the GP every 
six months for clinical review.
Concerns about data security and the confidentiality of patient records were expressed 
by GPs in response to several of the survey's questions. The main reason put forward 
for not having FHSAs store patient data was a potential lack of security. The 
following comment from one GP was typical:
"I am very worried about patient confidentiality in general - and particularly in 
connection with HIV/AIDS - what are the statutory requirements of pharmacists in this 
respect - 1 do not know."
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9.4.4 Family Health Services Authorities
The greatest number of GPs in Avon were working in suburban practices (Table 9.1), 
whereas the greatest number of Devon GPs were working in practices located in small 
towns. A higher number of GPs in Devon were working in rural practices than their 
colleagues in Avon. The majority of those practices that were classified as rural, were 
also dispensing practices in both FHSAs. Despite these differences in the profiles of 
GPs practising in Avon and Devon, only three differences were found between these 
two samples of GPs. Given the relatively weak statistical inferences in each case 
(0.01<p<0.05), these findings may be valid or could be statistical artefacts. Firstly, 
GPs in Avon were less likely to favour pharmacists keeping records for HIV 
positive/AIDS patients. This may be due to GPs' greater awareness of the possible 
incidence of HIV infection among drug abusers in the Bristol area. Secondly, GPs in 
Devon were less in favour than their colleagues from Avon of pharmacists issuing 
computer-generated patient information leaflets (Table 9.8). This may be accounted 
for at least partly by the considerable opposition of a number of GPs in Plymouth to 
the use of PILLS leaflets by a small multiple pharmacy group (Personal 
communication). Thirdly, a greater number of Devon GPs stated that they would refer 
to Stockley’s text on drug interactions^ than would their colleagues from Avon. 
There are two possible reasons for this. First the trial of smart cards in Exmouth in 
Devon^l may have raised awareness of potential drug interactions in those GPs in that 
area. Second, the company Exeter Data Base Systems, who produce Interfax (Section 
8.1.6.2) is situated in Devon. Again, the local nature of a company gathering drug 
interaction data and producing systems for GPs may raise the awareness of interactions 
amongst GPs from Devon. A greater awareness of the existence of potential drug 
interactions may increase demand for a reference book on the subject.
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Little support was shown for the concept of FHSAs maintaining patient records. 
Fewer than 5% of the respondents stated that FHSAs should keep patient medication 
records (Table 9.3). A possible reason for GPs not wanting FHSAs to store patient 
records is a fear of administrative bureaucracies holding confidential information. Four 
respondents stated explicitly that FHSAs should not hold patient data under any 
circumstances because of potential problems with a lack of security whereby patient 
confidentiality could not be guaranteed.
9.4.5 Retention of Records and Recording of Patients' Clinical Details 
for Selected Medical Conditions
Pharmacists at present can claim payment for maintaining PMRs for the elderly and 
confused. Table 9.5 shows the level of support amongst GPs for pharmacists 
maintaining records for these and other patient groups. High levels of support were 
shown for maintaining records for those patients who have experienced drug allergies 
and major adverse reactions, as well as for diabetics, asthmatics and epileptics. Lower 
levels of support were shown for two other important groups of patients: those with 
cardiac disorders and/or hypertension, or those with a history of peptic ulceration. 
There are important implications for the safe and appropriate use of non-prescription 
medicines in each of these conditions. Pharmacy medicines containing 
sympathomimetic agents such as phenylpropanolamine are significantly cardio-active, 
and should be used with caution in hypertensive patients. The risks of adverse drug 
reaction in patients suffering from cardiovascular disorders have been described in 
Section 7.4.4. Aspirin and ibuprofen, both widely-used analgesics, are contraindicated 
in patients with active peptic ulcer disease, and must be used with caution in those 
patients with a history of peptic ulcer. 185
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In the last decade, GPs have become used to working in larger practices with other 
health professionals who assist in providing patient care, for example specialist 
diabetes and asthma nurses. GPs will have become used to sharing certain patient 
information with nursing staffs and so may differentiate between the above patient 
groups in making a judgement as to for whom pharmacists should keep PMRs.
Two GPs raised the problem of patients' perception of their condition being at variance 
to their medical records. McElnay and Grainger-Rousseau have shown that total 
agreement between these two factors as being only 56.1%. 1^7 However, McElnay 
and Grainger-Rousseau point out that if a particular condition is omitted from an 
extended PMR, and a medication contraindicated for that patient is dispensed, then 
liability for breach of contract could be claimed by the patient. Clearly, this issue, also 
raised by one respondent during the survey of GPs, requires both legal and ethical 
debate.
9.4.6 Dispensing Doctors
A number of differences were found between dispensing and non-dispensing doctors. 
In general, dispensing doctors were less appreciative of the community pharmacists' 
role than their non-dispensing colleagues. Possible reasons for this are that they see 
the pharmacist as a perceived pseudo-commercial threat or merely that they have less 
regular professional contact with pharmacists resulting from pharmacists routinely 
dispensing prescriptions for their patients and are therefore less well-informed about 
the pharmacist's scientific and professional knowledge. The majority of non-dispensing 
doctors were in favour of pharmacists keeping PMRs, compared with a minority of 
dispensing doctors. Similarly, when presented with the hypothetical situation where 
primary health care professionals could have selective access to patient records, 
appropriate to their role, the majority of dispensing doctors were not in favour of 
community pharmacists having access, in contrast to a minority of non-dispensing
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doctors. Curiously, dispensing doctors also were less likely to favour access to patient 
records by ophthalmic opticians. This is possibly another example of dispensing 
doctors being concerned about a perceived commercial threat from other professional 
groups.
Differences were also found between the groups of dispensing and non-dispensing 
doctors in their opinions towards pharmacists recording details of patients' clinical 
conditions in PMRs; again the majority of dispensing doctors were not in favour, 
whereas the majority of non-dispensing doctors were in favour of the recording of 
clinical conditions.
Given the above lack of support or recognition from dispensing doctors for the 
community pharmacist, it is not surprising that dispensing doctors were very unlikely 
to seek the community pharmacist's opinion on potential drug interactions (Table
9.11). However, dispensing doctors were shown to be more likely than non-dispensing 
doctors to consult the ABPI Data Sheet C o m p e n d i u m ^  and to use District drug 
information centres for information about potential drug interactions.
9.4.7 The Influence of GP's Year of Registration
GPs who registered before 1962 were less likely than their more-recently registered 
colleagues to work in a computerised practice. This corresponds with our earlier 
finding for community pharmacists' use of PMRs, showing lower use among those 
pharmacists registering before 1961 (Figure 2.2).
Several encouraging trends were detected showing increased support among recently 
registered doctors for the community pharmacist's extended role in maintaining PMRs 
(Figure 9.1). Also, although the majority of GPs favoured the concept of selective 
access by community pharmacists to FHSA-held patient records, significantly fewer
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GPs registering in 1962 or earlier supported this concept than their more-recently 
registered colleagues (Figure 9.2). Support for community pharmacists recording 
patients' clinical conditions was highest among more-recently qualified GPs (Figure 
9.3), who also were more likely to favour pharmacists including the supply of non­
prescribed medicines in PMRs. Community pharmacists' use of PILLS type patient 
information leaflets was well supported, especially by those GPs registering since 1983 
of whom 93.0% were in favour (Table 9.8).
However in contrast to the above, recently registered GPs were less likely than their 
more experienced colleagues to "always" welcome information from community 
pharmacists about potential drug interactions (Figure 9.4). This finding is reinforced 
by the finding that few recently registered GPs cited the local community pharmacist as 
a source of information on drug interactions (Table 9.10).
Other observations on the influence of the GP's year of registration on the use of 
information sources about drug interactions were that more-recently registered GPs 
tended to show a greater preference for the BNF, and a lesser preference for 
MIMSES and the ABPI Data Sheet C o m p e n d i u m ^ ;  this would seem to reflect 
wider use of the new style BNF since its introduction in 1981. Recently-registered GPs 
will also have become used to the BNF as an important, concise reference during their 
hospital experience.
9.4.8 Patient Information Leaflets
Almost 80% of all respondents were in favour of pharmacists issuing PILLS-type 
patient information leaflets to patients (Table 9.8), with increased support shown 
among younger GPs. Respondents were generally positive about the effects of such 
leaflets on patient compliance. Despite the overall level of approval for patient 
information leaflets, many GPs expressed adverse opinions towards their use. One felt
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that existing leaflets needed to be tailored to an individual patient's needs. Another 
expressed concern that inadequately educated patients could not cope with such 
leaflets. The use of "American Data" was disapproved of by one GP.
Three respondents suggested that leaflets should only be given to patients with GPs' 
approval. One further GP made the suggestion that prescribers could indicate on 
prescription forms whether leaflets should be issued to patients. Developing this GP's 
suggestion, FP10 forms could be modified to include an "NL" (no leaflet) box, in the 
same way that an "NP" (nomen proprium) box already exists. In this way, prescribers 
could indicate that they did not want patients to be given specific information leaflets 
with dispensed medicines.
Another GP stated that the best way of providing product information to patients was 
by means of a leaflet attached to computer-generated FP10 prescription forms. This 
system would need to overcome the problems associated with the use of hand-written 
prescriptions. Finally one respondent expressed support for patient regimen charts 
following the recent publication of Raynor's work in the B M J}^  Patient regimen 
charts have also been successfully piloted in Spain by Codina et a l * 88
9.4.9 Drug Interaction Reference Sources
Our findings show that the BNF is widely accepted as a reference source on drug 
interactions, and was regarded as the standard reference source by virtually all 
respondents. Two respondents commented that the drug interaction information 
provided in the BNF needed to be more comprehensive. Another respondent 
expressed the need to have BNF-sourced drug interaction information regularly 
updated and provided on computer disk. This could then be incorporated into general 
practice computer systems.
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Over 50% of respondents stated that they would use the ABPI Data Sheet 
C o m p e n d i u m ^  t0 check a suspected drug interaction. However 15 respondents, 
albeit a very small percentage, stated that the ABPI Data Sheet C o m p e n d i u m * ^  
should be regarded as the standard reference source for drug interactions. The ABPI 
Data Sheet Com pendium **^ does not, of course, include generic products as such.
It is interesting that over twice as many GPs in Avon and Devon would consult local 
hospital pharmacy drug information units in preference to their regional drug 
information centre in Bristol. This is especially the case for dispensing doctors (Table
9.11). It is possible, of course, that local drug information centres are acting as an 
intermediary between the GP and the regional drug information centre in Bristol.
9.4.10 General Practitioners' Views on Community Pharmacists' Role 
Within Primary Health Care
This survey raised the question in GPs' minds of the role of the community pharmacist 
in primary health care, with particular reference to the clinical role of monitoring the 
safe and appropriate use of prescribed medication. The issue was well described by 
one GP who refused to respond to our questionnaire, but for a positive reason. He 
wrote:
"I did not return the original questionnaire because I believe it addresses the wrong 
question. Community Pharmacists should be full members of the Primary Health Care 
team and drawn into Health Centres; firstly to obtain ease of access for patients to 
pharmaceutical services, secondly to ensure the safety that regular dispensary services 
from the same site would achieve and thirdly to make the expertise of the pharmacist 
immediately available to the Primary Health Care team and ensure good 
communication with the prescribing doctor. Patient medication records cannot achieve 
the required degree of safety and in my view represent papering over the cracks of
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what is fast becoming an inadequate service based on out of date commercial pressures 
in the pharmaceutical profession."
Other GPs expressed a desire to have community pharmacies within or attached to 
their premises, providing better access to pharmaceutical services for their patients and 
the availability of the pharmacist to provide advice.
One general practitioner expressed appreciation over the usefulness of his local 
community pharmacist's service in monitoring for potential drug interactions, and went 
on to express some concern that pharmacists were not well funded for this important 
role. Another respondent expressed concern that pharmacists should receive proper 
remuneration for maintaining patient records.
Some concerns were expressed about the community pharmacist expanding his clinical 
role. One GP stated that he realised that his own workload would be increased by the 
pharmacist having a greater involvement in clinical review, and a further respondent 
commented that, although appreciative of the good working relationship with local 
pharmacies, he did not wish to get "bogged down in enquiries about clinical data on 
patients all the time." The implication of this respondent's comment is that the GP will 
need to spend time with the community pharmacist in discussing specific patients' 
problems. Some method of facilitating the means by which community pharmacists 
and GPs can be freed to have time to discuss patients' medication must surely be 
found, possibly by means of liaison groups as described by Blenkinsopp et a l 184
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Two further comments were less encouraging:
i) "I do not wish the community pharmacist's role to extend into clinical medicine. 
They should stick strictly to dispensing and not diagnosis, monitoring, 
counselling as this infringes the GP/patient relationship.”
ii) "I would not like to see the pharmacist's role intrude upon treatment and 
management of patients with hypertension and asthma etc.”
These comments express GPs' concerns about the perceived threat of the community 
pharmacist's role being expanded at the GP's expense, in terms of reducing the 
importance of the GP/patient relationship.
The commercial nature of the environment in which the community pharmacist 
practices was of concern to one GP, who stated that both he and his patients were 
confused by the potential conflict of interest between the sale of non-prescription 
medicines and the provision of impartial advice as per the BNF.
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9.5 Conclusions
1. The results of this survey show that the percentage of GPs using computer 
systems has continued to rise since 1991. GPs' use of computerised drug 
interaction monitoring software has increased since 1991, although it still 
remains low.
2. Despite a majority of GPs being in favour of community pharmacists 
maintaining PMRs, some GPs remain that unconvinced patients benefiting from 
pharmacy PMR use. High levels of support were indicated for pharmacists 
maintaining PMRs for the elderly and confused, and also for those patients 
experiencing major adverse drug reactions or allergies, diabetics, asthmatics 
and epileptics.
3. Support by GPs for retention of patients' data by FHSAs was very low.
4. Dispensing doctors were less supportive of the community pharmacist's role in 
maintaining PMRs than their non-dispensing colleagues.
5. A large majority of GPs expressed positive opinion towards the use of patient 
information leaflets of the PILLS-type by community pharmacists. Most 
respondents felt that the use of such leaflets had a positive effect on patient 
compliance.
6. The British National Formulary was GPs' most widely-used reference source on 
potential drug interactions. An overwhelming majority of GPs felt that the 
BNF should be accepted as the "standard” reference source on potential drug 
interactions.
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7. GPs hold mixed views on the community pharmacist's clinical role. Further 
work is required to develop and evaluate systems which facilitate the 




10.1 The Increasing Use of PMR Systems
In April 1991, 61.5% of our sample of 744 community pharmacies were maintaining 
PMRs (Table 2.12). This comprised of 55.4% who were using a computer system and 
6.1% who were using a manual system. A further 25.1% were either planning to 
install, or would possibly install a PMR system. One would expect, therefore that the 
use of PMR systems will have become more widespread in the last two years. Indeed, 
evidence has been published to support this prediction. In a survey of 293 pharmacies 
during November 1991, Jepson showed that 77.5% of his sample were maintaining 
PM Rs. 189 o f  these, 85% were maintaining computerised PM R  systems. Returns 
from the Royal Pharmaceutical Society's Inspectorate in 1992, showed that 73% of all 
pharmacies surveyed were using computerised PMR systems. 190
The results of the study described in Chapter 2 provide data on the use of PMR 
systems in England and Wales, but not in Scotland or Northern Ireland. However, one 
would not expect major differences in PMR use between England, Wales, Scotland and 
Northern Ireland. In a survey commenced during December 1990, Noble and 
MacDonald found that 57.5% of all pharmacy contractors in the Lothian and the 
Dumphries and Galloway health board areas were claiming payments for the use of 
PMR systems. 191 it is, of course, possible that the true number of pharmacies 
maintaining PMR systems was even higher, since some pharmacies could have been 
maintaining PMR records without claiming a fee for doing so. In their paper, Noble 
and MacDonald commented that the number of contractors claiming payment for PMR 
use was rising steadily as more contractors invested in computerised PMR systems.
From the results of our April 1991 survey (Table 2.12), and from Jepson's November 
1991 survey 189? together with the RPSGB Inspectorate's data 190, 0ne can postulate 
that the percentage of pharmacies in England and Wales using PMRs at the time of
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writing (September 1993) will be about 80-85%. While not universal in their use, the 
maintenance of PMRs can now be considered a normal part of the community 
pharmacist's professional practice.
10.2 Developments in Pharmacy Computer Use Since April 1991
There have been no radical changes in the availability of PMR systems in the UK over 
the last two years. During that time, the Littlefoot system has been marketed by 
Surgichem Ltd. for use with their Nomad monitored dosage system. The Littlefoot 
system is different from conventional PMR systems in that it maintains patient records 
on a portable rather than on a desktop computer. The portability of this system means 
that the pharmacist is able to take the system on domiciliary visits to patients' homes 
and residential care establishments, though the benefits of this have yet to be 
established.
The main development in pharmacy computer use over the last two years has been the 
incorporation of automated prescription endorsement facilities into PMR systems. 192- 
195 Automated prescription endorsement facilities have been incorporated primarily 
for commercial, as opposed to professional, reasons although one could argue that 
community pharmacists are better-placed to provide a professional service if they are 
able to maximise their remuneration for the service provided.
10.3 "Benchmark" Testing of Pharmacy Computer Systems
The RPSGB recently invited tenders for the evaluation of pharmacy computer 
systems. 196 jt is quite possible that suppliers of pharmacy computer systems will 
await the outcome of the benchmark testing project before embarking upon the 
development of new features or improvements to their systems. At the time of writing 
(September 1993), one can only speculate as to the results of the benchmark testing 
project. Although, as yet, there is no accepted "minimum" standard or specification
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for pharmacy computer systems, it is possible that one will be proposed as a result of 
the project. If that happens, some existing companies may cease to market PMR 
computer systems. Should a supplier of pharmacy software cease trading, pharmacies 
using that supplier's system will have difficulty in maintaining up-to-date drug product 
and interaction data files. Such a situation could present major difficulties for some 
pharmacists, given that one cannot easily transfer patient data between systems.
10.4 The Use of Computerised Information in the NHS
Weddell has stated that, for two reasons, "The National Heath Service is renowned for 
its underuse of computerized data. "*97 First, that clinicians and administrators may 
feel threatened as a result of computerisation, and second, that data held within NHS 
computers have been considered to be inaccurate. These views are supported by those 
of Leaning, who noted that information technology in the NHS had been perceived as 
a management tool of little clinical relevance, and that there had been professional 
concern that inappropriate computerisation may harm patient care. *98 However in his 
BMJ editorial, Leaning went on to describe a new information management and 
technology strategy for the NHS in England. The strategy's goal was to promote 
"better health for the nation" and had five principles: that information should be person 
based; systems should be integrated; management information should be derived from 
operational clinical systems; data should be secure and confidential; and data should be 
shared across the NHS. Similarly, in the USA, arguments are being made for the 
development of an integrated database, with shared information being available to the 
various user groups within the health care delivery system. *99
In November 1991, the Department of Health announced that it was to commission a 
project to draw up a pharmacy computer standard.44 Management consultants were 
asked to draw up guidelines for computer system designers and programmers that 
would ensure that data could be passed between computers. The implication of this
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was that methods of encoding patient data would be developed to facilitate the transfer 
of patient data between pharmacy and general medical practice computer systems. An 
advantage of this for both community pharmacists and general practitioners would be 
that they would not be obliged to use any particular software supplier. Should any 
particular supplier cease trading, then users of that supplier's system should be able to 
transfer their patients' data to another system without losing the integrity of the data. 
Furthermore, if pharmacists and general practitioners were not tied to any particular 
system, greater competition would ensue between system suppliers, possibly giving an 
impetus to software development.
The purpose of drawing up a pharmacy computer standard would be to develop and 
lay down compatible data formats. The basis of such formats are "minimum basic data 
sets", which are collections of core elements of information, that can be understood by 
different computers. For example, a Read code could be used to identify a disease 
state, a PIP code (Pharmaceutical Interface Product code) to identify a particular 
product, and a personal NHS number to identify an individual patient. It is planned to 
introduce a new-format all-digit NHS number by 1995.198 Elsewhere in Europe, the 
development of a minimum basic data set for use in Spanish general practice has been 
described by Gervas and Femandez.^OO
At the time of writing (September 1993), there has been little progress towards 
achieving minimum basic data sets in pharmacy, although the pharmacy computer 
benchmark p r o j e c t  196 should lead to some advancement.
Two possible methods of transferring a patient's data between one provider of health 
care and another are by electronic data exchange or by smart card (Section 1.4). It still 
is unclear which one of these methods will prove to be the method by which a patient's 
data will be transferred. The Exmouth smart card trial failed to demonstrate any
276
conclusive advantages in patient care.41 Despite this, a further trial of smart cards is 
taking place in Scotland 42
Electronic data exchange between general medical practices and community 
pharmacies has not yet been piloted in the UK, and so remains to be evaluated. 
However, a system of electronic data exchange has been piloted in Copenhagen, 
D enm ark .201 In that project, general practice and pharmacy computers were linked to 
a network via the public telephone system using standard computer modems. 
Prescription information was transmitted by the GP to the electronic mailbox of the 
retrieving pharmacy, whose computer regularly emptied the mailbox and sent a receipt 
to the GP's mailbox. Such a system could work in the UK, although the Medicines Act 
1968 would need to be amended in order for prescription-only medicines to be 
dispensed without a paper-based prescription form. If electronic data exchange 
enabled transfer of prescriptions in the UK, community pharmacists would still need to 
keep their own medication records for previously-dispensed medicines, unless some 
form of patient medication history could be encoded with the transmitted prescription; 
however, the latter procedure would seem impractical.
Electronic data exchange in UK primary health care does appear to have a promising 
future. The Scottish Pharmaceutical General Council has recently announced that the 
prescription pricing division of the Scottish Common Services Agency has proposed 
that the current method of sending paper prescriptions to the Prescription Pricing 
Authority for payment should be replaced by electronic data capture and 
transmission.200 The proposed system would become operational in 1995 and fully 
introduced at the end of 1998.
The leaders of the pharmaceutical profession together with individual pharmacists, 
both in community and hospital practice, must ensure that they make a full contribution 
to the development of new health care computer systems. Dasta et al have made such
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a case in a recent review article: "It is important that pharmacists become active 
participants in the development of systems that involve drug databases or drug therapy. 
As such, computers can run in harmony with pharmacists to provide optimal 
pharmaceutical care. "203
10.5 The Role of Family Health Service Authorities
FHSAs are gaining in importance in terms of influence over prescribing and the use of 
medicines in primary health care. Many FHSAs have appointed both medical and 
pharmaceutical advisers, one of their functions being to bring about more cost- 
effective prescribing. FHSAs are to be given the role of purchasers of pharmacy 
services in 1 9 9 5 - 9 6  when local budgets are i n t r o d u c e d . 2 0 4  n  j s  likely that FHSAs will 
have an increasing role in monitoring the "extended role" activities of community 
pharmacists, including the maintenance of PMRs. Hume et al have published two 
papers describing two Scottish health boards' monitoring of patient medication 
records, and the maintenance of a computerised database for monitoring community 
pharmacists' extended role contracts. 1 9 1 , 2 0 5
One could envisage a role for FHSAs in the context of storing patients' medical data, 
which could be accessed by both primary and secondary health care professionals, in a 
manner appropriate to their roles. Such a system would involve some form of 
electronic data exchange (Sections 1 . 4 . 2 ,  1 0 . 4 ) .  However, the survey of GPs, 
described in Chapter 9 ,  showed very little support among medical practitioners for 
FHSAs holding patients' medical data (Conclusion 9 . 5 . 3 ) .
10.6 Community Pharmacists' Access to Patient Information
The study presented in Chapter 7 has shown the important benefits of community 
pharmacists monitoring patients' therapy and intervening when appropriate. PMRs 
have been shown to be of particular benefit when monitoring for potential drug
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interactions between previously-dispensed and newly-prescribed medication, and also 
to prevent medication from being dispensed to patients for whom it is contraindicated. 
A community pharmacist must have available, at the time of supplying a product, 
sufficient information as to whether that product is safe for a patient to use. In the 
author's opinion, "sufficient" information should include a knowledge of the patient's 
medication history and any clinical condition for which a medicinal product may be 
contraindicated.
There are three currently-feasible ways in which the community pharmacist can elicit 
the information described above. First, he can ask the patient; this is far from ideal 
since the patient may neither give the correct information nor be the person presenting 
in the pharmacy. The second method is to enquire of the patient's general medical 
practice staff; this would be impractical for all medication supplies for the reason that it 
would be too time-consuming. In any case, the general practice surgery would be 
most unlikely to have details of medication prescribed by dentists, or that obtained 
without prescription. The third method is by the use of pharmacy-held PMRs, as 
described in Chapter 2. Pharmacy-held PMRs provide the potential saving of excess 
patient morbidity as a result of their use (Chapter 7), but they currently are imperfect. 
There are two primary reasons for this imperfection: many users do not record patients' 
clinical conditions, and records may be incomplete if patients do not obtain all their 
medication from the same pharmacy.
The author sees three potential ways to overcome the problem of incomplete 
information being stored within pharmacy-held PMRs.
First: the universal use of smart cards in the UK would mean that a patient could carry 
his medical record on a credit-card size smart card. However, the problems of high 
cost, card-failure and patients not bringing their cards to the surgery and the pharmacy 
have been described in Section 1.4.1. The author does not consider universal use of
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smart cards in primary health care as the solution to the problem of the community 
pharmacist having comprehensive information about a patient and his medication 
history.
Registration of patients with a particular pharmacy is the second potential way to 
overcome the present problem of the pharmacist not having complete information at 
his disposal. A capitation fee, perhaps for clearly-defined patient groups, should be 
paid to the community pharmacist for maintaining a patient medication record. Patient 
registration with a community pharmacy probably would not be difficult to organise 
and administer, given computerisation and experience of FHSAs in maintaining patient 
registers; therefore such a system could work. However, the current economic and 
political climate probably would mitigate against patient registration with a community 
pharmacy. It could be argued that, in the age of the "free-market" and "consumer- 
choice", patient-registration may encourage restrictive-practice and discourage 
competition between pharmacies for a patient’s custom. In practice, on grounds of 
convenience, some patients probably would not want to purchase non-prescription 
medicines always from the same pharmacy at which they obtain their prescribed 
medication.
The third, and the author's preferred, method of ensuring that community pharmacists 
have access to comprehensive patient information would involve electronic data 
exchange (Sections 1.4.2 & 10.4). Although it would not yet be feasible to have 
comprehensive electronic data exchange between providers of health care (Figure 1.1), 
continuing developments in computer t e c h n o l o g y ^ O b  might permit this method of 
transmitting a patient's information within the next few years. The problems to be 
overcome before developing a fully-functional system would include: having 
sufficiently powerful computers; ensuring adequate data security, and; limiting 
computer failure with consequent mainframe "down-time." Wherever, and on 
whatever computer, a patient's medical data would be stored, the community
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pharmacist would need access to the patient’s medication history and details of relevant 
clinical conditions. However, the pharmaceutical profession will have to convince the 
medical profession of the benefit to the patient of the community pharmacist having 
access to such data. Over 40% of the respondents in the survey of general 
practitioners (Chapter 9) did not see a role for the community pharmacist in 
maintaining PMRs (Section 9.4.3). Furthermore, only a very small minority of GPs 
supported the retention of patients’ medical data by FHSAs (Conclusion 9.5.3). This is 
a major obstacle to be overcome if networking of pharmacies and general practice 
surgeries is to become commonplace.
10.7 Recording of Patient Conditions
The recording of patient information, particularly clinical conditions, in pharmacy-held 
PMR systems has been described in Section 2.3.3 and Chapter 4. Details of patients' 
clinical conditions are required by the community pharmacist for two purposes. The 
first is to identify needs for service provision and the development of product 
inventories appropriate to clients' needs (Conclusion 4.5.3). The second is to be in a 
stronger position to prevent the supply of medication to patients for whom it would be 
contraindicated. An investigation of the first requirement, although arising from an 
audit of patients' clinical conditions recorded in a community pharmacy PMR system 
(Section 4.3), was considered beyond the scope of this thesis. The advantages of a 
community pharmacist being appraised of a patient's clinical conditions have been 
demonstrated successfully in the clinical intervention study presented in Chapter 7.
In addition to a pharmacist having access to relevant data (Section 10.6, above), one 
must consider what makes it important for the pharmacist to know about a particular 
clinical condition. Table 2.24 shows those clinical conditions that our sample of 744 
community pharmacists from the April 1991 survey (Chapter 2) recorded in their PMR 
systems, ranging from 7.2% of the respondents recording HIV infection, up to 75.9%
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of the respondents recording diabetes. In the January 1993 survey of PILLS-usqts 
(Section 4.2.1), diabetes was the clinical condition most frequently recorded by the 
respondents. In the audit of clinical conditions recorded in one particular community 
pharmacy (Section 4.3), where it was the policy to record all clinical conditions 
reported by patients, it was found that the recording of various disease states bore a 
close relationship to morbidity in the UK population as a whole. The results from the 
first (April 1991, Chapter 2) and second (January 1993, Section 4.2.1) surveys differed 
from the third (February 1993, Section 4.3) survey in that the clinical conditions 
recorded with the greatest frequencies were those in which certain medication may be 
contraindicated, for example: diabetes mellitus, asthma, epilepsy, hypertension, peptic 
ulcer. It is the author's opinion that, in the absence of fully comprehensive information 
about a patient's clinical condition, a community pharmacist should at least record in 
the PMR those conditions of the patient in which medication may be contraindicated.
10.8 The Use of Pharmacy-held Patient Record Databases
The possibility that auditing their PMRs would provide community pharmacists with a 
better knowledge of their clientele has been discussed in Section 4.3.4. 
Comprehensive pharmacy-held PMR databases also could be used as practice research 
resources. Recently, Beto et al used a "pharmacy computer prescription database", ie. 
a computerised-PMR system, to conduct a quality-of-life study of hypertensive 
patients in the USA.207 Beto et al sent a questionnaire to a non-random control 
sample of 635 patients, whose records were maintained on the pharmacy system, and 
to 100 randomly selected hypertensive patients who were taking one of three specific 
anti-hypertensive agents. Beto et al surveyed attitudes towards their research and 
found that the participating pharmacists and patients favoured, or did not object to, the 
research. However, the grant-awarding body expressed some ethical concerns when 
the sampling techniques were described in the grant proposal, although Beto et al 
stated that the APhA Code o f  E t h i c  08 js usecj as a basis to provide recommendations
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to examine and justify PMR investigative use. Ethical considerations arising from the 
computerisation of pharmacy, and the retention of patients' records have been 
discussed by McCarthy and Perrolle 209 They concluded that areas for discussion as a 
result of pharmacy computerisation were: the changing relationship between patient 
and pharmacist; the protection of confidential patient information; and the changing 
conditions under which patients are monitored and therapy decisions are made.
In the UK, the RPSGB's updated Code of Ethics, published in 1992, states, under the 
guidance of Obligation 4.2 of Principle Four, that data held in PMR systems may be 
used where necessary for the purpose of a medical research project which has been 
approved by a recognised ethical c o m m i t t e e . 2 1 0  Clearly, community pharmacists are 
well-placed and able to use their PMR databases as a research resource for such 
projects. For example, it is well known that the use of NSAIDs may precipitate 
bronchospasm in susceptible asthmatic patients, yet from the author's experience it is 
not uncommon in general practice for asthmatics to be prescribed NSAIDs, and 
subsequently require treatment with bronchodilators and/or increased doses of 
corticosteroids. A similar situation has been described by Paes in Holland. *28
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10.9 Recommendations
1. When dispensing prescribed medicines or supplying non-prescription 
medication, community pharmacists should follow a systematic clinical 
procedure, in addition to adhering to legal and NHS contractual requirements. 
The following procedure is proposed:
i) A pharmacist should check that a prescribed or recommended dose is 
appropriate for the patient.
ii) The pharmacist should ascertain that the product to be supplied is not 
contraindicated for that patient.
iii) The pharmaceutical form of the product to be supplied should be 
appropriate for the patient. For example, a pharmacist should assess 
the suitability of solid dose forms for young children.
iv) The pharmacist should ensure that the product to be supplied does not 
interact with other prescribed or non-prescription medication currently 
being, or recently taken by the patient. If the product to be supplied 
does interact with such medication, the pharmacist must assess critically 
the relevance and likely severity of the drug interaction for the patient 
when making a judgement as to whether to supply the product.
2. Community pharmacists should maintain or have access to PMRs for all 
patients.
3. A pharmacist must have access to sufficient information about a patient to 
make adequate judgements about whether to permit the supply of prescribed 
and non-prescription medication.
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4. Registration of patients with a particular pharmacy should be considered or 
otherwise, electronic data exchange systems must be researched and developed 
to enable the community pharmacist to access details about the supply of 
medicines from sources other than his own pharmacy. Pharmacists should 
record in each individual patient record those clinical conditions in which 
medication may be contraindicated.
5. There are hazards of not being able to detect contraindications or drug 
interactions due to more than one record being maintained for a given patient in 
the same pharmacy. There is a requirement for a method to be developed to 
minimise the risk of record-duplication. The creation of, and access to, a 
patient's PMR by means of the unique NHS number may be a way of achieving 
this objective.
6. Community pharmacists are making clinical interventions, using PMRs, to 
prevent: adverse drug interactions; the supply of contraindicated products; the 
supply of the wrong product, and; the supply of medication with an 
inappropriate dose. The profession must take action to increase awareness of 
this role among the general public, the medical profession, and Government 
policy-makers.
7. There are deficiencies in existing drug interaction monitoring software which 
must be eliminated. Internal audit of pharmacy computer databases by the 
system supplier, with external audit by appropriate experts would help to 
eliminate errors and omissions in the databases. The application of expert 
system programming techniques should be applied to drug interaction 
monitoring software to develop improved systems which take account of three 
or more interacting drugs or clinical conditions. The addition of referenced
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citations to drug interaction warnings, as is the case with some systems used in 
the USA, would enhance the quality assurance of computerised-PMR systems.
The BNF is widely accepted as a standard reference source on drug 
interactions. The availability of a frequently-updated on-line version of the 
BNF would be advantageous.
10.10 Proposals for Future Research
The April 1991 survey of 744 community pharmacies in England and Wales showed 
that over 61% of the respondents were maintaining PMRs (Conclusion 2.5.1). It is 
thought that 80-85% of community pharmacies are now maintaining PMRs (Section 
10.1). A further survey would be useful not only to confirm this, but also to establish 
the reasons why the remaining minority of pharmacists who are non-PMR-users have 
chosen not to establish a PMR system.
The clinical intervention survey described in Chapter 7 showed the potential benefits to 
patients of community pharmacists maintaining PMRs. Further work is required to 
establish cost-benefits which accrue as a result of clinical interventions made by 
community pharmacists using PMRs. Such work would involve an expert panel 
establishing the probability of adverse reactions arising had the community pharmacist 
not intervened. This would then require an evaluation of the costs of medical and 
paramedical involvement, hospitalisation, corrective drug therapy, and absence from 
employment resulting from morbidity associated with adverse reactions.
PMR databases held in community pharmacies could have a use in adverse drug 
reaction monitoring. Beta-adrenoreceptor antagonists and NSAIDs may produce 
bronchospasm in susceptible patients, particularly those with a history of obstructive 
airways disease. In spite of this, the author's community practice experience shows 
that these drugs are still prescribed for such patients when they are contraindicated. 
PMR systems could be improved, by researching and developing better methods of 
interrogating the databases, in order to determine the extent of this problem, and, 
furthermore, warn the pharmacist of those patients most at-risk. The pharmacist 
would then be able to use this information to advise patients' GPs to monitor them 
closely.
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The deficiencies of software used to monitor for potential drug interactions has been 
discussed in Chapter 8. The concept of "ternary systems” for evaluating potential drug 
interactions has been discussed in Section 8.4.8. Research is required to establish the 
exact need for such systems, that is, the number and importance of complex drug 
interactions involving three or more products must be determined. Furthermore, the 
number of specific clinical conditions in which a particular drug interaction may be of 
clinical significance must be determined. On the basis of such preliminary studies, 
suitable algorithms would be produced to develop the software, possibly involving 
expert system techniques.
The study of clinical intervention events produced evidence that GPs hold mixed views 
on the community pharmacist's clinical role. Research is required to develop and 
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Appendix 1: Statistical Methods 
Levels of Measurement
Statistical tests were chosen depending on the scale of measurement of the variables 
being measured. Measurements may either be on the nominal, ordinal or interval/ratio 
scale of measurement. Nominal measurement is categorical, based on variable names, 
and is used for frequency data, and is the weakest level of measurement. The chi- 
square test is the statistical test used in inferential statistics when measuring data at the 
nominal level.
Ordinal measurement is based on order or rank, where one variable is ranked higher or 
lower than another variable. However differences between ranks are not quantifiable. 
Non-parametric tests are used in inferential statistics when measuring data at the 
ordinal level.
Interval/ratio measurements are based upon distances between numbers which are 
quantifiable. Parametric tests are used in inferential statistics when measuring data at 
the interval/ratio level, and assume the data to come from a normally distributed 
population. Parametric tests provide the strongest level of measurement.
Statistical tests are devised and used such that an initial hypothesis (Hq) is stated, 
where there are said to be no differences between measured variables. A test statistic 
is calculated. If the value of the test statistic is greater than a given critical value, Hq 
may be rejected. Critical values vary with the significance level of a test. Generally, a 
significance level of p<0.05 is applied. That is, there is a less than 1 in 20 chance that 
the result of the statistical test could have occured by chance.
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Chi-Square Test For Independent Samples
When the data consist of frequencies in discrete categories, the chi-square test may be 
used to determine the significance of difference between two or more independent 
groups. The data are arranged into a frequency table in which the columns represent 
groups and each row represents a category of the measured variable.
For k independent samples, the null hypothesis (Hq) states that the groups are from the 
same population. The test statistic is given by
where njj = observed number of cases categorized in the rth row of theyth column 
Ejj = number of cases expected in the rth row andyth column when Ho is true.
number of degrees o f freedom in the frequency table. The number of degrees of 
freedom {df) is given by
d f = (number of rows -1) x (number of columns - 1 ).
Ho may be rejected if exceeds a critical value , at a given probability, for the
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Kruskal-Wallis One-way Analysis of Variance
The Kruskal-Wallis one-way analysis of variance by ranks is a non-parametric test used 
to decide whether k  independent samples are from different populations. The Kruskal- 
Wallis technique tests the null hypothesis that k  independent samples come from the 
same or identical populations with the same median. The data are cast into a two-way 
table with each column representing each successive sample or group. Each of the N  
observations are replaced by ranks, where all of the scores from the k samples are 
combined and ranked in a single series. The smallest score is replaced by rank 1, the 
next smallest by rank 2 and so on. The test statistic, H, is given by
where k  = number of samples or groups
nj = number of cases in theyth sample or group
N=  number of cases in the combined sample (the sum of the nfs)
Rj = sum of ranks in the yth sample or group
Rj= average of the ranks in the yth sample or group
R= (N+l)/2 = the average of the ranks in the combined sample.
Ties between two or more scores may arise. The variance of the sampling distribution 
is influenced (Siegel, 1988) by ties, and this can be corrected for in the calculation for 
H, where the H  statistic is given by:
where g= number of groupings of tied ranks
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t j  = number of tied ranks in the ith grouping
The effect of correcting for ties is to increase the value of H  and thus to make the 
result more significant than it would have been if no correction had been made. Hq 
may be rejected if H exceeds the critical value.
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Appendix 2. Survey Questionnaires and Documentation.
April 1991 Questionnaire and Covering Letter Sent to Pharmacies in 
National Survey and 124 PILLS System Users
Dear Fellow  Pharmacist
Patient Medication Records in Community Pharmacy
The Pharmacy P ra c tic e  Research U n it a t the School o f Pharmacy and 
Pharmacology, U n iv e rs ity  o f Bath is  conducting a research p ro je c t on 
the developing use o f p a t ie n t  m edication records (PMRs) in  community 
pharmacy.
We are examining how PMRs are c u rre n tly  being used in  a v a r ie ty  o f 
lo ca tio n s  and how t h e ir  use may fu r th e r  develop. W ith th is  o b je c tiv e , 
we are asking a number o f pharm acists, se lected  a t random from the  
Royal Pharm aceutical S ociety  o f Great B r i ta in 's  R eg is ter o f Premises, 
to  complete a questionnaire  about t h e ir  a tt itu d e s  to , and use o f , PMR 
systems.
We would be very g ra te fu l i f  you could f in d  a few minutes in  which to  
complete the enclosed questionnaire  and re tu rn  i t  in  the enclosed 
freepost envelope.
A l l  responses w i l l  be d e a lt  w ith  in  the s t r ic te s t  confidence and w i l l  
not be d isc losed  to  a th ir d  p a rty  under any circum stances. Results  
w i l l  be processed and stored in  a coded format which can on ly  be read 
by ourselves. The name and address o f the re le v a n t pharmacy w i l l  not 
be id e n t i f ia b le  from the data , which w i l l  on ly be used fo r  the  
purposes o f th is  study and not made a v a ila b le  fo r  o ther purposes.
Your response is  most im portant as i t  w i l l  enable us to  determ ine the  
curren t use o f PMRs, and to  p ro je c t p o te n t ia l uses. I f  you have any 
questions about our research we would be pleased to  hear from you.
Thank you fo r  your assistance.
Yours s in c e re ly
P h ilip  J Rogers John E Rees
Teacher P ra c t it io n e r  Professor o f Pharmaceutics
George F le tc h e r
Lecturer in  Pharmacy P rac tice  and Pharmaceutics
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PHARMACY PRACTICE RESEARCH UNIT 
SCHOOL OF PHARMACY AND PHARMACOLOGY 
UNIVERSITY OF BATH 
CLAVERTON DOWN 
BATH BA2 7AY
PATIENT MEDICATION RECORDS IN COMMUNITY PHARMACY
This questionnaire should be completed by the pharmacist 
normally in charge of the pharmacy.
All answers will be treated in the strictest confidence For office
and will not be disclosed to any third party under any use only
circumstances.
Please tick one box for each question unless 
otherwise specified.
SECTION A: THE PHARMACY
1. Is your pharmacy? Own _ 7
independent []
small multiple (group of ten or less pharmacies) [] 
large multiple (group of eleven or more pharmacies) []
ID _l-4
Reg  5-6
2. How would you describe the location of your pharmacy Loc _ 8
city centre (] suburban []
village or small town centre []
health centre [] within hospital []
supermarket "in-store" (] other (please specify) []
3. From which socio-economic group do the majority of SEG _ 9
your pharmacy's patients and customers come?
AB (middle class, professional, managerial) []
Cl (white collar workers) []
C2 (skilled working class) []
DE (semi or unskilled, those relying on social 
security or state pension)
n
Unable to classify, broad cross-section of the [] 
above
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4. What is the average number of total prescription Jte _ 10
items dispensed in the pharmacy each week?
0-199 [] 200-399 []
400-599 tl 600-799 □
800-999 [] 1000-1199 [ J
1200-1399 [] 1400+ []
SECTION B: THE PHARMACIST
5. What is the status of the pharmacist in charge of the Sta _ 11
pharmacy?
individual proprietor [] partner [ J
superintendent [] manager []
locum [] other [ 3
(please specify)
6. Is the pharmacist in charge male or female? Sex _ 12
male [] female []
7. What is the year of registration of 
charge?
the pharmacist in Yr _ 13
1986-1990 [] 1981-1985 []
1976-1980 [] 1971-1975 []
1966-1970 [] 1961-1965 []
1956-1960 [] 1955 or earlier []
8. To the nearest full-time 
pharmacists are normally 






1 [] 1.5 []
2 [] 2.5 []
3 [] more than 3 []
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SECTION C: ATTITUDES TOWARDS PATIENT MEDICATION RECORDS
Please tick the statement which best describes your 
agreement with the following statements.
Strongly Agree Feel Disagree Strongly 
agree neutral disagree
9. The use of PMRs
enables the community 
pharmacist to fulfil 
a more clinical role.
[] [] □ [] □ AttOOl 15




[] [] [] [] [] Att002 16
11. The use of PMRs wastes [] 
pharmacist time
[] [] □ [] Att003 17
12. The use of PMRs saves 
ancillary staff time.
[] [] [] [] [] Att004 18
13. On balance, PMRs give [] 
a financial benefit 
t. the pharmacist
[] [] [] [] Att005 19
SECTION D: USE OF PMR SYSTEMS
14. Does your pharmacy maintain a PMR system? YES [] Use _ 20
NO []
If YES, which type? manual []
computer-held [] 
"smart card" [] 




If your answer to question 14 was yes, please continue 
with question 15. If your answer to question 14 was no, 
please go straight to question 39.
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15. When did you install your current PMR system? Ins _ 21
1990 [] 1989 []
1988 [] 1987 []
1986 or earlier []








Other (please specify) []
17. How many patient records are currently held in the Pno _ 23
record system?
0-499 [] 500-999 (]
1000-2499 [] 2500-4999 []
5000 or more [] Don't know []




Elsewhere (please specify) []
19. Who normally uses the PMR computer keyboard to Ope _ 25





SECTION E: DETAILS OF PMRs RELATING TO PATIENTS
20. Do you enter details of previous medication history His _ 26
when initiating a patient's medication record?
Always [] Usually []
Sometimes [] Never []
Tf your answer was always, usually or sometimes, how 
is this achieved?
21. Which of the following patient details do you record 












hospital record number (if applicable)
22. Do you keep records for all your patients?
YES [] NO
If selective records are maintained which of the 
following patient groups do you include in your PMR?
all patients living locally []
patients over 60 []
those who have a lot of repeat prescriptions []
others (please specify) []
PatOOl _ 21 
Pat002 _ 28 
Pat003 _ 29 
Pat004 _ 30 
Pat005 _ 31 
Pat006 _ 32 
PatOOl - 33 
Pat008 _ 34 
Pat009 _ 35 
PatOlO _ 36 
PatOll _ 31 
Pat012 _ 38
Pat013 39
Pat014 _ 40 
Pat015 _ 41 
PatOl 6 _ 42 
PatOll 43
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23. Are any details of the following included in the PMRs 
which you hold for your patients?
GP's name 
GP's address
u GP's computer patient reference number
dentist's name 
dentist's address 
Family planning clinic 
hospital outpatients department 
"alternative" practitioners (please specify)
YES NO
PatO18 _ 44 
Pat019 _ 45 
Pat020 _ 46 
Pat 021 41
Pat022 _ 48 
PatO23 _ 49 
Pat024 _ 50 
Pat025 51
24. Do you include a record of allergies, sensitivities 
or idiosyncratic reactions to any of the following 
on the PMR?
YES NO
colour/preservative/flavourings [] [] A11001 _ 52
salicylates [] [] A11002 _ 53
penicillin [] [] A11003 _ 54
NSAIDS [] [] A11004 _ 55
Please state any other drugs or types of allergen 
which are recorded in this way.
25. Do you ever note the suitability of child-resistant Pat026 _ 56
closures for elderly and arthritic patients or those
who are otherwise incapacitated.?
YES [] NO []
26. Do you ever record prescription charge exemption for Pat027 _ 57
patients?
YES [] NO []
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27. Do you record any of the following conditions 



























[] ConOOl _ 58
[] Con002 _ 59
[] Con003 _ 60
[] Con004 _ 61
[] Con005 _ 62
[] Con006 _ 63
[] Con007 _ 64
[] Con008 _ 65
[] Con009 _ 66
[] ConOlO _ 67
[] ConOll _ 68
[] Con012 _ 69
[] Con013 _ 70
[] Con014 _ 71
[] Con015 _ 72
[] ConOl 6 _ 73
[] ConOl 7 _ 74
[] ConOl8 _ 75
[] ConOl 9 _ 76
[] Con020 _ 77
[] Con021 _ 78
[] Con022 _ 79
[] Con023 _ 80
[] Con024 _ 1
[] Con025 _ 2
Num 3-4
3 1 7
28. How do you amend your PMR if a patient dies?
Do nothing [] 
Archive record on computer [] 
Print and retain record [] 
Delete all patient details []
29. What action do you take if a patient leaves the area?
Make a note in the PMR []
Give a printout of PMR to patient []
Supply a printout of PMR to another []
pharmacy with patient's permission
None of the above []
30. Do you ever include the following details about 




occupation [] [] Pat030 _ 7
smoking habits [] [] Pat 031 _ 8
alcohol consumption [] [] PatO32 _ 9
height/ weight [] [] PatO33 _ 10
Do you include results from any of the following 
diagnostic tests in your PMR?
YES NO
In-pharmacy blood pressure readings [] n Pat034 _ 11
In-pharmacy serum cholesterol level [] t] Pat035 _ 12
In-pharmacy pregnancy test results [] t] Pat036 _ 13
32. Do patients ever ask to see their records as provided 





33. Are patients ever reminded about their rights to 
access their record?
YES [] NO []
Pat038 15
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SECTION F: DETAILS OF PMRs RELATING TO PRODUCTS
34. Do you ever use the PMR to record sales of OTC ProOOl _ 16
medicines to patients on your PMR system?
NO []
Counter-prescribed medicines only []
All purchased medicines []
35. Which of the following details are recorded for 
dispensed medicines in the PMR?
YES NO





date of supply 
prescriber's name 
type of prescription ie NHS/ private
expiry date 
batch number
manufacturer of generic products 
product supplier/ wholesaler 




Pro005 _ 20 
Pro006 _ 21 
ProOO? _ 22 
Pro008 _ 23 
Pro009 _ 24 
ProOlO _ 25 
ProOll _ 26 
Pro012 27 
Pro013 _ 28 
ProOl4 29
36. Do you ever use your PMR to prevent excess medication Pro015 _ 30
from being dispensed to patients on repeat 
prescription (Eg. 100 tablets prescribed every 28 days 





37. Are any of the following details recorded about 
dressings and appliances?
YES NO
type [] [] Pro016 _ 31
size [] [] ProOl7 _ 32
re-order code [] [] Pro018 _ 33
normal supplier [] [] ProOl9 _ 34
38. Are records maintained on the PMR system for patients Pro020 _ 35 




Do not supply oxygen []
39. In principle, how do you label medication which is Lab _ 36 
prescribed "as directed", "as before", or where no
directions are stated?
Label exactly as per the prescription []
consult the patient and label [] 
with the directions given
contact the prescriber/receptionist [] 
and label with the directions given
label with directions held in the PMR []
Other (please specify) []
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SECTION G: PATIENT INFORMATION LEAFLETS
Some PMR systems produce printed patient information 
leaflets giving details of drug action, instructions 
and possible side effects.





Please tick the statement which best describes your 
agreement with the following statements.
Strongly Agree Feel Disagree Strongly 
agree neutral disagree
41. Patient information [] 
leaflets reinforce 
information given to 
patients by prescribers.
[] [] [] [] Lea002 38
42. Patient information []
leaflets reinforce 
information given to 
patients by pharmacists.
43. Patient information []
leaflets which give 
information about side 
effects may worsen 
compliance by alarming 
patients.
44. Patient information []
leaflets provide a basis 
for discussion between 
pharmacist and patient.
45. Pharmacists who issue []
patient information 




46. More widespread use of [] 
patient information 
leaflets would improve 
patient compliance.




































SECTION H: FUTURE RESEARCH
In the next stage of our research, we shall want to find 
out what pharmacists do with the information that is 
stored in the PMR and will be looking at how the use of PMRs 
may improve patient care, by comparing data gathered from 
pharmacies with and without PMRs.
48. Would your pharmacy be prepared to assist in a further 
survey involving monthly collection of a limited amount 
of data about the nature and number of interventions 
made by pharmacists in connection with prescribed and 
counter-prescribed medication? The record sheet will 




I Would like more information []
Thank you very much for your kind co-operation with this 
survey. If you have any further comments on this survey 
or on how you use PMRs, we would be very grateful if you 
could write them below.
Philip J Rogers 
George Fletcher 
John E Rees
Pharmacy Practice Research Unit 
School of Pharmacy and Pharmacology 




Follow-up Questionnaire Sent to Pharmacies Which had Installed a PMR 
System During 1990
P h a r m a c y  P r a c t i c e  R e s e a r c h  U n i t  
S c h o o l  o f  P h a r m a c y  a n d  P h a r m a c o l o g y  
F R E E P O S T  ( S N 1 5 4 8 )
U n i v e r s i t y  o f  B a t h  
B a t h  B A 2  7 L Z
P atien t M edication Records (PMRs? in  Community Pharmacy
id
Please rate each of the following reasons for purchasing a PMR 
system on a scale of 1 (very important) to 5 (very unimportant / 
not relevant).
<Very Important Very Unimportant /  Not
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ Relevant*
1 2 3 4 5
Availability of NHS remuneration
Competition from other pharmacies
Head office policy
Necessary to update computer equipment
Need to provide an improved clinical service
Sales promotion
To enhance working relationship with GPs/ receptionists
To keep abreast of professional changes
Other reasons (please state)
How do you rate your current system on a scale of 1 (excellent) to 5 
(poor): ______
Are there any features which you would like as a part of your PMR 
system, which your current system does not have?
Please return this form in the enclosed FREEPOST envelope. 
Thank you for your cooperation.
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PILLS User Survey January 1993.
PHARMACY PRACTICE RESEARCH UNIT 
SCHOOL OF PHARMACY AND PHARMACOLOGY 
UNIVERSITY OF BATH 
CLAVERTON DOWN 
BATH BA2 7AY
PATIENT MEDICATION RECORDS IN COMMUNITY PHARMACY
This questionnaire should be completed by the pharmacist normally in charge of the pharmacy.
All answers will be treated in the strictest confidence and will not be disclosed to any third party 
under any circumstances
Please tick one box for each question unless otherwise specified
SECTION A: THE PHARMACY
1. When was your PILLS system installed?
1987 or before [ ] 1988 [ ]
1990 [ ] 1991 [ ]
2. Do you use the PILLS multi-user system? Yes [ ]
3. How would you describe the location of your pharmacy
city centre [ ] suburban [ ] village or small town centre [ ]
health centre [ ] within hospital [ ] supermarket "in-store" [ ]
other [ ], please specify ____________
4. From which socio-economic group do the majority of your pharmacy's patients and 
customers come?
AB (middle class, professional, managerial) [ ] Cl (white collar workers) [ ]
C2 (skilled working class) [ ]
DE (semi or unskilled, those relying on social security or state pension) [ ]
Unable to classify, broad cross-section of the above [ ]
5. What is the year of registration of the pharmacist in charge of the pharmacy?
1991-2 [ ] 1986-1990 [ ] 1981-1985 [ ]
1976-1980 [ ] 1971-1975 [ ] 1966-1970 [ ]
1961-1965 [ ] 1956-1960 [ ] 1955 or earlier [ ]
1989 [ ] 
1992 [ ] 
No [ ]
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SECTION B: PATIENTS' CLINICAL CONDITIONS
6. How many patient records are on file in your system? ________
This number is obtained by typing /Q at the patient name prompt, followed by your file access code. 
The required information is then presented on-screen.
NB. This information is needed to compare percentages of patients with various conditions between 
different types of pharmacy, parts of the country etc.
7. Do you record any patient conditions or drug allergies in your PILLS system?
Yes [ ] No [ ]
If your answer to question 7 was No, there is no need to complete question 8. If you answered Yes to 
question 7, please complete question 8.
8. How many patients are recorded as having each of the conditions listed in the table below?
This information is obtained by typing /PF at the patient name prompt, followed by D and the code 




































Please list any other conditions from leaflet number 523 (copy on page 4) which are regularly 
recorded in your system.
Thank you very much for your kind co-operation with this survey. If you have any further comments 
on the survey, the PILLS system, or on how you use PMRs, we would be very grateful if you could 
write them below.
Philip J Rogers 
George Fletcher 
John E Rees
L e a fle t no: 523. CONDITIONS
At th is  pharmacy, as you know, we have one of the most advanced computer 
systems in use in any pharmacy in the country. We make a computer record of 
each and every prescription medication which we dispense for you. This is  
repeated for each occasion that you bring a prescription to us for dispensing. 
All records are of course treated in complete confidence, as required by the 
Royal Pharmaceutical Society and the data protection act. Access to the 
computer is  only allowed to our pharmacist and dispenser.
One of the benefits of keeping records is  that we can check that the medicine 
can be safely taken by you. Some people have a medical condition or illn ess  
that makes i t  unwise to take some medicines. It w ill help us check for th is i f  
you underline any of the following conditions that you have so that your record 
can be altered.
Some of the conditions w ill be very strange to you. Do not worry i f  you do not 
understand them, because i f  they did apply to you you would have been told by 
your doctor. If you require any help or advice, speak to the pharmacist.
Some of the conditions w ill only apply for a time, for example i f  you are 
pregnant or breast feeding. When they no longer apply you should t e l l  your 





A V block (conduction problems in heart)
Blood disorders Blood vessel disease






Bone marrow depression 
Brain disorders 
Bronchitis 





























Headache (severe or frequent)
Heart fa ilu re Hypercalcaemia
Printed: 12.11.1993
Hyperkalaemia Hypertension Hyperthyroidism
Hypochlorhydria (low stomach acid) Hypothyroidism
Infection (severe) Intestinal problems
Jaundice (pregnancy or drugs) Kidney disease
Lactation (breast feeding)
Liver disease Lung disease









Sickle ce ll anaemia 
Spastic paralysis (children)
Stroke Surgery, major, expected
Systemic lupus erythaematosus 
Thromboembolism Thrombophlebitis
Thyroid function impairment 
Toxaemia in pregnancy Urination d iff ic u lty  














Mental or emotional problems
Nerve or brain disease
Optic n eu ritis












When you have underlined conditions that apply to you, please f i l l  in the part 
of the form below and hand to the pharmacist.
SURNAME .......................................................... Forenames
DATE OF BIRTH (For a child under 13 only): ___
ADDRESS ..............................................................................
The Pharmacy University of Bath
Antibiotic Compliance Questionnaire (February 1992)
Dear Patient
This questionnaire is part of a survey being undertaken onx how patients take antibiotics. It is totally 
anonymous, since no personal details are recorded. Please do take a couple of minutes to complete the 
questions below and return the questionnaire in the attached FREEPOST envelope. Do not place any 
postal stamps on the envelope.
For questions I and 2 the information can be found on your medicine label.
1. What is the name of your antibiotic? [ ]
2. How many doses were supplied? Number of tablets [ ]
Number of capsules [ ] Number of ml of liquid [ ]
3. Did you take the whole course of medicine? Yes [ ] No [ ]
If your answer to question 3 was yes, please go straight to question 6. If your answer was no, please 
continue with question 4.
4. If you did not take the whole course, was this because of:
Side-effects [ ]
Feeling better [ ]
Any other reason (please state below) [ ]
5. How much was left when you finished your antibiotics? Number of tablets [ ]
Number of capsules [ ] Approximate amount of liquid [ ]
6. When did you take your antibiotic? With or after food [ ]
On an empty stomach [ ]
At your convenience [ ]
7. Did you experience any of the following side-effects, while taking your antibiotic?
Rash [ ] Sickness [ ] Diarrhoea [ ]
Headache [ ] Indigestion [ ]
Dizziness [ ] Others (please state below) [ ]
8. Please list any other medicines you were taking at the same time as your antibiotic.
9. Are you male [ ] or female [ ]?
10. How old are you? 15-24 [ ] 15-34 [ ] 35^ 4  [ ] 45-54 [ ]
55-64 [ ] 65-74 ( ] 75+ [ ]
11. Did you receive a leaflet with your antibiotic? Yes [ ] No [ ]
12. If yes did you read and understand it? Yes [ ] No [ ]
Thank you for completing this questionnaire.
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Survey of Pharmacy Computer Systems Used in North America (June 1992).
Please complete and return to: Philip J Rogers
T eacher-Practitioner





As part of a research project investigating the international use of pharmacy computer systems, we
would be most grateful if you could provide the following information about your Company's system.
System Supplier: System Name:
Please tick one box for each question, unless otherwise stated.
Section A: Database and Coding Information
How would you describe the database(s) used within your system? Flat file [ ]
Relational [ ]
Other / don’t know [ ]
Who is the owner / supplier of the database used within your system? First DataBank [ ]
Me di-Span [ ]
Produced in-house [ ]
Other, please specify [ ]
Are any of the following external coding systems used? ICD-9 [ ]
ICD-10 [ }
READ [ ]
Other (please specify) [ ]
Section B: Drug and Product Information
Does your system provide information about drug dosage, including paediatric and geriatric dosing?
Yes [ ] No [ ]
Is information provided on adverse drug reactions (ADRs)?
Yes [ ] No [ ]
If yes, which of the following are provided?
Severity of ADR, eg. major / minor Yes [ ] No [ ]
ADR incidence Yes [ ] No [ ]
Signs and symptoms of ADR Yes [ ] No [ ]
Differentiation of allergies, overdose and toxic effects
Yes [ ] No [ ]
Section C: Drug Interactions
Does your system monitor prescription records for the possibility of drug-interactions?
Yes [ ] No [ ]
If yes, how many levels of significance are provided? [ ]
Is information provided about the possible effect of a particular drug interaction?
Yes [ ] No [ ]
Who provides the drug interaction information for your system? First DataBank [ ]
Medi-Span [ ]
Produced in-house [ ]
Other, please specify [ ]
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Are references given for drug interactions?
If yes, which of the following sources are used?







Section D: Patient Information
Does your system have a facility to record a particular patient's medical conditions?
Yes [ ] No [ ]
If yes, does the patient database cross-reference with the drug database to warn pharmacists when 
drugs are prescribed for patients, for whom they are contra-indicated or inappropriate?
Yes [ ] N o  [ ]
Are different levels of severity shown? Yes [ ] No [ ]
Does your system allow users to record drug allergies?
Yes [ ] N o [ )
Can the results of clinical tests, eg. serum cholesterol, be recorded?
Yes [ ] N o  [ ]
Does your system provide information leaflets
a) with dispensed medicines Yes [ ] N o  [ ]
b) about common medical conditions Yes [ ] No [ ]
Section E: Residential Care Services
Does your system feature the following for use by consultant pharmacists within residential nursing 
homes?
a) drug regimen review Yes [ ] No [ ]
b) drug utilisation review Yes [ ] No [ ]
Section F: Management Information
Are the following facilities provided by your system?
Stock control / automatic stock ordering Yes [ ] No [ ]
Drag usage enquiry, eg. by doctor Yes [ ] No [ ]
Prescription costing Yes [ ] No [ ]
Please use the space below to note any other major features of your Company's system which have not 
been covered by the above questions.
Thank you for taking the time to complete this questionnaire, the results from which will help us 
determine the variety of use of pharmacy computer systems in North America.
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Clinical Intervention Sheet With Example Entries
P H A R M A C Y  P R A C T I C E  R E S E A R C H  U N I T  
S C H O O L  O F  P H A R M A C Y  A N D  P H A R M A C O L O G Y  
U N I V E R S I T Y  O F  B A T H  
C L A V E R T O N  D O W N  
B A T H  B A 2  7 A Y
CLINICAL INTERVENTION EVENT RECORD SHEET












28/1/92 Cl Propranolol A Y Phoned GP to alter to 
Bendrofluazide
30/1/92 M2 Digoxin 0.25mg Tabs C Y Patient should have had 
0.125mg Tabs














N o t e s :
INTERVENTION CATEGORIES
Cl Contraindicated prescribed drug
C2 Contraindicated OTC drug
E Emergency supply of prescription-only medicine
11 Drug interaction between two drugs on presented 
prescription
12 Interaction between drug on presented prescription and 
drug previously dispensed
13 Drug interaction with OTC medicine
Ml Prescription error-incorrect drug on presented 
prescription
M2 Prescription error-incorrect strength on presented 
prescription
M3 Prescription error-incorrect dose on presented 
prescription
M4 Prescription errors incomplete/incorrect patient details 




C Cardio-vascular disease inc. cardiac failure, hypertension, 
clotting disorders
D Diabetic
E Expectant mothers, pregnant 
F Fits, epileptic 
G Geriatric, elderly patients 
H Hepatic impairment 
I Immuno-suppressed 
M Mentally ill, psychiatric 
O Ophthalmic disorders, eg. glaucoma 
P Parkinson's disease 
R Renal impairment
S Skin diseases 
T Thyroid patients 
U Peptic Ulcer 
Y Young patient (paediatric)
N Not listed above, miscellaneous
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A Survey of General Medical Practitioners' Views on Primary Care Patient Medication 
Records (April 1993)
We would be most grateful if you could complete this questionnaire and return it to us in the enclosed Freepost envelope. 
All individual responses will be treated in die strictest confidence and will not be disclosed to a third party under any 
circumstances.
Please tick one box for each question unless otherwise specified.
SECTION A: YOUR PRACTICE
1. How would you describe the location of your practice?
City centre [ ] Suburban [ ] Small town [ ]
Rural [ ] Other, please specify [ ]
2. Is your practice fund-holding? Yes [ ] No [ ]
3. Is your practice a dispensing practice? Yes [ ] No [ ]
4. What was your year of registration as a doctor?
1952 or earlier [ ] 1953-62 [ ] 1963-72 [ ]
1973-82 [ ] 1983-92 [ ]
SECTION B: PRACTICE COMPUTERISATION
5. Is your practice computerised? Yes [ ] No [ ]
I f  your answer to question 5 was Yes please continue with question 6. I f  your answer was No please go 
straight to question 8.
6. For which of the following do you use your computer system?
Monitoring for potential drug interactions? Yes [ ] No [ ]
Viewing of clinical data on patients during consultation
Yes [ ] No [ ]
Viewing of clinical data on drugs during consultation
Yes [ ] No [ ]
7. Does your practice computer have a modem and software, enabling on-line communication to other 
computer systems?
Yes [ ] No [ ]
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SECTION C: HOLDING OF MEDICATION RECORDS IN PRIMARY CARE
Who do you think should hold patients' medication records?
Please tick relevant box(es) i f  you agree.
FHSAs [ ] Patients [ ] Pharmacists [ ]
Prescribers [ ] Other(s), please specify [ ]
Planned integration of computer systems within the NHS may lead to FHSAs, or another 
authority, being able to provide a record database from which practitioners can selectively gain 
access to patient record data, which they need to execute their role. Which of the following 
professionals, in contract with FHSAs, do you feel should be permitted to do this?
Please tick relevant box(es) i f  you agree.
Community pharmacists [ ] Dentists [ ] General practitioners [ ]
Ophthalmic opticians [ ] Other(s), please specify below [ ]
SECTION D: PHARMACY-HELD PATIENT MEDICATION RECORDS
Current research shows that about 70% of community pharmacies maintain patient medication 
records. Since patients are free to have prescriptions dispensed at the pharmacy of their choice, 
many pharmacy-held patient medication records will be only partially complete. Registration with a 
pharmacy, selected by and convenient to the patient would enable more comprehensive records to be 
maintained. Do you think that patient registration with one pharmacy would be beneficial for?
All patients [ ]
Selected groups of patients, with chronic conditions [ ]
No patients [ ]
Pharmacists are encouraged, through the receipt of a small NHS fee, to maintain records for 
two groups of patients: the elderly and the confused. A few pharmacies maintain records only for 
these patient groups; however, most pharmacies will maintain records for patients with a much 
wider range of conditions. For which of the following patient groups should pharmacists maintain 
medication records?
Please tick relevant box(es) i f  you agree that pharmacists should keep medication records for:
Asthmatics [ ] Confused patients [ ] Diabetics [ ]
Elderly [ ] Epileptics [ ] HIV+ / AIDS patients [ ]
Ostomy patients [ ] Patients with a history of peptic ulceration [ ]
Patients having experienced drug allergies or major adverse reactions [ ]
Patients with cardiac disorders and/or hypertension [ ]
Patients with renal or hepatic impairment [ ]
Please list any other groups of patients, for whom you feel pharmacists should keep medication 
records.
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12. Many pharmacists use computer packages that facilitate the recording of patients' clinical 
conditions, enabling the monitoring of patients for contraindicated medication, for example 
non cardio-selective beta-blockers in asthmatic patients. Do you think that community 
pharmacists should include the recording of clinical conditions as part of their patient medication 
record profiles?
Yes [ ] No [ ]
I f  your answer to question 12 was No, please go straight to question 14. I f  your answer was Yes, please 
continue with question 13.
13. If pharmacists are to incorporate clinical conditions into patient records, how do you think
that this should be achieved?
By inference, using patients' medication profiles [ ]
Asking patients, using a confidential questionnaire form [ ]
Through formal contact with GP and/or practice staff, with assurance 
of confidentiality [ ]
Other, please specify [ ]
14. Some pharmacists use computer systems that produce patient information leaflets at the time of 
dispensing a prescription, an example of which is enclosed. The purpose of the leaflet is to 
reinforce counselling given to patients by prescribers and/or pharmacists, and to provide additional 
information on the correct use and potential side effects of prescribed products.
Do you feel that pharmacists should provide additional product information to patients in 
this way?
Yes [ ] No [ ]
Do you consider that the use of such patient information leaflets :
Improves patient compliance [ ] Has no effect on compliance [ ]
Worsens patient compliance [ ] 1 am not sure [ ]
15. Some pharmacists record the supply of non-prescription medicines as part of a patient's medication 
profile. Do you think that this should be normal practice for:
Please tick relevant box(es)
All non-prescription medicines [ ]
Medicines recently declassified from Prescription Only 
Medicines to Pharmacy Medicines, e.g. vaginal imidazoles, 
Hydrocortisone 1% cream [ ]
All patients [ ]
Certain patient groups only [ ]
This should not be part of the community pharmacist's role [ ]
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SECTION E: DRUG INTERACTIONS
16. Most patient medication record computer systems used in community pharmacies provide 
information about potential drug interactions. Depending on circumstances, pharmacists will either 
inform the prescriber of the interaction, counsel the patient, assess the interaction as clinically 
insignificant, or ascertain that the patient has previously taken an interacting drug combination 
without noticeable adverse effect.
Do you welcome information about potential drug interactions from pharmacists?
Always [ ] Often [ ] Sometimes [ ]
Seldom [ ] Never [ ]
17. Which reference source(s) would you normally use if you suspected a possible drug interaction?
ABPI Data Sheet Compendium [ ] British National Formulary [ ]
Drug Interactions, (Stockley) [ ] Local community pharmacist [ ]
Hospital pharmacy /district drug information centre [ ] MIMS [ ]
Regional drug information centre [ ] Your practice computer system [ ]
Other(s), please specify below [ ]
18. Research has shown that there is considerable variation between lists of potential interactions 
provided by various computer systems used in medical and pharmaceutical practice, arising 
from the use of different reference sources and clinicians' opinions. Do you think that the 
interaction information given by the BNF should be taken as the usual standard reference 
source in primary care?
Yes [ ] No [ ]
If the BNF is not acceptable as a standard reference source for drug interactions, which of the 
above (Q. 17) or other sources should be considered a standard reference.
Thank you very much for your co-operation with this survey. If you have any further comments on the use of 
patient medication record systems, we would be most grateful if you could write them below.
Philip J Rogers 
George Fletcher 
John E Rees
Pharmacy Practice Research Unit 
School of Pharmacy and Pharmacology 
University of Bath
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Appendix 3. Clinical interventions associated with drug interactions between newly* 
prescribed and previously-dispensed medicines.
Drug affected Interacting drug Outcome
Frusemide Co-amilofruse Frumil deleted from new Rx for Lasix + Capoten
Phenytoin Cimetidine Alter to ranitidine
Aminophylline Erythromycin Altered to flucloxacillin
Atenolol Diltiazem Aminophylline added
Burinex K Cephalexin Ceporex discontinued
Migril Erythromycin Change to Oxytetracycline
Salbutamol Co-tenidione Changed to Adalat Retard
Aminophyline Ciprofloxacin Changed to Co-trimoxazole
Parstelin Lomotil Changed to Dioralyte
Carbamazepine Ciprofloxacin Changed to Distaclor. Ciproxin prev. disp. elsewhere!
Theophylline Ciprofloxacin Changed to Magnapen
Theophylline Cimetidine Cimetidine dose reduced
Captopril Co-amilofruse Frumil changed to frusemide
Captopril Co-amilofruse Frumil changed to frusemide
Captopril Ketoprofen Ibuprofen gel used instead
Enalapril Diclofenac innovace dose reduced
Co-tenidione Nifedipine Nifedipine discontinued
Co-amilozide Lithium Patient to have blood test
Warfarin Mefanamic acid Ponstan not dispensed
Cisapride Cisapride Prepulsid & Alimix both prescribed
Nifedipine Prochlorperazine Prochlorperazine dose reduced
Aminophylline Ciprofloxacin Reduce Phyllocontin dose by 50%
Aminophylline Clarithromycin Reduced Phyllocontin dose
Atenolol Nabumetone Relifex discontinued
Captopril Slow K Slow K discontinued
Theophylline Clarithromycin Stop Nuelin
Co-proxamol Paracetamol Stop paracetamol
Oxprenolol Pseudoephedrine Sudafed not supplied. Patient back to surgery
Theophylline Ciprofloxacin Theophylline dose reduced
Nifedipine Verapamil Verapamil stopped
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Appendix 4: Interacting Drug Pairs Reported During the Period August 1991-July 1992. Drug interactions in 
bold text are discussed in Chapter 8 of the text.
Interacting Drug Pair: Published Reference Sources: PMR Computer systems:
Drugl BNF group Drug2 BNF group j BNF Stockley Martindale Data Sheet Richardson AAH Park PILLS Chemtec
Gaviscon 1010101 Oxytetracycline 5010300; Y Y Y No Y ++ 2 Possible Minor
Gaviscon 1010101 Ciprofloxacin 5011200| Y Y Y No Y ++ 3 Possible Minor
Gaviscon 1010101 Prednisolone EC 6020100; No
Gaviscon 1010101 Penicillamine 10010300j Y Y No Y ++ 3 Possible Minor
Cimetidine 1030100 Aluminium hydroxide 10101ooj Y?
Cimetidine 1030100 Atenolol 2040000: Y Y Y Y
Ranitidine 1030100 Nifedipine 2060200| Y?
Cimetidine 1030100 Theophylline 30103001 Hazardous Y Y Y Y ++++ 1 Probable Moderate
Cimeditine 1030100 Lorazepam 4010200| Y Y Y Y + 3 Minor
Cimetidine 1030100 Phenytoin 4080100! Hazardous Y Y Y Y +++ 1 Probable Moderate
Digoxin 2010000 Frusemide 2020200; Hazardous Y Y Y Y ♦ 1 Probable Minor
Digoxin 2010000 Diumide K 2020800! ♦ 1 Probable Minor
Digoxin 2010000 Amiodarone 2030200! Hazardous Y Y Y Y +++ Probable Moderate
Digoxin 2010000 Diltiazem 2060200; Hazardous Y? Y Y +++ 2 Probable Minor
Digoxin 2010000 Verapamil 2060200; Hazardous Y Y Y Y +++ 2 Probable Moderate
Digoxin 2010000 Aminophylline 3010300!
Digoxin 2010000 Quinine 5040100! Hazardous: Y +++ 1 Probable Moderate
Bendrofluazide 2020100 Prednisolone 6030100! Y Y Y Y +++ 2 Possible Minor
Amiloride 2020200 Enalapril 2050500! Hazardous • Y Y Y +++ 2 Probable Moderate
Bumetanide 2020200 Prednisolone 6030200! Y Y Y Y +++ 3 Possible Minor
Frusemide 2020200 Prednisolone 6030200| Y Y Y Y +++ 3 Possible Minor
Frusemide 2020202 Captopril 2050500! Hazardous Y? Y Y ♦ 2 Probable Moderate
Key;
?=unclear Highest level, where ranked; Hazardous ++++ 1 Probable Major
NA=not available on system +++ 2 Moderate
Y=interaction listed j ++ 3 Minor
Lowest level, where ranked; Y + Possble
Interacting Drug Pair:
Drugl BNF group !Drug2 BNF group BNF
Spironolactone
:
20203001 Lisinopril 2050500 Hazardous
Spironolactone 2020300! Lithium 4020300
Co-amilozide 2020400j Doxazosin 2050400 Hazardous
Co-amilofruse 2020400; Captopril 2050500 Hazardous
Dyazide 2020400 j Indomethacin 10010100 Y
BurinexK 20208001 Diumide K 2020800
BurinexK 2020800; Captopril 2050500 Hazardous?
Burinex K 2020800 j Cephalexin 5010200
Navldrex K 2020800; Indomethacin 10010100 Y
Disopyramide 2030100i Erythromycin 5010500 Hazardous
Amiodarone 20302001Warfarin 2080200 Hazardous
Propranolol 2040000j Amiodarone 2030200 Hazardous
Propranolol 20400001 Methyldopa 2050200
Atenolol 2040000I Captopril 2050500 Y?
Atenolol 20400001 Enalapn! 2050500 Y?
Atenolol 20400001 Diltiazem 2060200 Hazardous
Atenolol 2040000! Nifedipine 2060200 Hazardous
Bisoprolol 2040000! Diltiazem 2060200 Hazardous
Co-tenidione 20400001 Nifedipine 2060200 Hazardous
Propranolol 2040000! Nifedipine 2060200 Hazardous
Propranolol 20400001Verapamil 2060200 Hazardous
Sotazide 2040000: Salbutamol 3010101
Acebutolol 2040000!Pseudoephedrine 3100000 Hazardous
Atenolol 2040000|Pseudoephedrine 3100000 Hazardous
Metoprolol 2040000! Pseudoephedrine 3100000 Y
Key: ............................... f ............. ...........................i
?=unclear Highest level, where ranked Hazardous
NA=not available on system
Y=interaction listed i
Lowest level, where ranked Y
Published Reference Sources: PMR Computer systems:






+++ 2 Probable Moderate
++ Probable Minor
+++ 2 Probable Moderate
+ 2 Possible Minor
+ 2 Probable Moderate
+ 2 Possible NA
+++ 2 Probable Moderate
++++ 1 Probable Moderate




+ 1 Probable Moderate
+ 2 □ossible Moderate
+ 1 Probable Moderate
+ 2 Possible Moderate
+ 2 Possible Moderate
+++ Probable Moderate
+♦+ 2 Probable Moderate
+ 2 Probable Moderate
+ 2 Probable Moderate
+ 2 Probable Moderate




Interacting Drug Pair: Published Reference Sources: PMR Computer systems:
Drugl BNF group Drug2 BNF group I BNF Stockley Martindale Data Sheet Richardson AAH Park PILLS Chemtec
Propranolol 2040000j C hlorpromazine 4020100-! Y Y + 3 Possible Minor
Co-tenidione 2040000j Ergotamine 4070401! Y Y Y Y +++ 3 Possible Moderate
Atenolol 204000011ndomethacin 10010100j Y Y Y + 2 Minor
Atenolol 2040000' Nabumetone 10010100j + Minor
Propranolol 2040000 Xylometazoline 12020200'j Hazardous 2 Moderate
Methyldopa 2050200 Salbutamol 30101011 Y (iv only)
Lisinopril 2050500 Pseudoephedrine 3100000'j Y?
Captopril 2050600 Potassium citrate 7040300! Hazardous Y Y Y Y +++ 2 Probable
Enalapril 2050500 Cymalon 7040300! Hazardous Y Y Y NA NA NA
Captopril 2050500 Slow K 9020102! Hazardous Y Y Y Y +++ 2 Probable
Captopril 2050500 Ketoprofen 10010100! Y ? Y + 2 Possible
Enalapril 2050500 Diclofenac 10010100! Y Y? Y ♦ 2 Possible
Enalapril 2050500 Allopurinol 10010400! Y Y Y Y
Nifedipine 2060200 Verapamil 2060200!
Diltiazem 2060200 Aminophyline 3010300; Hazardous Y? Y +++ 1 Probable Moderate
Verapamil 2060200 Theophylline 3010300! Hazardous Y? Y Y +++ 1 Probable Moderate
Nifedipine 2060200 Prochlorperazine 4020100'; Y? 2 Possible Minor
Warfarin 2080200 Dipyridamole 2090000! Hazardous Y Y +++ 1 Probable Dangerous
Warfarin 2080200 Bezafibrate 21200001 Hazardous Y Y Y Y ++++ 1 Probable Moderate
Warfarin 2080300 Aspirin 4070100! Hazardous Y Y Y +++ 1 Probable Dangerous
Warfarin 2080200 Co-proxamol 4070101; Hazardous Y Y Y Y +++ 2 Probable Moderate
Warfarin 2080200 Carbamazepine 4080100! Hazardous Y Y Y Y +++ 1 Probable Moderate
Warfarin 2080200 Erythromycin 5010500! Hazardous Y Y Y Y +++ 2 Probable Moderate
Warfarin 2080200 Ibuprofen 10010100; Hazardous? Y ? 1 Probable Moderate
Warfarin 2080200 Mefenamic acid 100101001 Hazardous Y Y +++ 1 Probable Moderate
Key;
?=unclear Highest level, where ranked! Hazardous ++++ 1 Probable Major
NA=not available on system +++ 2 Moderate
Y=interaction listed ++ 3 Minor
Lowest level, where ranked! Y + Possble
Interacting Drug Pair: 
iDrugl BNF group ;Drug2 BNF group
| Warfarin 2080200! Phenytoin 4080100
jSalbutamol 30101011 Beclomethasone 3020000
j Salbutamol 3010101 j Actifed Co Linctus 3090200
j Salbutamol 3010101 \ Actifed expectorant 3090200
jSalbutamol 3010101 jBenyffn 3090200
j Aminophylline 3010300! Clarithromycin 5010500
j Aminophylline 3010300; Erythromycin 5010500
jTheophylline 3010300j Erythromycin 5010500
i Aminophylline 3010300! Ciprofloxacin 5011200
j Theophylline 3010300 j Ciprofloxacin 5011200
jMucron 3 ‘iOOOOO\Beny1ln Day & Night 3100000
jTerfenadine 3040000; Erythromycin 5010500
j Diazepam 4010100jTrimipramine 4030100
j Nitrazepam 4010100jDothiepin 4030100
j Nitrazepam 4010100! Amitriptyline 4030100
j Nitrazepam 4010100jlmipramine 4030100
jTemazepam 4010100; Amitriptyline 4030100
! Triazolam 4010100!Co-beneldopa 4090100
: :
jTemazepam 4010100jGriseofulvin 5020000
: Chlordiazepoxide 4010200 j Doxepin 4030100
Lorazepam 4010200! Amitriptyline 4030100
iLorazepam 4010200; Imipramine 4030100
jTemazepam 4010200; Dothiepin 4030100
jButobarbitone 4010300jCo-proxamol 4070101
; Haloperidol 4020100; Lithium 4020300
j Key:
;?=unclear
;NA=not available on system
jY=interaction listed:;
Highest level, where ranked
Lowest level, where ranked
Published Reference Sources: PMR Computer systems:
Stockley Martindale Data Sheet j Richardson AAH Park PILLS Chemtec
Y Y ? ++++ 2 Probable Moderate
Possible
NA NA Probable Moderate
Y Y Y Y ++++ 1 Probable Moderate
Y Y Y Y ++++ 1 Probable Moderate
Y Y Y Y ++++ 1 Probable Moderate
Y Y Y Y ++++ 1 Probable Moderate












Y Y + 2 Possible Moderate




Interacting Drug Pair: Published Reference Sources: PMR Computer systems:
iDrugl BNF group Drug2 BNF group BNF Stockley Martindale Data Sheet Richardson AAH Park PILLS Chem tec
j Thioridazine 4020100 Amitriptyline 4030100 Y 3 Possible Minor
j Thioridazine 4020100 Co-careldopa 4090100 Y Y +++ 2 Possible Minor
j Thioridazine 4020100 Oxybutinin 7040200 Y ++ NA Possible Minor
I Lithium 4020300 Bendrofluazide 2020100 Hazardous Y Y Y Y +++ 1 Probable Minor
! Lithium 4020300 Paroxetine 4030400 Hazardous NA Y ♦ NA Probable Moderate
| Lithium 4020300 Ibuprofen 10010100 Hazardous Y Y Y Y +++ 2 Probable Moderate
! Lithium 4020300 Indomethacin 10010100 Hazardous Y Y Y Y +++ 2 Probable Moderate
| Lithium 4020300 Naproxen 10010100 Hazardous Y Y Y Y +++ 2 Probable Moderate
; Amitriptyline 4030100 Phenelzine 4030200 Hazardous Y Y Y Y +++ 1 Probable Moderate
jDothiepin 4030100 Phenelzine 4030200 Hazardous Y Y Y Y +++ 1 Probable Moderate
jTrimipramine 4030100 Phenelzine 4030200 Hazardous Y Y Y Y +++ 1 Probable Moderate
jDothiepin 4030100 Aspirin 4070100
jlmipramine 4010200 Phenytoin 4080100 Hazardous Y Y +++ 2 Probable Minor
j Amitriptyline 4030100 Cyclo-Pmgynova 6040200 Y Y 3 Minor
j Prochlorperazine 4060000! Sodium valproate 4080100 Hazardous? +++ 2 Probable Minor
■j Paracetamol 4070100 Co-proxamol 4070101 Y Possible Moderate
! Paracetamol 4070100 Co-dydrarmol 4070101 Y Possible Moderate
i Aloxipirin 4070100 Methotrexate 8010300 Hazardous Y Y ++++ Probable Moderate
;Co-proxamol 4070101 Benorylate 4070100 Y Possible Moderate
iCo-dydramol 4070101 Co-codamol 4070101 Y Possible Moderate
iCo-dydramol 4070101 Co-proxamol 4070101 Y Possible Moderate
jCo-proxamol 4069781 Tylex 4070101 Y Possible Moderate
j Solpadol 4070101 Codeine phosphate 4070200
jCo-codamol 4070101 Migraleve 4070401 Y Possible Moderate
jCo-proxamol 4070101 Migravoss 4070401 Y + 3 Possible Minor
j Key:
j?=unclear Highest level, where ranked Hazardous ++++ 1 Probable Major
i NA=not available on system +++ 2 Moderate
jY=interaction listed ++ 3 Minor







| Penicillin V 
| Penicillin V 
! Penicillin V 
j Penicillin V 
| Penicillin V 
j Penicillin V 
! Penicillin V 
| Penicillin V 
j Penicillin V 
! Penicillin V 
































































































!NA=not available on system 
iY=interaction listed
Highest level, where ranked! Hazardous
Lowest level, where ranked;
Published Reference Sources: PMR Computer systems:
Stockley Martindale Data Sheet Richardson AAH Park PILLS Chemtec
Y Y Y +++ 2 Possible
Y Y Y +++ 1 Probable
+ 3 Possible
Y Y Possible
Y Y 3 Possible
Y Y 3 Possible
3 Possible
Y Y 3 Possible
Y Y Possible
Y Y 3 Possible
Y Y NA Possible
Y Y 3 Possible
Y Y 3 Possible
Y Y Possible
Y Y ++ 3 Possible
Y Y ++ 3 Possible
Y Y ++ 3 Possible
Y Y ++ Possible
Y Y ++ 3 Possible
Y Y ++ NA Possible
Y Y ++ 3 Possible
Y Y ++ 3 Possible
Y Y Y ++ 3 Possible
Y Y Y ++ 3 Possible










Drugl BNF group iDrug2 BNF group i BNF
Co-amoxiclav
i
5010103 Logynon 7030100S Y
Co-amoxiclav 5010103 Mervelon 7030100! Y
Co-amoxiclav 5010103 Microgynon 30 7030100| Y
Co-amoxiclav 5010103 Microval 7030100! Y
Amoxycillin 5010103 Femodene 7030200; Y
Cefaclor 5010200 Logynon 7030100|
Cefaclor 5010200 Logynon ED 7030100!
Cefaclor 5010200 Man/elon 7030100j
Cefuroxime 5010200; Binovum 7030100;
Cephadrine 5010200! Microgynon 30 70301001
Cephadrine 5010200 Ovranette 7030100j
Cephalexin 5010200 Logynon 70301001
Oxytetracycline 5010300 Gliclazide 60102011
Doxycycline 5010300 Femodene 70301001
Doxycycline 5010300 Microgynon 30 7030100{ Y
Oxytetracycine 5010300 Trinordiol 7030100! Y
Oxytetracycline 5010300 Logynon 7030100j Y
Oxytetracycline 5010300 Microgynon 30 7030100j Y
Oxytetracycline 5010300 Microgynon 30 7030100| Y
Tetracycline 5010300 narvelon 7030100; Y
Tetracycline 5010300 Microgynon 30 7030100j Y
Deteclo 5010300 Ferrous sulphate 9010101! Y
Minocycline 5010300 Ferrous gluconate 9010101! Y
Oxytetracycline 5010300 Ferrous sulphate 9010101! Y
Deteclo 5010300 Calcium & Vitamin D 9050101! Y
Key:
?=unclear Highest level, where ranked! Hazardc




Lowest level, where ranked; Y
Published Reference Sources: PMR Computer systems:


























Y ++ 3 Possible
Y ++ Possible
Y ++ 3 Possible
Y Possible









Y ++ 3 Possible Minor
Y ++ 3 Possible Minor
Y ++ 3 Possible Minor
Y ++ 3 Possible Minor
Y ++ 3 Possible Minor
Y ++ 3 Possible Minor
Y ++ Possible Minor
Y ++ 3 Possible Minor
Y ++ 2 Possible Minor
Y ++ 2 Possible Minor
Y ++ 2 Possible Minor
++ 3 Possible Minor





Interacting Drug Pair: Published Reference Sources: PMR Computer systems:
Drugl BNF group ;Drug2 BNF group j BNF Stockley Martindale Data Sheet Richardson AAH Park PILLS Chemtec
Oxytetracycline 5010300j Calcium & Vitamin D 9050101! Y Y Y Y ++ 3 Possible Minor
Erythromycin 5010500! Dianette 7030100! Y 3 Possible
Erythromycin 5010500;Logynon 7030100j Y Y 3 Possible
Erythromycin 5010500j Marvelon 7030100! Y Y Possible
Erythromycin 50105001 Microgynon 30 70301OOj Y Y 3 Possible
Co-trimoxazole 5010800 j Glibenclamide 6010201! Hazardous Y Y Y Y +++ 2 Probable
Co-trimoxazole 5010800!Logynon 7030100! Y Y Y Possible
Co-trimoxazole 5010800j Microgynon 30 7030100! Y Y Y Possible
Trimethoprim 5010800!Logynon 7030100; Y Y 3 Possible
Trimethoprim 5010800! Marvelon 7030100j Y Y Possible
Trimethoprim 5010800; Microgynon 30 7030100j Y Y 3 Possible
Trimethoprim 5010800 \ Minulet 7030100! Y Y NA Possible
Metronidazole 5011100j Minulet 7030100| Y? Y NA Possible
Ciprofloxacin 5011200jEtoldac 100101001 Probable
Nitrofurantoin 50113001 Minulet 7030100! Y Y Y NA Possible
Disodium etidronate 6060200! Calcium & Vitamin D 9050101! Y NA ++ Possible Minor
Methotrexate 8010300; Folic acid 9010200; Possible
Tiaprofenic acid 10010100! Diclofenac 10010100j
Naproxen 10010100j Diclofenac 10010100j
Yellow Fever Vaccine 14040000!Typhoid Vaccine 14040000! NA NA NA NA NA
Key: 5 ;
?=unclear Highest level, where ranked! Hazardous ++++ 1 Probable Major
NA=not available on system i ! +++ 2 Moderate
Y=interaction listed I
: ++ 3 Minor
Lowest level, where ranked; Y + Possble
Appendix 5. Business Addresses of Companies Listed in the Text









Liverpool L24 9NF 
England




Worcs. B60 2EW 
England
Boehringer Ingelheim Ltd 
Ellesfield Ave 
Bracknell 
Berks RG12 4YS 
England
Boots The Chemists Ltd 
Thane Road West 








Lancashire PR5 3QS 
England
Condor Corporation 
Marketing Technical Support 
2060 Oak Mountain Drive 
Post Office Box 189 
Pelham AL 35124 
USA
Digital Simplistics Inc




Etreby Computer Company, Inc 




Exeter Data Base Systems Ltd






First Data Bank 
The Hearst Corporation 












Herts SG5 1NQ 
England
Hadley Hutt Computing Ltd. 
George Bayliss Road 
Droitwich
Worcestershire WR9 9RD 
England























Park Systems Ltd 
6 Vulcan Street 
Liverpool L3 7BG 
England
Professional Drug Systems Inc.





QS/1 Data Systems 
P.O.Box 6052 
8045 Howard Street 
Spartanburg, SC 29304 
USA
RenLar Systems 





Reynadyne Data Systems Inc. 
2301 Avenue J 






Bredbury Park Industrial Estate 
Bredbury
Stockport SK6 2TD 
England
VAMP Health 
The Bread Factory 
la Broughton Street 
London SW8 3QJ 
England
